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Abstract 
Diabetic nephropathy (DN) is the most prevalent type of chronic kidney disease (CKD) 
in the western world, and represents the leading cause of end stage renal disease. 
DN develops as a complication of diabetes mellitus, and thus the pathogenesis is 
defined by systemic changes in blood glucose and often increased blood pressure. 
Tubulointerstitial renal fibrosis is causal to the destruction of the kidney fine structure, 
but the specific mechanisms driving it are still poorly understood. DN is a sterile 
inflammatory process, since immune infiltrates increase with disease progression and 
tissue fibrosis, in the absence of external pathogens. Myeloid cell types are found to 
be increased in DN, and macrophages and dendritic cells (DC) have been proposed 
to act as drivers of fibrotic processes in CKD. The recently described kidney specific 
myeloid CD209 and CD14 positive phenotype of mononuclear phagocytes (2+MoPh) 
was reported to be enriched in CKD.  
Using a set of cDNA microarrays and a bioinformatics deconvolution approach, 
2+MoPh-associated gene signatures were shown to be significantly increased in 
human DN biopsy samples, as compared to healthy controls. The increase of 2+MoPh-
related genes correlated with a decrease in renal function. Additionally, transcriptomic 
regulation of key homeostatic pathways was found to be altered in samples with 
enhanced 2+MoPh signals. To establish direct effects on these pathways, a reporter 
vector and cloning system specifically generated for this study was used for co-
incubation experiments carried out using in-vitro polarized 2+MoPh and immature DC 
control cells. The results showed strong activation of the Hedgehog, WNT, TGFβ and 
MAPK pathways in model parenchymal cells by co-incubation with 2+MoPh cells. The 
nature of the signals exerted by 2+MoPh cells in co-culture was found to be 
protein/peptide based, not reliant on cell-cell contact, and not exosome mediated. 
Small molecule antagonist studies identified MAPK components as playing a central 
role in the activation seen. Using a compiled gene list derived from the four pathways 
identified in the in-vitro validation study, a weighted gene co-expression analysis 
(WGCNA) was then used to identify co-regulated gene modules across the four 
pathways, and associated with an increase in 2+MoPh gene signatures in the DN 
patient transcriptomic data. Further study of the individual genes correlated with 
2+MoPh presence identified a pronounced MAPK-associated signature. Together, 
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these findings suggest a strong MAPK based component as a driving force of fibrosis 
in DN.
 III
  
Zusammenfassung 
Diabetische Nephropathie (DN) ist der prävalenteste Typus der chronischen 
Niereninsuffizienzen (CNI) in der westlichen Welt und die Hauptursache für 
Nierenversagen. Diabetische Nephropathie entsteht als Komplikation von Diabetes 
mellitus und die Pathogenese ist daher definiert durch systemische Änderung des 
Blutzuckerspiegels und häufig durch erhöhten Blutdruck. Tubulointerstitielle Fibrose 
ist dabei für die Zerstörung der Nierenfeinstruktur verantwortlich, über die 
Mechanismen die diesen Prozess vorantreiben ist allerdings kaum etwas bekannt. DN 
ist ein steriler Entzündungsprozess, da Immunzellinfiltrate mit voranschreitender 
Krankheit und Fibrose zunehmen, ohne dass externe Pathogene vorhanden sind. 
Myeloische Zelltypen treten im Verlauf der DN vermehrt auf und Makrophagen und 
Dendritische Zellen (DC) werden als treibende Kraft für die fibrotischen Prozesse in 
CNI diskutiert. Über den vor Kurzem beschriebenen nierenspezifischen myeloischen 
CD209 und CD14 positiven Phänotyp der Mononukleären Phagozyten (2+MoPh) 
wurde eine Anreicherung in CNI berichtet. 
Mittels cDNA-Microarrays und einem bioinformatischen Dekonvolutionsansatz wurde 
gezeigt, dass 2+MoPh assoziierte Gensignaturen signifikant erhöht in menschlichen 
DN Biopsien, verglichen mit gesunden Kontrollen, vorliegen. Die Erhöhung korrelierte 
mit einer Reduktion der Nierenfunktion. Weiterhin wurden Veränderungen in der 
transkriptionellen Regulation homöostatischer Schlüsselsignalwege in Proben mit 
erhöhten 2+MoPh Signalen nachgewiesen. Mittels einem eigens für diese Studie 
generierten Reportervektor- und Klonierungssystem wurden Kokultur-Experimente mit 
in-vitro polarisierten 2+MoPh und unreifen DC als Kontrollen durchgeführt, um die 
direkten Auswirkungen auf diese Signalwege zu bestimmen. Als Ergebnis zeigte sich 
eine starke Aktivierung der Hedgehog, WNT, TGFβ und MAPK Signalwege in 
parenchymalen Modellzellen bei Kokultur mit 2+MoPh. Die Signale mit denen 2+MoPh 
Zellen in Kokultur Einfluss nehmen wurden als Protein/Peptid basiert, unabhängig von 
Zell-Zell Kontakten und als nicht auf Exosomen basierend bestimmt. Eine zentrale 
Rolle für MAPK Komponenten konnte in Studien mit niedermolekularen Antagonisten 
belegt werden. Eine Gesamtgenliste bestehend aus den vier in-vitro identifizierten 
Signalwegen wurde als Basis für eine gewichtete Genkoexpressionsanalyse 
(WGCNA) verwendet um koregulierte Genmodule zu identifizieren. Dabei wurden 
gefundene Module auch mit der Gensignatur für 2+MoPh im transkriptionellen DN-
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Patientendatensatz assoziiert. Weitere Analysen der mit der 2+MoPh Präsenz 
korrelierenden Einzelgene zeigten eine ausgeprägte MAPK-assoziierte Signatur. 
Zusammen deuten diese Ergebnisse auf eine starke MAPK basierte Komponente als 
treibende Kraft für fibrotische Prozesse in DN hin.
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1 Introduction 
1.1  Chronic Kidney disease 
Chronic kidney disease (CKD) is defined by the gradual loss of kidney function which 
can eventually be reduced to life threateningly low levels [1]. While the kidney serves 
many functions, such as regulating blood pressure and bone formation, and control of 
red blood cell production, CKD is usually diagnosed by loss of the kidney’s filtration 
and reabsorption functions via measurement of serum creatinine levels and 
albuminuria [2-4]. Clinically, CKD is stratified into three levels of severity based on 
albuminuria, and five based on serum creatinine, through the calculation of an 
estimated glomerular filtration rate (eGFR) value (volume of fluid filtered by the renal 
glomerular capillaries per unit time). These values are then used to gauge the amount 
of kidney damage present in a specific case [1, 5]. Since the kidney has many 
functions, the symptoms of kidney damage are also widespread. While early CKD 
stages are usually asymptomatic, later stages can lead to hypertension, anemia, 
uremia, fluid volume overload and a number of electrolytic imbalances, generally 
severely limiting quality-of-life [6, 7].  
 
Figure 1. Overview of the kidney and its functional units, the nephrons. A) Renal 
arteries B) Ureter C) Medulla D) Cortex E) Arteriole F) Venule G) Glomerulus H) 
Proximal tubule I) Loop of Henle J) Distal tubule K) Collecting duct. Adapted from 
http://my.clevelandclinic.org 
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CKD is rarely diagnosed as an isolated disease, and thus, usually has causal co-
morbidities like hypertension, diabetes, and cardiovascular diseases [8]. Treatment of 
these comorbidities is the principal component of patient care, which is even more 
important since presence of CKD increases the risk of acute kidney injury (AKI), an 
abrupt loss of kidney function, which can be caused by exposure to nephrotoxic 
compounds, inflammatory processes in the kidney, or an obstruction of the urinary 
tract. Episodes of AKI can be life threatening, and if survived, often cause additional 
damage to the kidney already suffering from CKD [9, 10]. If CKD progresses to stage 
five, also known as end-stage renal disease (ESRD), kidney function is usually so 
impaired that renal replacement therapy by dialysis or kidney transplantation is 
required [11]. 
With an incidence of 500 million afflicted, CKD occurs in about 1 out of 10 individuals, 
especially in industrial nations with western life styles [12]. The most common cause 
for end stage renal disease and the required renal replacement therapy in Germany 
is type II diabetes, followed by nephrosclerosis caused by high blood pressure [13].   
 
1.1.2 Diabetic nephropathy 
Diabetic nephropathy (DN) is the leading cause of ESRD, accounting for 32% of all 
instances of renal replacement therapy. While DN is a serious complication of 
diabetes, only an estimated 20-40% of diabetics develop kidney complications, 
suggesting a genetic component to disease progression [14, 15]. 
A series of underlying causes of diabetic nephropathy are currently discussed [16, 17]: 
Hyperfiltration caused by increased pressure in nephrons leads to nephrosclerosis of 
the glomeruli. Increased blood glucose levels leading to accumulation of extra cellular 
matrix in the glomeruli and enhanced glycosylation of surface and matrix proteins. 
Reduction of nephrin, a structural protein of the slit diaphragm, can be observed in 
patients suffering from DN, compromising the filtration function. Elevated blood sugar 
inhibits thrombomodulin expression in glomeruli, which under normoglycemic 
conditions activates protein C, leading to reduced apoptosis of endothelial cells and 
podocytes. Finally, a number of growth factors and cytokines are dysregulated and 
lead to changes of the kidney milieu, activating inflammatory and wound healing 
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programs, with an enhanced recruitment of monocytes/macrophages into the various 
kidney compartments including the tubulointerstitial regions [18-20]. 
Clinically, DN is diagnosed by presence of albuminuria and can be stratified based on 
histological analysis of kidney biopsies [21]. The parameters analyzed are thickening 
of glomerular basement membranes and the mesangium, as well as the level of 
scarring (sclerosis) of kidney tissue and glomeruli with concurrent hyaline deposition 
[22]. Importantly, many patients with DN progress towards CKD even after glucose 
levels have been effectively reduced through medication [23]. The mechanisms driving 
progressive CKD are not well understood, but are believed to involve a complex 
chronic scarring process linked to enhanced leukocytic infiltrates. These infiltrates may 
act by modulating the status of homeostatic pathways within the target tissue either 
directly or indirectly, leading to morphological alterations as evidenced by increased 
ECM deposition by parenchymal fibroblasts and epithelial cells [24-27]. 
 
1.1.2 Alterations in signaling pathways during progressive DN 
With the scope of morphological changes in DN, and the prevalence of infiltrating 
immune cells, dramatic changes in homeostatic signaling networks can be observed 
with disease progression [28-31]. To analyze and quantify these changes, a number 
of strategies have been employed ranging from various imaging techniques such as 
immunohistochemistry, to transcriptomic profiling techniques based on cDNA 
microarrays or next generation sequencing approaches, and finally by the application 
of proteomic analysis [32-35]. 
Using transcriptomic profiling, a strong association of the WNT signaling pathway with 
progressive DN has been previously described by our group [36, 37]. Similarly, the 
TGFβ/SMAD (transforming growth factor beta / SMAD) pathway is strongly associated 
with disease progression [34]. As both of these pathways have been implicated in 
wound healing programs, as well as fibrotic processes, their activation seems to be 
largely context dependent. A potential explanation for this context dependency could 
be association with the Hedgehog pathway, which can exert control over WNT 
signaling during development [38], and has also been shown to activate fibroblasts 
during CKD, in part, through non-canonical mechanisms not currently understood [39, 
40]. Since non-canonical activation of GLI1/GLI2 (the GLI name comes originally from 
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Glioblastoma), the central transcription factors of Hedgehog signaling pathway, has 
been shown to occur via kinase driven processes, JNK (Janus kinase) and other 
MAPK (mitogen-activated protein kinase) are interesting candidate pathways for non-
canonical Hedgehog pathway activation [41]. JNK signaling is critical in mediating 
cytokine signals by recipient cells, and is overexpressed in progressively damaged DN 
kidneys, leading to a general association with the process of progressive fibrosis [42]. 
Finally, the more recently described Hippo signaling pathway, originally identified for 
its function to regulate organ size, has also been implicated in CKD [43]. Since it 
shares important pro-fibrotic target genes like connective tissue growth factor (CTGF) 
and cysteine-rich angiogenic inducer 61 (CYR61) with TGFβ/SMAD signaling, the 
involvement of the Hippo signaling cascade is strongly suggested during fibrotic 
processes. Additionally, Hippo signaling has been shown to be highly receptive to 
mechanical cues that would arise during scarring and the resultant stiffening of tissue 
[43, 44]. 
 
1.1.3 Homeostatic signal transduction pathways 
Regulatory protein networks help define homeostasis in cells and their ability to react 
to external stimuli. This makes the study of signaling protein interactions in cells a 
cornerstone of cell biology [45]. Signal transduction pathways usually originate at a 
receptor on the cell surface, which can bind either surface molecules of other cells, or 
factors present in the surrounding micromilieu of the cell [46]. In this way, cells can 
react to nutrients, stress inducing molecules (e.g. pathogen-associated molecular 
pattern, PAMPs or damage-associated molecular pattern, DAMPs) but also to 
secreted signaling molecules, such as cytokines or growth factors released from other 
cells or cell types [47-49]. Upon binding to the receptor, signals are transmitted via 
individual signaling molecules in a stepwise process. Generally, the signaling cascade 
ends with modulation of downstream target gene expression by either the activation 
or blockade of specific transcription factors associated with the pathway.  
In this way, cells and tissues can react to a wide range of stimuli without the need for 
physical presence of each individual cell at the original stimulus. Most signal 
transduction pathways were originally identified via knock-out studies in 
embryogenesis, and usually disruption of these pathways led to extreme and often 
embryonic lethal phenotypes [50]. 
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1.1.4 Hedgehog signaling 
The Hedgehog signaling pathway was originally identified in Drosophila melanogaster 
via random mutagenesis studies during larval development [51]. Most of the pathway’s 
signaling components are highly conserved in higher eukaryotes and remain incredibly 
important for embryogenesis [52]. The signaling cascade is also important for normal 
homeostasis, with disruptions having the potential to cause various cancer forms [53, 
54]. In addition, the pathway has been shown to be very important in stem cells, where 
it can be induced to help control the replacement of cells in damaged tissues [55]. The 
two Hedgehog ligands Indian hedgehog (IHH) and Sonic hedgehog (SHH) are 
expressed in tubular epithelial cells, and Hedgehog signaling in the primary cilium is 
linked to widespread effects on renal homeostasis [56]. Defects in ciliary Hedgehog 
signaling are associated with polycystic kidney disease [57]. 
The human canonical Hedgehog cascade is triggered when one of the three 
Hedgehog ligands SHH, IHH or Desert Hedgehog (DHH) bind to Patched (PTCH) 
receptors. Canonical Hedgehog signaling can occur in an autocrine or paracrine 
manner. Binding of one of the three ligands to the PTCH1 receptor leads to blockage 
of Smoothened (SMO), an inhibitor of GLI1/2 activation. Release of this blockade in 
turn activates the GLI1/GLI2 transcription factors, leading to nuclear localization and 
transcription of target genes [52]. 
In addition to the canonical activation mode, there are non-canonical GLI1/2 activation 
modes originally identified in cancer studies [58, 59]. The TGFβ/SMAD pathway can 
directly activate transcription of the GLI1 and GLI2 genes, and in turn, upregulate 
Hedgehog activity [60]. Also, activation of GLI1/2 by growth factors has been shown 
to occur via receptor tyrosine kinases (RTK), for example, the epidermal growth factor 
receptor (EGFR) and fibroblast growth factor receptor (FGFR), but also through 
heterotrimeric G-proteins [61, 62]. This mode of activation is mediated by 
phosphoinositide 3-kinase (PI3K) and/or MAPK/MEKs [63-65]. PI3K derived GLI1/2 
activation is thought to occur via AKT serine/threonine kinase (AKT), while MAPK/MEK 
activation leads to ERK activation, and either direct activation of GLI1/2 via 
phosphorylation, or indirectly via Jun proto-oncogene (JUN) activation in the nucleus. 
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Figure 2. Canonical and non-canonical GLI activation in the Hedgehog signaling 
pathway. In the canonical Hedgehog signaling pathway, the binding of one of the 
three Hedgehog ligand molecules SHH, DHH or IHH to PTCH1 leads to inactivation 
of SMO, a potent inhibitor of GLI1/2 activation. This results in activation of GLI1/2 and 
translocation to the nucleus where transcriptional control of Hedgehog target genes 
occurs. Additionally, GLI1/2 can be activated via TGFβ/SMAD signaling and by growth 
factor associated receptors via kinase cascades as explained in chapter 1.1.4. 
 
 
1.1.5 TGFβ/SMAD and BMP/SMAD signaling 
The classical TGFβ signaling pathway, originally identified by the ability of TGFβ 
ligands to induce morphological changes in rat cell culture, has been shown to be 
centrally important in embryogenesis and in the maintenance of general tissue 
homeostasis, as well as in regulation of immune responses, wound healing and tissue 
fibrosis [66-68]. The TGFβ superfamily consists of a large number of related proteins, 
though the summary here will focus on the three classical TGFβ ligands, and the bone 
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morphogenetic proteins (BMPs). For all members of the TGFβ family, a heterodimer 
of Type I and Type II TGFβ receptors is required for signaling.  
 
Figure 3. TGFβ and BMP driven SMAD activation pathways. In the canonical TGFβ 
signaling pathway, detection of one of the three ligand molecules (TGFB1-3) by a Type 
I/Type II receptor heterodimer leads to phosphorylation of R-SMADs. Phosphorylated 
R-SMADs bind to co-SMAD4 and are shuttled to the nucleus where they modulate 
transcription. BMP signaling occurs parallel with different SMADs. Additional signaling 
processes via other kinases are explained in chapter 1.1.5 
 
Upon the binding of a TGFβ ligand to a receptor dimer, the intracellular regulatory R-
SMAD proteins become phosphorylated [69]. This occurs via the function of the SMAD 
anchor for receptor activation (SARA), acting as an adaptor protein. The 
unconventional nomenclature of SMAD proteins stems from the homology the 
mammalian proteins exhibit with both Drosophila “Mothers against decapentaplegic” 
(MAD) and Caenorhabditis elegans Sma [70]. Phosphorylated R-SMADs have a high 
affinity for recruitment of co-SMADs, SMAD proteins which are not phosphorylated, 
Introduction   8
 
but co-operate during signaling. In case of the canonical TGFβ signaling cascade, 
SMAD2/3 act as R-SMADS with SMAD4 acting as a Co-SMAD. The resulting 
heterodimers are then shuttled into the nucleus and initiate transcription of target 
genes. In the highly similar BMP signaling cascade, BMP2/4/7 bind to the receptor 
dimer which leads to R-SMAD1/5/8 phosphorylation and binding to co-SMAD4 [70].  
There are also non-canonical components of the signaling cascade [71-73]. MAP 
Kinases can also lead to R-SMAD phosphorylation, allowing downstream signaling of 
other pathways to regulate the activation of state of SMAD signaling. Interestingly, 
some components of TGFβ/SMAD and BMP/SMAD signaling have been shown to 
feed back into MAPK/MEK and ERK pathways to modulate downstream JNK signaling 
[74]. 
 
1.1.6 WNT signaling 
The WNT signaling network was originally identified in two independent studies, one 
using Drosophila mutagenesis as a developmental model, and one study on 
cancerogenesis [75-77]. Later it was found that the genes identified were actually 
functionally and structurally homologous to each other, and the gene family was 
dubbed WNT (a combination of “Wingless” from the Drosophila studies and 
“Integration”/INT from the cancer studies). These early findings highlighted the 
potential importance of WNT signaling in homeostasis and during development [78].  
In the canonical WNT signaling pathway, one of the 19 human WNT ligands binds to 
a complex of a “Frizzled” receptor (FZD) and low-density lipoprotein receptor-related 
protein (LRP) [79]. This in turn leads to recruitment of the β-catenin destruction 
complex to LRP and deactivates it by dephosphorylation of Axin and Dishevelled 
(DSH). In this state, the normally unstable β-catenin accumulates in the cytoplasm, 
and is then shuttled to the nucleus where it enhances transcription via association with 
the T-cell factor/lymphoid enhancing factor (TCF/LEF) transcription factors. In addition 
to the canonical WNT signaling pathway, at least two other non-canonical signaling 
cascades have been identified, dubbed the WNT-Ca2+ pathway and the WNT-planar 
cell polarity (WNT-PCP) pathway. These pathways do not involve β-catenin [80]. 
In the WNT-Ca2+ pathway, named for its function in regulation of intracellular calcium 
levels, WNT ligands bind to Frizzled receptors, but in the context of heterotrimeric G-
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proteins [81]. This leads to activation of specific domains of DSH, and via the G-protein 
interaction, activation of Phospholipase-C (PLC). PLC then cleaves 
phosphatidylinositol 4,5-bisphosphate (PIP2) generating diacylglycerine (DAG) and 
inositol trisphosphate (IP3). Detection of IP3 by the endoplasmatic reticulum (ER) 
triggers calcium release. Increased calcium then activates Ca2+/calmodulin-dependent 
protein kinase II (CaMKII) and Calcineurin. CaMKII in turn, activates the NFAT 
transcription factors [81, 82]. 
 
Figure 4. Canonical and non-canonical WNT signaling. The three known human 
WNT signaling pathways are comprised of canonical WNT/β catenin, the 
WNT/Calcium pathway and the WNT planar cell polarity pathway. For a description of 
the three pathways refer to chapter 1.1.6 
 
In the WNT/PCP pathway, WNT ligands bind to Frizzled receptors, and an as of yet 
unidentified co-receptor, to activate DSH, which then binds Dishevelled-associated 
activator of morphogenesis 1 (DAAM1) [83]. DAAM1 in turn activates the Rho 
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GTPase, and finally Rho-associated kinase (ROCK). The WNT/PCP pathway has 
been shown to regulate the cytoskeleton. Additionally, DSH can also activate JNK 
signaling via Ras-related C3 botulinum toxin substrate 1 (RAC1) [84]. 
 
1.1.7 Hippo signaling 
The Hippo signaling pathway was originally identified in Drosophila developmental 
studies. Mutants in Hippo signaling exhibited overgrowths and other defects in organ 
size control [85]. More recently alterations of Hippo signaling genes have been 
described in various cancers highlighting the importance during normal tissue 
homeostasis [86, 87]. Follow-up studies have shown that Hippo signaling can be 
activated by loss of cell-cell contact and mechanical cues, as well as by some lipids 
and growth factors [88]. Hippo has been shown to be a major component in the 
regulation of renal interstitial fibrosis [43]. 
Under normal tissue conditions, Hippo signaling is deactivated, which manifests by 
phosphorylation of yes-associated protein 1 (YAP1) and WW domain-containing 
transcription regulator protein 1 TAZ(WWTR1), the transcriptional co-activators central 
to the pathway [89]. In the phosphorylated state, YAP1 and TAZ are retained in the 
cytoplasm, where they can modulate other pathways such as TGFβ/SMAD and WNT, 
and also act on cell adhesion and polarization pathways together with the 14-3-3 
proteins. The phosphorylation of YAP1 and TAZ is mediated by a kinase cascade 
comprising serine/threonine-protein kinase 4 (STK4, mostly referred to as MST1/2) 
and the downstream serine/threonine-protein kinase LATS (LATS1/2) kinases, 
together with the protein salvador homolog 1 (SAV1) and MOB kinase activator 
(MOB1A/B) scaffold proteins. How the initial activation of MST1/2 occurs in 
vertebrates is not entirely understood, but a few likely components have been 
identified or inferred from Drosophila: The atypical cadherins FAT1-4, the FERM 
domain-containing apical proteins FRMD6 and NF2 and the WW domain-containing 
apical proteins WWC1-3 [90-93]. If the activity of the signal transduction cascade is 
lost or inhibited, YAP1 and TAZ are no longer phosphorylated and are shuttled to the 
nucleus. There they cooperatively modulate transcription with specific families of 
transcription factors, most notably the Runt-related transcription factor (RUNX) and 
TEA domain family members (TEAD) [94].  
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Figure 5. The Hippo signaling pathway. By an as of yet not fully understood 
mechanism, high cell densities lead to activation of the MST and subsequently 
phosphorylation of LATS kinases. LATS then phosphorylates YAP1 and TAZ, the 
transcriptional co-activators central to the Hippo signaling pathway. Phosphorylated 
YAP1 and TAZ are kept in the cytoplasm by phosphorylation and 14-3-3 protein 
binding. In low cell density situations, unphosphorylated YAP1 and TAZ are shuttled 
to the nucleus and modulate transcription. For a description of the three pathways 
refer to chapter 1.1.7 
 
In addition to the core Hippo genes, there are additional modulations that occur 
through crosstalk with other pathways [95-97]. Some lipids such as lysophosphatidic 
acid and sphingosine-1-phosphate have been shown to block the Hippo 
phosphorylation cascade, leading to transcriptionally active YAP1 and TAZ [98]. This 
is thought to occur via the Rho GTPase. A similar blockage of phosphorylation has 
been shown for receptor tyrosine kinase (RTK) based on growth factor binding leading 
to activation of Ras, MAPK and phosphorylation of LIM Domain-Containing Protein 
Ajuba, which then blocks phosphorylation [99-101]. 
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1.1.8 MAPK, JAK/STAT and JNK/SAPK pathways 
 
Figure 6. ERK/MAPK, JAK/STAT and SAPK/JNK pathways. Both the ERK/MAPK 
and SAPK/JNK pathways use tiered kinase cascades to transmit signals from cell 
surface receptors to transcription factors in to the nucleus. This complicated signaling 
mechanism allows for multiple levels of modulation and signal amplification inside the 
cell. JAK/STAT signaling shares many signaling components, but lacks the tiered 
mechanism. For specifics see chapter 1.1.8 
 
The family of mitogen-activated protein kinases (MAPK) was originally identified in the 
context of growth factor signaling, but subsequently many more signaling processes 
involving MAPK were identified [102-104]. The general mechanism of MAPK is a tiered 
phosphorylation cascade usually starting with a MAPK kinase kinase 
(MAPKKK/MAP3K) which then phosphorylates, and activates a MAPK kinase 
(MAPKK/MAP2K) which in turn phosphorylates a final MAPK. This MAPK can then 
phosphorylate a wide range of proteins including transcription factors, or additional 
signaling molecules, to pass on a specific signal [105]. Signal specificity is usually 
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conferred by the associated receptors, but also by the binding affinity between the 
kinases, and in some cases, by the actions of specific scaffold proteins that tie 
signaling components to each other. While it may seem uneconomic for cells to have 
three steps of phosphorylation, this allows for multiple levels of regulation and signal 
amplification [106].  
The extracellular signal–regulated kinases (ERK1/2, now also known only as MAPK) 
pathway was originally described as a morphogenic pathway that reacts to the 
presence of growth factors mediated through receptor tyrosine kinases (RTKs) such 
as epidermal growth factor receptor (EGFR) [107]. Upon binding a ligand, the receptor 
is autophosphorylated through a conformational change, which then allows the binding 
of docking molecules and guanine exchange factors, ultimately leading to the 
activation of RAS proteins (KRAS proto-oncogene, GTPase and HRAS proto-
oncogene, GTPase). RAS can then go on to activate the RAF proto-oncogene 
serine/threonine-protein kinase, which phosphorylates the first MEK or MAPKK 
(MAP2K1/2). This leads to phosphorylation of ERK/MAPK, which can then regulate 
downstream transcription factors like Fos proto-oncogene, AP-1 transcription factor 
subunit (FOS), v-myc avian myelocytomatosis viral oncogene homolog (c-MYC or 
MYC), and cAMP responsive element binding protein (CREB) [103]. 
In contrast, the c-Jun N-terminal kinases (JNK/Janus kinases), also known as stress 
activated kinases (SAPK), are not only activated by growth factors, but also by a 
plethora of stress related signals [108]. Additionally, there is significant cross talk 
between the various regulatory cascades. JNK activation can start out with a G-protein 
coupled receptor (GPCR) or an RTK, both of which can trigger the activation of ras-
related C3 botulinum toxin substrate 1 (RAC1), which can then in turn activate 
MAP3K9 or MAP3K1, and continue the signaling cascade through MAP2K7 or 
MAP2K4, and which ends with MAPK8/9/10 (also known as JNK1/2/3) [109]. These 
kinases then have the potential to activate a set of transcription factors such as the 
Jun proto-oncogene, AP-1 transcription factor subunit (c-Jun/JUN), activating 
transcription factor (ATF), tumor protein p53 (p53/TP53) and Nuclear factor of 
activated T-cells (NFAT4) [108]. 
Even though JAK/STAT signaling is not a true MAP kinase based process, it is very 
closely linked to MAPK/JNK. JAKs are bound to surface receptors and upon detection 
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of cytokines and growth factors their kinase activity is increased, and they recruit and 
phosphorylate STAT proteins [110, 111]. They then undergo dimerization and 
translocate to the nucleus where they can activate transcriptional targets. STATs 
however can also be phosphorylated by ERK and JNK, so JAK/STAT is not a truly 
separate pathway [112]. 
 
1.1.9 Interactions between signaling pathways 
All of these homeostatic signaling pathways were originally defined in a very focused 
way. Generally, by the identification of interaction partners for previously identified 
pathway proteins, and thus, led to an expansion of the signaling cascades using 
phenotypic or transcriptional changes as read outs of their biologic importance [113]. 
However, while the pathway concept is a needed abstraction to grasp and study these 
mechanisms, experimental data suggest that, in reality, the individual pathways are 
much less clearly divided, and rather form larger networks by influencing each other 
(also referred to as pathway crosstalk) [114]. This can occur on various levels, with 
some being more obvious, such as the direct interaction of signaling proteins, some 
less so, like in the changes in the dynamics of transcription by competition or 
cooperative binding to DNA [115]. This also means that changes that, for example, 
occur from small genetic aberrations, can lead to defects in what at first look appear 
to be unrelated processes. Additionally, the interactions between pathways cause 
most signaling processes to occur in a context dependent manner, depending on 
either the type of recipient cell, or the type and status of the signaling cell [116-118]. 
This can be caused by different types of signaling molecules expressed, or by a lack 
of receptors for such a pathway, which together with the multitude of signals being 
exerted and received at a given time and in a specific micro milieu, can lead to 
unexpected activation patterns in the recipient cells. 
Currently known signaling interactions of the homeostatic pathways detailed here are 
summarized in Figure 7. For most of these interactions there is no true ‘upstream’ or 
‘downstream’ orientation, with the exception of the Hedgehog – WNT interaction, 
where WNT ligands are among the Hedgehog/GLI expressed target genes [38].  
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Figure 7. Interactions of signaling pathways. This scheme summarizes known 
interaction patterns between signaling pathways. For more information, see 1.1.9. 
For the other pathways, the picture is less clear, as most interactions are cytoplasmatic 
and modulate, rather than cause, signaling events. This is especially true for the 
MAPK/SAPK networks which can have significant impact on the activation state of all 
of the other pathways [63, 119-123]. Hippo signaling has been also shown to modulate 
the activity of WNT and TGFβ/SMAD signaling, but mostly in the cytoplasmatic and 
thus phosphorylated and transcriptionally inert state of YAP1/TAZ [95, 97]. 
Additionally, some specific pro fibrotic target genes associated with the TGFβ/SMAD 
pathway are shared targets of Hippo signaling [87]. Finally, WNT – TGFβ/SMAD 
interactions have been studied in great detail because both of these pathways share 
important functions during wound healing and development, and both had been 
discovered relatively long ago [96, 124]. 
 
1.1.10 The human immune system 
The immune system as a whole is a complex system comprised of organs, cell types 
and soluble factors, with the main function of defending the host organism from foreign 
pathogens. The most crucial aspect is thus the detection and elimination of foreign 
components, while tolerating the host. Upon detection of foreign, potentially harmful 
factors or antigens, an immune reaction is triggered [125, 126].  
The human immune system is comprised of two major branches, the innate and the 
adaptive immune system. The innate immune system is much older evolutionarily, and 
allows the detection and direct action against pathogens by causing inflammatory 
reactions. It is comprised of dendritic cells, macrophages, granulocytes, mast cells, 
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natural killer (NK) cells and the complement system [127]. Upon detection of an 
antigen or danger signal (PAMP, pathogen associated molecular pattern) by pattern 
recognition receptors (PRR) the cells become activated, and start producing pro-
inflammatory cytokines and chemokines to attract additional leucocytes to the source 
of the infection. NK cells kill infected and otherwise anomalous cells, such as cells with 
altered major histocompatibility complex (MHC) class I phenotypes. Phagocytes take 
up and kill pathogens. Lastly, the complement system, a series of secreted factors, 
generated in the liver bind to the surface of bacteria and other pathogens, and through 
a cascade of reactions, opsonize them to be targeted for destruction, while attracting 
more immune cells to the location [128]. 
After the original steps of host defense have begun, the adaptive immune system 
comes into play. The name adaptive stems from the capability to generate an antigen-
specific response to pathogens, and then to memorize this response, to allow for faster 
host defense in the future [129]. The most important cells in the adaptive immune 
system are T- and B-cells. Both need to be activated by antigen contact to perform 
their functions. T-cells are subdivided into more subclasses, based on their expression 
of CD4 and CD8. Both types of T-cells express a specific receptor (T-cell receptor, 
TCR) and can only be activated by antigen presentation in context with a MHC 
molecule on an antigen-presenting cell (APC). Almost every cell can function as an 
APC, from “professional” immune cells like dendritic cells, macrophages and B-cells, 
to regular cells infected with pathogens. CD8 positive (+) cells use this co-receptor to 
detect antigens in context with MHC class I molecules on APCs and upon activation 
act as cytotoxic T-cells or killer T-cells, inducing apoptosis in the infected cell by 
release of cytotoxins [130-132].  
CD4+ T-cells detect antigens presented by MHC class II molecules. MHC class II is 
expressed on antigen presenting cells like macrophages and dendritic cells, and CD4+ 
T-cells are not generally cytotoxic, earning them the name helper-T cells. Upon 
activation, they secrete cytokines, which activate CD8+ T-cells and macrophages and 
express the surface proteins required to activate B-cells. Not all CD4+ T-cells are pro-
inflammatory though, as they can also mature to regulatory T-cells, which counteract 
inflammatory signals [133, 134]. 
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Finally, B-cells can detect pathogens when they bind to antibodies on its surface. Upon 
binding, the complex of antibody and pathogen is taken up, cleaved proteolytically and 
presented on the cell surface in context with MHC class II molecules. Helper T-cells 
can then detect the antigen/MHC II complex and activate the B-cell. Upon activation, 
the B-cell begins to divide and differentiate into plasma cells, which then secrete large 
amounts of the detected antibody. This allows for a highly specific immune response 
and the specific targeting of pathogens by the immune system [135]. 
The adaptive immune system can form an immunological memory, which happens 
upon activation of T and B-cells, when some of their offspring form long-lived memory 
cells, which, upon reactivation allow for rapid and highly efficient immune responses 
to known pathogens [136].  
 
1.1.11 Immune system in the kidney and the myeloid phenotype 
ercDC/2+MoPh 
The kidney resident immune cells are mostly comprised of dendritic cells and 
macrophages, which are largely restricted to the tubulointerstitial space [137-139]. 
Both of these cell types are categorized as “professional” phagocytes, meaning their 
main function is taking up pathogens, albeit in different functional contexts [140]. 
Macrophages, which contain many lysosomes, classically function to clear apoptotic 
cells, directly kill pathogens and to secrete pro inflammatory factors like interleukin-1 
(IL1), interleukin-6 (IL6), and TNF-alpha (TNFα). However, more recently, additional 
functions have been identified, like the secretion of growth factors during healing 
processes and immune modulatory functions depending on their state of polarization 
[141-143]. In this regard, it is thought that the resident myeloid cells may also play key 
roles in the regulation of tissue homeostasis. Dendritic cells, classically defined by 
their role in antigen presentation to T and B-cells in the lymph nodes, can also 
influence immune regulation by modulating surrounding immune or parenchymal cells 
via the secretion of cytokines and chemokines [144-147]. The divide between different 
subpopulations of monocytic cells is now seen as a rather artificial separation, and a 
new concept of a myeloid phenotypic continuum has subsequently been proposed 
[148, 149]. This concept is supported by the identification of specific renal 
mononuclear phagocytes (rMoPh) in the kidney, myeloid derived cells that express 
both macrophage and DC markers, and thus do not easily fall into either category 
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[150]. One such phenotype of DC has recently been identified in human kidneys and 
originally described as “ercDC” for its tendency to be highly enriched in examples of 
renal cell carcinoma [151]. This myeloid subtype is characterized by expression of 
CD209/DC-SIGN and CD14, and for the purpose of this thesis, has been dubbed 
2+MoPh (double positive, CD209+, CD14+ mononuclear phagocytes). Importantly, this 
cell type is also found in normal kidneys under homeostatic conditions. Reports have 
also suggested that 2+MoPh become enriched in CKD [139]. This phenotype is of 
special interest in progressive kidney disease. While it expresses T-cell activating 
markers, it is very inefficient at stimulating naïve T-cells and does not secrete IL-12 
after CD40 ligand contact, while also expressing Fascin at lower levels than seen in 
IL-4/GM-CSF immature DCs (imDC). Both of these factors are required for the 
activation of T-cells, either by promoting the differentiation of T-cells or for the 
formation of the immunological synapse. Ex-vivo isolated 2+MoPh were recently used 
by our collaborator (Prof. Dr. Elfriede Nößner) for an in-depth transcriptomic and 
functional study of the cell type (Brech et al. submitted). Additionally, a 2+MoPh-like 
phenotype can be generated from peripheral blood monocytes in-vitro through co-
culture with renal epithelial cell or renal cell carcinoma conditioned media allowing for 
more detailed characterization and experiments (Brech et al. submitted). 
 
1.1.12 Renal damage, inflammation and fibrosis  
The renal pathology caused by diabetes is considered a sterile inflammation, since 
there are usually no external pathogens involved [152]. It is thought to be caused by 
damage occurring to parenchymal cells and subsequent cell death and/or matrix 
remodeling with the release of damage-associated molecular patterns (DAMPs) which 
can be detected by DCs [137, 143-145, 147]. This damage promotes an influx of 
immune cells into the kidney, which then influence the surrounding parenchymal cells, 
a process that once a certain threshold is reached, can propagate itself. Coinciding 
with this increased infiltration of immune cells, fibrosis of the tubulointerstitium or 
glomerulosclerosis can be observed, a pathology in which aberrant deposition of extra 
cellular matrix (ECM) leads to destruction of the kidney fine structure and loss of 
function in the nephrons. 
Introduction   19
 
The mechanisms by which this deposition of ECM is induced are not fully understood, 
but the influx of immune cells may be a defining factor. Since not all kidneys undergo 
fibrotic processes, the composition of immune cells may be the deciding factor whether 
chronic damage or regeneration of damaged tissue occurs [153]. Similarly, while the 
changes occurring to signaling networks have been documented, separation of cause 
and effect has proven difficult, and it has not been shown whether alterations occur 
due to immune infiltrates or other sources secondary to the progressing disease 
process. 
1.2 Rationale of this study 
In broad terms, the aim of this study was to further our understanding of the alterations 
of signaling networks in the kidney in the context of progressing kidney damage and 
shifting composition of immune cell infiltrates. Specifically, to elucidate the potential 
effect of specific myeloid cell phenotypes on parenchymal cells. To this end, studies 
of signaling processes conferred by the 2+MoPh phenotype in comparison to classical 
imDC phenotype were conducted. 
According to our hypothesis, the composition and level of myeloid infiltrates during 
DN, in comparison to healthy kidneys, may represent an important factor for the 
developing disease and during its advancement to ESRD. Specifically, myeloid 
infiltrates may directly alter the homeostatic status of key regulatory pathways in 
kidney parenchyma through a paracrine or juxtracrine manner. The presence of 
specific myeloid cells (2+MoPh) will have a measureable effect on the homeostatic 
pathways in model kidney parenchymal cells linked to tissue repair and fibrosis. 
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1.3 Specific Aims of this study 
To better elucidate the pathophysiologic role of a defined myeloid cell population in 
DN, two strategies were employed: One based on transcriptomic analysis of diabetic 
nephropathy patient data, and one using a novel in-vitro system to study the direct 
effects on signaling exerted by the myeloid cells. 
 In the first stage, diabetic nephropathy (DN) samples taken from human 
biopsies were analyzed transcriptomically via cDNA microarray technology to 
screen for alterations in known homeostatic pathways, as compared to biopsy 
samples taken from normal kidney transplants just prior to implantation. DN 
microarray samples were then screened using a bioinformatics tool for the 
presence of CD209/DC-SIGN+, CD14+ 2+MoPh to assess whether their 
presence was increased relative to healthy kidneys. To this end, a bioinformatic 
deconvolution method, which can distinguish between myeloid signatures, and 
effectively calculate the amount of these cells in complex transcriptomic data 
was applied.  
 The second stage sought to validate the direct effects of 2+MoPh cells on the 
activation of relevant pathways in experimental parenchymal cells. To this end, 
a series of pathway specific reporter and expression vectors were designed and 
established for use as a platform for co-culture studies with immune cells. For 
this approach, HEK293 (renal) cells served as model parenchymal cells, and 
in-vitro-polarized immature DCs ‘imDCs’ and 2+MoPh were compared and 
contrasted for their ability to induce specific signaling pathways. The signaling 
pathways identified in the in-vitro screen were then analyzed in more detail in 
the transcriptomic DN database using diverse bioinformatics approaches.  
 The ultimate goal was to identify core homeostatic pathways and associated 
genes that correlate with the presence of 2+MoPh during progressive DN as 
potential therapeutic targets.
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2 Materials 
2.1 Cell culture 
2.1.1 Cells and cell lines 
Cell line Origin Medium 
Hek293, adherent human 
embryonic kidney cell line 
ATCC CRL-1573, 
Manassas, Virginia 
(USA) 
DMEM 
+ 10 % FBS 
+ 1% P/S 
Mono-Mac-6, acute monocytic 
leukemia cell line 
Leibnitz Institute DSMZ 
ACC124, 
Braunschweig, 
(Germany) 
RPMI 1604 
+ 10% FBS 
+ 1% NEAA 
+ 1% Sodium pyruvate 
+ 900µg/ml Insulin 
+ 1mM Oxalacetic acid 
+ 1 % P/S 
THP-1, acute monocytic 
leukemia cell line 
ATCC TIB-202, 
Manassas, Virginia 
(USA) 
RPMI 1604 
+ 10% FBS 
+ 1 % P/S 
2+MoPh, CD209 / DC-SIGN+, 
CD14+ monocytic phagocytes, 
generated from primary human 
peripheral blood mononuclear 
cells 
Prof. Dr. Nößner,    
Core facility für 
Immunanalytik 
Helmholtz Zentrum 
Munich (Germany) 
Assay medium: 
RPMI1640 
+ 10% FCS 
+ 1% NEAA 
+ 1% Sodium Pyruvate 
imDC, IL-4/GM-CSF immature 
DCs, generated from primary 
human peripheral blood 
mononuclear cells 
Prof. Dr. Nößner,    
Core facility für 
Immunanalytik 
Helmholtz Zentrum 
Munich (Germany) 
Assay medium: 
RPMI1640 
+ 10% FCS 
+ 1% NEAA 
+ 1% Sodium Pyruvate 
2.1.2 Culture media and additives 
Name Manufacturer 
RPMI 1604 Medium +GlutaMAX Gibco, Thermo Fisher Scientific, Waltham 
(USA) 
Dulbeccos Modified Eagle Medium 
(DMEM) + GlutaMAX  
Gibco, Thermo Fisher Scientific, Waltham 
(USA) 
Fetal bovine serum (FBS) Merck/Biochrom GmbH, Berlin (Germany) 
Penicillin/Streptomycin (P/S)  Merck/Biochrom GmbH, Berlin (Germany) 
Minimum Essential Medium Non 
Essential Amino Acids (NEAA) 
Gibco, Thermo Fisher Scientific, Waltham 
(USA) 
Sodium Pyruvate 100mM (100X) Gibco, Thermo Fisher Scientific, Waltham 
(USA) 
Human Insulin solution Merck/Sigma-Aldrich GmbH, Munich 
(Germany) 
Oxalacetic acid Merck/Sigma-Aldrich GmbH, Munich 
(Germany) 
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Name Manufacturer 
Hygromycin B Roche Diagnostics, Mannheim (Germany) 
Puromycin Invivogen, SanDiego (USA) 
Zeocin Invivogen, SanDiego (USA) 
Blasticidin Invivogen, SanDiego (USA) 
Geneticin / G418 Merck/Sigma-Aldrich GmbH, Munich 
(Germany) 
Doxycyclin Hyclate Santa Cruz Biotechnology, Dallas (USA) 
2.1.3 Cell culture chemicals 
Name Manufacturer 
Dulbeccos Phosphate Buffered Saline 
(DPBS) 
PAN-Biotech GmbH, Aidenbach 
(Germany) 
Trypsin/EDTA Solution (T/E)  PAN-Biotech GmbH, Aidenbach 
(Germany) 
Trypan Blue 0.4% Solution Lonza AG, Basel (Switzerland) 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt, (Germany)  
 
2.2 Microbiology 
2.2.1 Bacteria strains 
Strain Origin Genotype 
DH5α Addgene, Cambridge 
(USA) 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 
deoR nupG Φ80dlacZΔM15 Δ(lacZYA-
argF)U169, hsdR17(rK- mK+), λ– 
MACH-1 T1R Invitrogen, Thermo 
Fisher Scientific, 
Waltham (USA) 
F– Φ80lacZΔM15 ΔlacX74 hsdR(rK–, 
mK+) ΔrecA1398 endA1 tonA 
DB3.1 Invitrogen, Thermo 
Fisher Scientific, 
Waltham (USA) 
F– gyrA462 endA1 Δ(sr1-recA) mcrB mrr 
hsdS20(rB–, mB–) supE44 ara-14 galK2 
lacY1 proA2 rpsL20(SmR) xyl-5 λ– leu 
mtl1 
2.2.2 Bacterial media 
LB Medium per liter 
10g Bacto Tryptone BD, Franklin Lakes (USA) 
10g NaCl Roth, Karlsruhe (Germany) 
5g Yeast Extract BD, Franklin Lakes (USA) 
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LB Agar Plates per liter 
10g Bacto Tryptone BD, Franklin Lakes (USA) 
10g NaCl Roth, Karlsruhe (Germany) 
5g Bacto Yeast Extract BD, Franklin Lakes (USA) 
15g Bacto Agar BD, Franklin Lakes (USA) 
SOC Medium 
5g Yeast Extract BD, Franklin Lakes (USA) 
20g Bacto Tryptone BD, Franklin Lakes (USA) 
10mM NaCl Roth, Karlsruhe (Germany) 
2,5mM KCl Roth, Karlsruhe (Germany) 
10mM MgCl Roth, Karlsruhe (Germany) 
10mM MgSO4 Roth, Karlsruhe (Germany) 
20mM Glucose Roth, Karlsruhe (Germany) 
2.2.3 Microbiology solutions 
Ampicillin Stock solution 
50mg/ml Ampicillin Roth, Karlsruhe (Germany) 
70%  Ethanol Merck, Darmstadt, (Germany) 
30% H2O  
Kanamycin Stock solution 
10mg/ml Kanamycin Roth, Karlsruhe (Germany) 
100% H2O  
Chloramphenicol Stock solution 
34mg/ml Chloramphenicol Serva, Heidelberg (Germany) 
100% Ethanol Merck, Darmstadt, (Germany) 
Spectinomycin Stock solution 
100mg/ml Spectinomycin Merck/Sigma-Aldrich GmbH, Munich 
(Germany 
50%  DMSO Merck/Sigma-Aldrich GmbH, Munich 
(Germany 
50% H2O  
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Bacteria freezing medium, per liter 
132.3mM KH2PO4 Merck, Darmstadt, (Germany) 
21mM Sodium Citrate x 2H2O Merck/Sigma-Aldrich GmbH, Munich 
(Germany 
3.7mM MgSO4 x 7H2O  Roth, Karlsruhe (Germany) 
68.1mM (NH4)2SO4 Roth, Karlsruhe (Germany) 
459.3mM K2HPO4 x 3H2O Merck, Darmstadt, (Germany) 
35.2% 
(w/v) 
Glycerol Roth, Karlsruhe (Germany) 
 H2O  
CaCl2 Solution (for competent bacteria) 
60mM CaCl2 Merck, Darmstadt, (Germany) 
15% (w/v) Glycerol Roth, Karlsruhe (Germany) 
10mM PIPES, pH7 Merck, Darmstadt, (Germany) 
 H2O  
2.3 Buffers and solutions for molecular biology 
Name Manufacturer 
Restriction enzyme buffers                    
1.1, 2.1, 3.1, Cutsmart 
New England Biolabs, Ipswich (USA) 
T4 DNA Ligase buffer New England Biolabs, Ipswich (USA) 
Antarctic Phosphatase buffer New England Biolabs, Ipswich (USA) 
Phusion HF buffer New England Biolabs, Ipswich (USA) 
Phusion GC buffer New England Biolabs, Ipswich (USA) 
Thermo Pol Buffer New England Biolabs, Ipswich (USA) 
dATP 100mM Fermentas, Thermo Fisher Scientific, 
Waltham (USA) 
dGTP 100mM Fermentas, Thermo Fisher Scientific, 
Waltham (USA) 
dTTP100mM Fermentas, Thermo Fisher Scientific, 
Waltham (USA) 
dCTP100mM Fermentas, Thermo Fisher Scientific, 
Waltham (USA) 
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5X Tris Borate EDTA (TBE) Solution per litre 
54g Tris Roth, Karlsruhe (Germany) 
27,5g  Borate Merck, Darmstadt, (Germany) 
20ml 0.5ml EDTA Roth, Karlsruhe (Germany) 
 H2O  
6X Loading Buffer for Agarose Gels 
0.25% 
(w/v) 
Bromphenol Blue Roth, Karlsruhe (Germany) 
0.25% 
(w/v) 
Xylen-Cyanol FF Merck, Darmstadt, (Germany) 
30%  
(v/v) 
Glycerol Roth, Karlsruhe (Germany) 
 H2O  
Electroporation buffer 1M 
5mM KCl Merck, Darmstadt, (Germany) 
15mM MgCl Roth, Karlsruhe (Germany) 
120mM Na2HO4/NaH2PO4 pH7.2 Merck, Darmstadt, (Germany) 
50mM Mannitol Merck/Sigma-Aldrich GmbH, Munich 
(Germany 
2.4 Enzymes 
Name Manufacturer 
DNAse I Qiagen, Hilden, (Germany) 
RNase A Roche, Basel (Switzerland) 
T4 DNA Ligase New England Biolabs, Ipswich (USA) 
Taq DNA-Polymerase (5 U/µl) New England Biolabs, Ipswich (USA) 
Phusion DNA-Polymerase New England Biolabs, Ipswich (USA) 
Calf Intestinal Phosphatase New England Biolabs, Ipswich (USA) 
Antarctic Phosphatase New England Biolabs, Ipswich (USA) 
EcoRI Roche Diagnostics, Mannheim (Germany) 
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Restriction Enzymes, New England Biolabs, Ipswich (USA) 
AccI, AgeI-HF, AleI, ApaI, ApaLI, AvrII, BsrGI, BamHI, BglII, BstBI, ClaI, EcoRI, 
Eco53KI, EcoRV, FspI, KpnI-HF, MfeI, HindIII-HF, MluI, NcoI, NdeI, NheI, NotI-HF, 
PacI, PciI, PmlI, PvuI, SacII, SalI, SapI, ScaI-HF, SfiI, XbaI, XhoI, 
 
2.5 Size Standards for electrophoresis 
Name Manufacturer 
1 kb ladder Thermo Fisher Scientific, Waltham (USA) 
2 log ladder New England Biolabs, Ipswich (USA) 
2.6 Recombinant proteins and peptides 
Name Manufacturer 
rhWNT3A R&D/bio-techne, Minneapolis (USA) 
rhTGFB1 Acris/Origene, Herford (Germany) 
rhSHH Bio-Techne GmbH, Wiesbaden 
(Germany) 
rhEGF Bio-Techne GmbH, Wiesbaden 
(Germany) 
2.7 Small molecule agonists and antagonists 
Name Manufacturer/Source 
Rapamycin LC Laboratories, Woburn (USA) 
 
PD98059 Merck/Sigma-Aldrich GmbH, Munich 
(Germany) 
Wortmannin Merck KGaA, Darmstadt (Germany) 
GW3965 Gift from Prof. Gröne, Heidelberg 
(Germany) 
GANT61 Merck/Sigma-Aldrich GmbH, Munich 
(Germany) 
Lysophosphatidic Acid Enzo, Farmingdale (USA) 
 
 
 
Materials   27
 
2.4 Primers 
Primer name Sequence 
TCF7_FW_P5P2 GGGGACAACTTTGTATACAAAAGTTGTAAGCTCGGATCCA
CTAGTAAC 
TCF7_RV_P5P2 GGGGACCACTTTGTACAAGAAAGCTGGGTTGCCTCAGAA
GCCATAGAG 
Gli1_FW_P5P2 GGGGACAACTTTGTATACAAAAGTTGTACCTCTGAGACGC
CATGTTC 
Gli1_RV_P5P2 GGGGACCACTTTGTACAAGAAAGCTGGGTTCCCTTAGGAA
ATGCGATCTG 
SMAD4_FW_P5
P2 
GGGGACAACTTTGTATACAAAAGTTGTATTAGTGAACCGT
CAGATCTC 
SMAD4_RV_P5
P2 
GGGGACCACTTTGTACAAGAAAGCTGGGTTGTGGTTTGTC
CAAACTCATC 
SMAD3_FW_P5
P2 
GGGGACAACTTTGTATACAAAAGTTGTACAGAGCTCGTTT
AGTGAACC 
SMAD3_RV_P5
P2 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCACTGGAGT
GGCAACTTC 
YapIS127A_FW
_P5P2 
GGGGACAACTTTGTATACAAAAGTTGTACAGTCGACACCA
TGGACTAC 
YapIS127A_RV_
P5P2 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCTGCCTGAG
GGCTCTATAAC 
CMV_Pro_FW GGGGACAAGTTTGTACAAAAAAGCAGGCTTACGATGTACG
GGCCAGATA 
CMV_Pro_RV GGGGACAACTTTTGTATACAAAGTTGTAGCAGTGGGTTCT
CTAGTTAGC 
Yap1WT_FW_P
5P2 
GGGGACAACTTTGTATACAAAAGTTGTAAGCTCGGATCCA
CTAGTAAC 
Yap1WT_RV_P5
P2 
GGGGACCACTTTGTACAAGAAAGCTGGGTTAGCGAGCTCT
AGCATTTAGG 
CMVTO-fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTAAGGCCCTTT
CACTCATTAG 
CMVTO-rv GGGGACAACTTTTGTATACAAAGTTGTCCGGTGTCTTCTAT
GGAG 
TAZ_FW_P5P2 GGGGACAACTTTGTATACAAAAGTTGTAGTGAACCGTCAG
AATTGATC 
TAZ_RV_P5P2 GGGGACCACTTTGTACAAGAAAGCTGGGTTCACTGGAGT
GGCAACTTC 
NR1H2_fw_GW GGGGACAACTTTGTATACAAAAGTTGTAATGTCCTCTCCTA
CCACGAGTTC 
NR1H2_rv_Stop
_GW 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTCACTCGTGG
ACGTCCCAGAT 
NR1H3_fw_GW GGGGACAACTTTGTATACAAAAGTTGTAATGCCCCACTCT
GCTGGG 
NR1H3_rv_STO
P_GW 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTCATTCGTGC
ACATCCCAGATCTC 
Gaussia_P5P2_
FW 
GGGGACAACTTTGTATACAAAAGTTGTAATCCAGCCACCA
TGGGAGTC 
Gaussia_P5P2_r
v 
GGGGACCACTTTGTACAAGAAAGCTGGGTTGGCCGCTTA
GTCACCACC 
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2.5 Plasmids and vectors 
Name Manufacturer 
pcDNA6.2/V5-PL-DEST Thermo Fisher Scientific, Waltham (USA) 
pcDNA6/TR Thermo Fisher Scientific, Waltham (USA) 
pT-Rex-DEST30 Thermo Fisher Scientific, Waltham (USA) 
pHOOK2 Thermo Fisher Scientific, Waltham (USA) 
pGL3-Promoter Promega, Fitchburg (USA) 
pN3 Bar-Gluc Gift from Peter Neth, LMU Munich 
pBlue-loxP-PGK-gb2-hyg-loxP BCCM/LMBP #6665, Zwijnaarde 
(Belgium) 
NR1H2 cDNA clone HsCD00438678, DNASU, Tempe (USA) 
NR1H2 cDNA clone HsCD00004021, DNASU, Tempe (USA) 
NR1H3 cDNA clone HsCD00442548, DNASU, Tempe (USA) 
GLI K12 #16419, Addgene, Cambridge (USA) 
WWP-Luc #16451, Addgene, Cambridge (USA) 
pCEP4 Smad4 #16483, Addgene, Cambridge (USA) 
SBE4-Luc #16495, Addgene, Cambridge (USA) 
pHR TCF4 #16514, Addgene, Cambridge (USA) 
pcDNA Flag Yap1 #18881, Addgene, Cambridge (USA) 
Luciferase-pcDNA3 #18964, Addgene, Cambridge (USA) 
3XFlag pCMV5-TOPO TAZ WT #24809, Addgene, Cambridge (USA) 
3XFlag pCMV5-TOPO TAZ (S89A) #24815, Addgene, Cambridge (USA) 
8xGTIIC-luciferase #34615, Addgene, Cambridge (USA) 
pcDNA3-HA-TCF1 #40620, Addgene, Cambridge (USA) 
pENTR-3xFLAG-YAP1-S127A #42239, Addgene, Cambridge (USA) 
SMAD3 WT expression vector Gift from Prof. Groene, DKFZ, Heidelberg 
(Germany) 
SMAD3 constitutively active mutant 
expression vector 
Gift from Prof. Groene, DKFZ, Heidelberg 
(Germany) 
 
Materials   29
 
2.6 Kits 
Kit Manufacturer 
InnuPREP Plasmid Mini Prep Analytik Jena AG, Jena (Germany) 
InnuPREP Plasmid Midi Prep Analytik Jena AG, Jena (Germany) 
ZymoPURE Plasmid Maxiprep Kit Zymo Research Corp, Irvine (USA) 
Exo-Spin Exosome Purification Kit Cell Guidance Systems Ltd, Cambridge 
(UK) 
MultiSite Gateway Pro Plus Thermo Fisher Scientific, Waltham 
(USA) 
Gateway LR Clonase II Plus Thermo Fisher Scientific, Waltham 
(USA) 
Gateway BP Clonase II Thermo Fisher Scientific, Waltham 
(USA) 
Purelink RNA Mini Kit Thermo Fisher Scientific, Waltham 
(USA) 
BioLux Gaussia Luciferase Assay Kit New England Biolabs, Ipswich (USA) 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific, Waltham 
(USA) 
2.7 Other laboratory equipment 
Device Manufacturer 
vapo.protect thermocycler Eppendorf, Hamburg (Germany) 
Thermomixer comfort Eppendorf, Hamburg (Germany) 
Megafuge 1.0R Thermo Fisher Scientific, Waltham 
(USA) 
Biofuge pico Thermo Fisher Scientific, Waltham 
(USA) 
Rotanta 460R Hettich, Tuttlingen (Germany) 
L70 Ultracentrifuge Beckman, Brea (USA) 
Lumat LB 9507 Berthold, Bad Wildbad (Germany) 
GENios plate reader Tecan, Männedorf (Switzerland) 
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2.8 Chemicals 
Name Manufacturer 
Agarose ultrapure Thermo Fisher Scientific, Waltham 
(USA) 
Aqua ad injectabilia Braun, Melsungen (Germany) 
β-Mercaptoethanol Roth, Karlsruhe (Germany) 
Bromphenolblue Sigma Aldrich, Taufkirchen (Germany) 
Calciumchloride (CaCl2) Merck, Darmstadt (Germany) 
Ethylenediaminetetraacetic acid (EDTA) Merck, Darmstadt (Germany) 
Acetic acid Merck, Darmstadt (Germany) 
Ethanol, absolute Merck, Darmstadt (Germany) 
Ethidiumbromid 1% Merck, Darmstadt (Germany) 
Isopropanol Merck, Darmstadt (Germany) 
Methanol, absolute Merck, Darmstadt (Germany) 
Magnesiumchloride Merck, Darmstadt (Germany) 
MOPS (3-(N-
morpholino)propanesulfonic acid) 
Roth, Karlsruhe (Germany) 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
Sigma Aldrich, Taufkirchen (Germany) 
Sodium Acetate Merck, Darmstadt (Germany) 
Sodium chloride Sigma Aldrich, Taufkirchen (Germany) 
tris(hydroxymethyl)aminomethane (Tris) Merck, Darmstadt (Germany) 
Hydrochloric acid Roth, Karlsruhe (Germany) 
2.8 Disposables and other materials 
Name Manufacturer 
Cell culture plates TPP, Trasadingen (Switzerland) 
Cell culture flasks TPP, Trasadingen (Switzerland) 
Cell scrapers TPP, Trasadingen (Switzerland) 
Conical centrifuge tubes 15ml/50ml BD Biosciences, Franklin Lakes, USA 
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2.9 Antibodies for flow cytometry 
Specificity  Label Species
/  
Clone Manufacturer  Dilution  Staining  
CD14  PB  Mouse 
IgG2a, κ  
M5E2  BD  1:25 Surface 
CD14  PerCP- 
Cy5.5 
Mouse 
IgG1, κ  
61D3  eBioscience  1:10/1:5+  Surface 
CD163 PerCP
Cy5.5 
Mouse 
IgG1, κ 
GHI/61 Biolegend 1:10 Surface 
CD209  APC  Mouse 
IgG2a, κ  
DCN46  BD  1:10 Surface 
CD209  PE  Mouse 
IgG2b, κ  
DCN46  BD  1:10/1:4+  Surface 
CD40  FITC  Mouse 
IgG1, κ  
5C3  BD  1:10 Surface  
CD64  FITC  Mouse 
IgG1, κ  
22 Beckman 
Coulter  
1:10 Surface  
CD80 PE Mouse 
IgG1, κ 
L307.4 BD 1:16.6 Surface 
HLA-DR/ 
MHC-II  
FITC  Mouse 
IgG2a, κ  
L243  BD  1:25 Surface 
Isotype  -  Mouse 
IgG1, κ  
MOPC21  BD  1:500 intracellular  
Isotype  A700  Mouse 
IgG1, κ  
MOPC21  BD  *  Surface 
Isotype  APC  Mouse 
IgG1, κ  
11711 R&D Systems  *  Surface 
Isotype  APC  Mouse 
IgG2a, κ  
HOPC 
1F/12  
Jackson  *  Surface 
Isotype  FITC  Mouse 
IgG1, κ  
MOPC21  BD  *  Surface 
Isotype  FITC  Mouse 
IgG2a, κ  
G155-178  BD  *  Surface 
Isotype  FITC  Mouse 
IgM  
IS5-20C4  Miltenyi Biotec  *  Surface 
Isotype  PE  Mouse 
IgG1  
MOPC21  BD  *  Surface 
Isotype  PE  Mouse 
IgG2b, κ  
MPC-11  Biolegend  *  Surface 
Isotype  PE  Ratte 
IgG2a, κ  
R35-95  BD  *  Surface 
Isotype  PE-
Cy7  
Mouse 
IgG1, κ  
MOPC21  BD  *  Surface 
MerTK  APC  Mouse 
IgG1, κ  
125518 R&D Systems  1:5 Surface 
MSR1 APC Mouse 
IgG2B 
351615 R&D Systems 1:5 Surface 
VSIG4 - Rabbit Polyclonal abcam 1:50 Surface 
* adjusted to antibody used 
 
Materials   32
 
2.10 Software 
Software Manufacturer Usage 
Prism Graphpad Software, La Jolla 
(USA) 
Statistical tests and 
Graphing 
Canvas 12 ACD Software, Victoria 
(Canada) 
Diagrams and 
Illustrations 
R including the 
bioconductor package 
Open source projects, found 
at their respective websites 
https://www.bioconductor.org/ 
and https://www.r-project.org/ 
Microarray analyses 
including deconvolution 
analyses 
Genomatix Software 
suite 
Genomatix GmbH, Munich, 
(Gemany) 
Pathway mapping 
Progenesis QI software 
for proteomics 2.0 
Nonlinear Dynamics, 
Newcastle upon Tyne (UK) 
Proteomics 
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3 Methods 
3.1 Microarray analysis 
3.1.1 Samples 
A total of 17 DN samples (calculated eGFR MDRD mean of 44, median of 46 and 
standard deviation of 25) and 30 living donor (LD) controls were obtained from the 
European Renal cDNA Bank (ERCB) and microdissected for microarray analysis 
[154]. To this end, total RNA from the tubulointerstitial compartments was isolated, 
reverse transcribed, linearly amplified, and hybridized on Affymetrix microarrays in 
collaboration with Prof. M. Kretzler, University of Michigan, Ann Arbor [35, 36, 155, 
156]. 
3.1.2 Robust multichip average (RMA) analysis, batch correction and 
filtering 
In initial analyses of microarray samples, all data was normalized using the RMA 
Algorithm [157] and annotated at EntrezGene level using current Custom CDF Files 
from Brainarray (http://brainarray.mbni.med.umich.edu/Brainarray/) [158]. All data was 
batch corrected [159] and log transformed using the GenePattern pipeline [160]. 
Filtering for expressed genes was done by applying a cutoff of the median of the non-
human Affymetrix control probe sets plus two times their SD. 
3.1.3 GeneRanker analysis 
Processed gene lists were assigned to biologic processes using the GeneRanker 
software, which is part of the Genomatix software suite (Munich, Germany). Analysis 
was carried out using default parameters and using the literature mining based 
pathway database [161]. 
3.1.3 Deconvolution analysis to selectively identify 2+MoPh cells in 
complex data 
To estimate the proportion of 2+MoPh cells in mixed samples (i.e. the 2+MoPh score), 
the procedure suggested by Abbas [162] was followed. First, 61 2+MoPh marker genes 
were identified using pamr (nearest shrunken centroid method) on a training set 
comprising 6 and 182 samples taken from 2+MoPh cells, and various control cell types, 
respectively. Then the mean expression values for each marker gene in all 2+MoPh 
samples were calculated. The coefficient of a linear model of marker gene expression 
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value in each mixed sample based on the corresponding means was obtained from 
the ercDC pool, that then served as an estimate of the fraction of 2+MoPh, the 
deconvolution score of the mixed sample. This was done in collaboration with Prof. 
Dr. E. Nößner and Dr. D. Brech, Helmholtz Zentrum München and Dr. Tobias Straub, 
LMU Core Facility, Bioinformatics Biomedizinisches Centrum. 
3.1.4 Weighted Gene Correlation Network Analysis (WGCNA) 
A signed coexpression network was generated using the Weighted Gene Correlation 
Network Analysis (WGCNA) package as implemented in the R statistical software with 
the default parameters and a minimum module size set to 30 [163]. 
3.2 Cell culture 
3.2.1 General cell culture  
The culture of human cells and cell lines was performed in a laminar flow hood to 
prevent contamination. All reagents were pre-warmed to 37°C in a water bath prior to 
use. All cells were incubated at 37°C and 5% CO2. 
For subculturing, adherent cells were washed with PBS and subsequently detached 
using Trypsin-EDTA solution at room temperature. The reaction was stopped by 
adding double the volume of medium containing 10% FCS (or more if the medium 
contained less FCS) and the cells were pelleted by centrifugation for 3 min at 220 x g 
(rt). Subsequently, the cell pellet was resuspended in fresh medium and a fraction was 
seeded into the respective cell culture vessel.  
Suspension cells were resuspended prior to subculturing and subsequently a fraction 
of the culture medium according to the desired split factor was transferred into a new 
cell culture flask, which was then filled up with fresh medium to the desired end 
volume. 
3.2.2 Freezing and thawing of cells 
All cells were frozen in 20% of their respective culture medium + 60% FCS + 10% 
DMSO in sealable cryotubes. The tubes were cooled to -80°C over a 24 h period in an 
isopropanol container prior to transferring them into a liquid nitrogen container. For 
thawing, the frozen cell suspensions were rapidly thawed in a 37°C water bath and 
immediately transferred into a cell culture vessel filled with prewarmed medium. The 
medium was replaced after 18 h to remove DMSO. 
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3.2.3 Counting cells 
Cell counts were determined using a Neubauer chamber. The cover slip was attached 
to the chamber so that “Newton’s rings” were visible. This is used as a means of 
determining optimal distance between counting chamber and cover slip, and is 
important as the chamber is calibrated to the resulting volume. One part of the cell 
suspension was mixed with Trypan Blue solution in a 1:3-1:5 ratio, depending on cell 
line and density, staining dead cells blue. 10 μl of this mixture were immediately 
pipetted into the chamber. Only living cells were counted in all the quadrants of the 
chamber. The number of cells per ml suspension could then be calculated. The count 
(x) multiplied by the dilution and divided by the quadrants counted gave a number of 
x*104cells/ml cell suspension. 
3.3 Molecular biology 
3.3.1 Freezing and thawing of bacteria 
For long-term storage of E. coli strains, 900 μl of an overnight culture was mixed with 
100 μl freezing solution for bacteria (10x) and frozen at -80°C. To establish cultures 
from frozen cells, a small amount of frozen bacteria was streaked onto an appropriate 
agar plate and incubated at 37°C overnight. Subsequently, a liquid culture in LB 
Medium was established from a single colony on that plate. 
3.3.2 Preparation of agar plates 
For the preparation of microbiological agar plates, 1X LB medium was prepared with 
an added 1.5% of Agar and autoclaved. Upon reaching a temperature of 60°C, when 
required, appropriate antibiotics were added (Ampicillin: 100 μg/ml final concentration; 
Kanamycin: 50 μg/ml final concentration; Chloramphenicol: 25µg/ml final 
concentration) and the solution was cast in Standard 10cm Petri dishes. Plates were 
stored in plastic bags at 4°C. 
3.3.3 Restriction digestion of DNA 
DNA was cut using restriction enzymes. To cut 1 μg DNA, 1 unit of restriction enzyme 
was used per hour. In cases when large amounts of DNA had to be cut, the amount 
of enzyme and/or the incubation time was increased accordingly. To minimize 
unspecific cutting due to high Glycerol content, no more than 10% of Enzyme final 
volume was used. All digestions were performed in a buffer suitable for the respective 
Methods   36
 
enzyme(s) (diluted to 1x) at the temperature suggested by the manufacturer (37-
65°C). 
3.3.4 Separation of DNA fragments by electrophoresis 
To separate DNA fragments for analytical or preparative purposes, agarose gel 
electrophoresis was used. The concentration of agarose was chosen according to the 
expected fragment sizes and varied between 0.6% and 3% agarose. Gel solutions 
were prepared in 0.5x TBE buffer with added ethidium bromide and heated in a 
microwave oven to dissolve the agarose and cast in horizontal gel chambers. 
For the electrophoresis, all samples and a size standard [2 log ladder, New England 
Biolabs, Ipswich (USA)] were mixed with loading buffer for agarose gels (6x) to yield 
a 1x final concentration of loading buffer and loaded into the wells. Using 0.5x TBE 
buffer at 170 V, electrophoresis was performed and the gels were subsequently 
photographed under UV light for documentation. In the case of preparative gels, the 
respective bands were cut out of the gel under UV light and DNA was extracted from 
the gel fragments using a commercial kit (Qiagen Gel Extraction Kit) according to the 
manufacturer´s instructions. 
3.3.5 Determination of DNA and RNA concentrations 
The concentrations of DNA and RNA in solutions were determined using a Nanodrop 
ND-1000 spectrophotometer [Thermo Fisher, Waltham (USA)]. All determinations 
were performed according to the manufacturer´s instructions using the appropriate 
buffer as control (Water, TE, Elution Buffer). 
3.3.6 Dephosphorylation of DNA ends 
In case cleavage and separation of plasmids led to compatible overhangs, to prevent 
re-ligation of linearized vectors, their 5´ DNA ends were dephosphorylated. To this 
end, 5 units of Antarctic phosphatase per pmol 5´ ends was added to the sample and 
the mixture was incubated at 37°C for 1 h. The reaction was stopped by heat 
inactivation at 65°C for 15 min. Prior to the next cloning step, the dephosphorylated 
DNA was purified using a commercially available kit (Qiagen PCR Cleanup Kit) 
according to the manufacturer´s instructions. 
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3.3.7 Assembly of short synthetic DNA elements for reporter constructs 
To synthetically generate short (up to 200 base pairs) inserts for reporter vectors, 
single stranded Oligos were ordered [Thermo Fisher, Waltham (USA) or Biomers, Ulm 
(Germany)]. These oligos were designed such that the two strands would be 
compatible for annealing by designing them as reverse complements of each other. In 
addition, the oligos were designed with overhangs compatible to the ones created by 
restriction enzymes, allowing for direct ligation into cleaved vector backbones. 
3.3.8 Ligation of DNA fragments 
For ligation of vector backbone and insert DNA, separate reactions were prepared 
using an insert:vector molar ratio of 3:1 and 10:1, respectively. A third reaction 
containing only vector DNA served as negative control. All reactions were performed 
in a total volume of 20 μl containing 400 U (1 μl) T4 DNA ligase and 2 μl 10x T4 DNA 
ligase buffer overnight at room temperature. 
3.3.9 Preparation and transformation of competent E. coli MACH-1 
Chemically competent E. coli were prepared in-house as a vessel for propagation and 
selection of cloned plasmids. To this end, 4 ml of an overnight liquid culture of E. coli 
MACH-1 in LB medium was diluted 1:100 into fresh LB medium and incubated at 37°C 
and 250 rpm and left to grow till reaching an OD600nm of 0.375. Subsequently, the 
suspended bacteria were aliquoted into 50 ml aliquots, incubated on ice for 5 min and 
afterwards centrifuged for 10 min at 1600 x g (4°C). After discarding the supernatant, 
each aliquot of bacteria was resuspended in 10 ml ice-cold CaCl2 solution and the 
centrifugation step repeated. After that, the supernatant was discarded again, each 
aliquot of bacteria was resuspended in 10 ml fresh ice cold CaCl2 solution and stored 
on ice for 30 min. Following another centrifugation as detailed above, the pelleted 
bacteria were resuspended in 2 ml CaCl2 solution and frozen at -80°C in 50µl Aliquots. 
For transformation of competent E. coli MACH-1 bacteria using ligation reactions, 
varying amounts of DNA were used, depending on the cloning method, but 
corresponding to 10-100 ng DNA. The frozen bacteria were rapidly thawed and 50 μl 
of suspension were added to the DNA. Following an initial incubation on ice for 10 min, 
the mixture was heated to 42°C for 45 sec and immediately cooled on ice again. The 
transformed bacteria were suspended in 250 µl SOC medium and incubated for 60 
min at 37°C and 400 rpm. Subsequently, the suspension was plated onto agar plates 
containing the appropriate antibiotic for selection of successfully transformed colonies 
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and incubated over night at 37°C. The next day, single colonies were picked and 
transferred into liquid cultures in order to prepare plasmid DNA. 
3.3.10 Isolation and analysis of plasmid DNA from transformed bacteria 
Plasmid DNA was isolated from transformed bacteria using commercially available kits 
(Innuprep Plasmid Mini kit for liquid cultures up to 1.5 ml; ZymoPURE Plasmid Maxi 
kit for liquid cultures up to 150 ml) according to the manufacturers´ instructions. 
Following plasmid DNA isolation, analytical restriction digestions were performed 
using appropriate restriction enzymes (see 3.3.3) and the resulting fragments were 
analyzed by gel electrophoresis (see 3.3.4). 
3.3.11 Polymerase chain reaction (PCR) 
For the cloning steps presented here, a large number of Polymerase chain reactions, 
some with large products, were carried out using a Polymerase with a 3’->5’ 
exonuclease function [Phusion High-Fidelity DNA Polymerase, New England Biolabs, 
Ipswich (USA)] to ensure a very low level of mismatches. All PCR products were 
evaluated and purified by agarose gel electrophoresis to remove primers and potential 
falsely primed products.  
The general PCR protocol used was: 
Step Temperature Time Number of cycles 
Initial denaturation 98°C 5 min 1 
Denaturation 98°C 30s  
Annealing Depends on Primers 30s 30 
Extension 72°C 30s / kbase  
Final extension 72°C 10 min 1 
 
3.3.12 Sequencing of DNA 
DNA sequencing, using the Sanger method of chain-terminating dideoxynucleotides, 
was performed by GATC Biotech, Konstanz. Since a large number of constructs were 
sequenced, there is a large number of individual primers that were used for the 
sequencing of PCR templates. The most commonly used however were:  
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Vector Primer Name Sequence 
pSBTET.Reporter 
Variants 
Enhancer_FW CATGTCTGGTCGAATCCATC 
pSBTET.Reporter 
Variants 
Enhancer_RV CGATGCAGATCAGGGCAAAC 
pENTR221 Variants M13 FW TGTAAAACGACGGCCAGT 
pENTR221 Variants M13 RV CAGGAAACAGCTATGACC 
pSBDEST Variants T7 TAATACGACTCACTATAGGG 
pSBDEST Variants pSBDEST_RV GGTTCCTTCCGGTATTGTC 
pSBDEST Variants V5_RV ACCGAGGAGAGGGTTAGGGAT 
 
3.4 Cloning Strategies 
3.4.1 Adaptation of the pGL3-Promoter vector for Gaussia Luciferase 
 
 
Figure 8. Cloning scheme for the 
generation of the reporter vectors, Step 1. 
In the first cloning step, the minimal promoter 
element and the luciferase were to be 
replaced in the commercially available pGL3-
Promoter vector. For details refer to 3.4.1 
 
 
 
The first step in the generation of the reporter vectors (see 3.4.2) was modification of 
the commercially available pGL3-Promoter Vector [Promega, Fitchburg (USA)]. The 
original pGL3-Control Promoter reporter vector used Firefly Luciferase optimized for 
low background activity, and a minimal Promoter based on the Simian virus 40 (SV40). 
To reduce background activity, this minimal promoter had already been reduced to the 
core 197 bp.  
In a first cloning step, the intracellular Firefly luciferase was replaced with the codon 
optimized version of the secreted luciferase taken from Gaussia princeps, obtained 
pGL3-Promoter
5010 bp
CMV Min
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via PCR from the WNT specific reporter vector pN3-BAR-Gluc. After a few preliminary 
experiments, the background activity level with this SV40 minimal promoter was 
deemed too high, and the SV40 minimal promoter was replaced by a 35 bp long stretch 
of the cytomegalovirus promoter (CMV Min) which significantly reduced background 
activity. The resulting vector was named pGL3-CMVMin-GLuc. 
3.4.2 Modifications of pCDNA6/TR for Sleeping Beauty compatibility 
 
 
 
Figure 9. Cloning scheme for the 
generation of the reporter vectors, Step 2. 
In the second cloning step, Sleeping Beauty 
transposase inverted terminal repeats were 
integrated into the pCDNA6/TR vector. For 
details refer to 3.4.2 
 
 
As a basis for the generation of the complex pSBTET.Reporter vectors, the 
commercially available pcDNA6/TR [Thermo Fisher, Waltham (USA)] vector was 
chosen. This vector was deemed suitable as it already contained an optimized and 
humanized expression cassette for the TET-Repressor protein from the Tn10 
transposon in enteric bacteria [164]. In these bacteria, the TET-repressor protein 
serves to tightly regulate expression of the resistance gene for tetracycline. This 
regulatory capacity has been adapted for use in inducible eukaryotic systems to allow 
for rapid and highly sensitive de-repression of Tet-Operator controlled promoters. To 
further optimize the potential for the generation of stable transfectants, the principle 
expression cassettes for both the eukaryotic selective marker Blasticidin and the 
expression cassette for the TET-Repressor protein were flanked with recognition sites 
(inverted and direct repeats) for the Sleeping Beauty (SB) transposase [165-167]. This 
allowed efficient introduction of transfected genetic cargo into the host cell genome 
when co-transfected with an expression vector for the SB transposase, thus 
generating stable transfectants. The resulting vector was named pCDNA6TR/ITR. 
pcDNA6/TR
7239 bp
pC
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3.4.3 Generation of pSBTET.Reporter by fusion of the modified pGL3 
Promoter and pCDNA6/TR-ITR 
 
 
Figure 10. Cloning scheme for the 
generation of the reporter vectors, 
Step 3. In the final cloning step, a 
fusion of the generated pGL3-
Promoter based reporter element and 
the Sleeping Beauty-adapted 
backbone was generated. For details 
refer to 3.4.3 
 
 
 
The final step for the generation of the pSBTET.Reporter plasmids was fusion of the 
aforementioned (3.4.1 and 3.4.2) pGL3-CMVMin-GLuc and pCDNA6TR/ITR vectors 
resulting in a vector that was Sleeping Beauty transposable, expressing the TET-
Repressor and carrying a Gaussia luciferase based reporter cassette, with expression 
of the Blasticidin selection marker to screen for stable transfectants. The plasmids 
were cut and ligated together resulting in the pSBTET.reporter. [168] 
3.4.4 Generation and insertion of transcription factor specific reporter 
elements 
To generate transcription factor specific reporter elements to act as pathway reporters, 
single stranded oligomers were assembled as in 3.3.7 with compatible XhoI, PstI 
overhangs and ligated into the cleaved pSBTET.reporter vector backbone as detailed 
in 3.3.8. 
  
Gaussia Luc CMVMin
SV40Min
RE
pcDNA6/TR
8375 bp
pSBTET.Reporter
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Sequences of reporter elements: 
 
AP-1 Binding element (6x multimer): TGACTCA, Linker Sequence: TCAAGCA 
(https://www.addgene.org/40342/ [169]) 
GLI binding element (8x multimer): GACCACCCAC 
(http://www.sabiosciences.com/reporter_assay_product/HTML/CCS-6030L.html) 
TEAD binding element (8x multimer): ACATTCC, varying linker sequences 
(https://www.addgene.org/34615/, [170]) 
LXR binding element (3x multimer): TGACCAGCAGTAACC 
(http://www.sabiosciences.com/reporter_assay_product/HTML/CCS-0041L.html) 
TCF/LEF binding element (12x multimer): ATCAAAG, 
[171] 
SMAD binding element (5x multimer): AGCCAGACAGT 
(http://www.sabiosciences.com/reporter_assay_product/HTML/CCS-017L.html) 
 
 
 
 
Figure 11. Accessible Cloning Sites in pSBTET.Reporter vectors. 
Magnified region of pSBTET.SMAD serves as illustration of restriction sites available 
to modify these vectors. The minimal promoter is replaced by digests with XhoI and 
BsrGI, while the transcription factor responsive elements are replaced by PstI and 
XhoI digests. This allows for easy adaptation of the reporter vectors to other pathways, 
or even replacement of both RE and Minimal Promoter with a full human promoter by 
digest with PstI and BsrGI. 
 
hGaussia LucCMVMinSMAD RE
Responsive Element and Minimal Promoter Cloning Map
PstI XhoI BsrGI
200 400 600
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3.4.5 Generation of pSBDEST by Fusion of pCDNA6/TR-ITR and 
pcDNA6.2 V5 PL-DEST 
 
Figure 12. Cloning scheme for the 
generation of the Destination vectors. 
Similar to the reporter vectors, MultiSite 
Gateway compatible destination vectors 
were adapted to Sleeping Beauty 
transposase-ready vector by the addition 
of ITRs, in addition, variants with other 
selective markers were generated to 
allow for co-transfection with the 
Blasticidin selection carrying reporter 
vectors, or multiple destination vectors. 
For details see 3.4.5 
 
 
 
To generate a highly flexible cloning system, also compatible with the Sleeping Beauty 
transposon strategy, a promoterless commercial multi-site Gateway cloning vector 
was modified. Multi-Site Gateway cloning allows the rapid generation of complex 
transgenes via the recombination of up to four fragments into a single Destination 
vector in a defined orientation and order. Since the backbone region of 
pCDNA6TR/ITR had high sequence identity to pCDNA6.2/V5-PL-DEST, this vector 
was selected and used as donor for the Gateway cassette. Both pCDNA6TR/ITR and 
pCDNA6.2/V5-PL-DEST were cut using BglII. This digest cleaved out the TET-
Repressor expression cassette from pCDNA6TR/ITR, but retained the backbone, 
including the Sleeping Beauty compatible ITRs/DRs. The same enzymatic digest of 
pCDNA6.2/V5-PL-DEST released the Gateway cloning acceptor cassette. After 
agarose gel purification, the resultant fragments were ligated, resulting in pSBDEST.B. 
Additionally, the system was made more flexible by replacing the Blasticidin selection 
marker with a selection of either Hygromycin, G418/Geneticin or Zeocin, resulting in 
pSBDEST.H, pSBDEST.G and PSBDEST.Z [168]. This allows the parallel selection 
of multiple plasmids in the same cell. 
pSBDEST.B/H/G/Z
7800 bp
Hygromycin
G418
Zeocin
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3.4.6 Generation of Entry Clones 
 
Figure 13. Cloning of compatible 
Entry Clones. For the generation of 
compatible Multi-Site Gateway Entry 
clones, PCR products with attP 
overhangs were generated for 
sequences of interest. This was 
accomplished by using primers 
consisting of a homologous region 
and Gateway-cloning compatible attP 
overhangs. In a so-called “BP-
reaction” the overhangs are 
recombined into a donor vector. For 
details see 3.4.6 
 
 
 
 
Entry clones serve as building blocks for MultiSite Gateway reactions. To generate an 
entry clone, a template was PCR amplified using specific primers carrying long, vector 
and reaction specific overhangs which allowed for recombination reactions. All PCR 
reactions were carried out as specified in 3.3.11.  
Entry clones for various promoters and coding DNA sequences (CDS) were generated 
in BP reactions according to the Multi-Site Gateway Manual, using the donor vectors 
supplied in the MultiSite Gateway Pro Plus Kit [Thermo Fisher, Waltham (USA)]. PCR 
Templates for these constructs were purchased from either Addgene (Cambridge, 
USA) or DNASU (Tempe, USA), for a list see Section 2.5. 
To verify the all Entry clones, each individual clone was screened through restriction 
digests and gel electrophoresis; positive clones were then verified by partial 
sequencing. 
 
Template
CMV/TO
Primers with attP Overhangs
CMV/TOattB1 attB5r
PCR
Gateway BP reaction+pDONR221
Vector
pENTR221-CMV/TO.Pro
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3.4.7 Generation of Expression vectors 
To generate expression constructs, two-fragment Multi-Site Gateway reactions were 
carried out using an Entry clone for a desired promoter fragment, and a second Entry 
clone carrying the CDS for the gene of interest (see Figures 14 and 15). The only 
Gateway-Destination vectors used were pSBDEST variants. All MultiSite Gateway LR 
reactions were carried out according to the Multi-Site Gateway Manual and using 
Gateway LR Clonase II Plus [Thermo Fisher Scientific, Waltham (USA)]. To verify all 
Expression clones, each one was screened by restriction digests and gel 
electrophoresis and positive clones then verified by sequencing. 
Figure 14 
Overview of multi-
site Gateway 
cloning.  
Gateway cloning is 
a cloning strategy 
based on Integrase 
(Int) from Phage λ 
and Integration host 
factors (IHF a and 
IHF b) from E. coli in 
tandem with specific 
overhangs required 
for recombination. A 
Using specific 
primer over-hangs, 
PCR products are 
generated with 
flanking Gateway 
cloning compatible 
recombination 
sequences (attB 
sites). B-C via in-
vitro BP reactions 
with compatible 
donor vectors, Entry 
clones are generated, with resulting attL recombination sites. D In an LR reaction 
(another in-vitro reaction), recombination between fitting LR overhangs leads to 
directed and ordered insertion of multiple entry clones into a destination vector. E The 
resulting expression vector carries the inserts in sequence. By recombination attB 
sites have been generated. Both BP and LR reactions are strictly selected by 2 
mechanisms: Positive selection via Kanamycin/Ampicillin selection in the donor/entry 
vector backbone and negative selection by ccdB. ccdB is a suicide gene in E.coli and 
every donor or destination vector carries it. If it isn’t replaced by recombination, 
transfected E.coli die. So only E. coli which are Kanamycin/Ampicillin resistant from 
recombined vectors survive.  
attB1 attB5
A) PCR Product
with att Overhangs
attB5r attB2
attP1 attP5 attP5r attP2
pDONR Vector
attL1 attR5 attL5 attL2
C) Entry Clones
attR1 attR2
attL1 attR5
attL5 attL2
Destination vector
attB1
attB5
attB2
E) Expression vector
B) BP Reaction
D) MultiSite LR reaction
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Figure 15 Example of the multi-
site Gateway reactions 
performed in this study. Multi-
site gateway cloning was used to 
generate an inducible GLI1 
overexpression vector under the 
control of the CMV/TO promoter. 
The principle of the technique is 
explained in figure 15. 
 
 
 
 
 
 
 
 
3.5 In vitro experiments 
3.5.1 Stable transfection of cells by electroporation 
To generate stable transfectants in cell lines, host cells were co-transfected with a 
Sleeping Beauty transposase compatible reporter, and/or expression vector, and an 
additional expression plasmid carrying the transposase enzyme gene in 2:1 ratio.  
Electroporation was used as the main strategy to transfect cells. In practice, 
electroporation reactions were carried out using either an Amaxa Nucleofector IIB 
[Lonza, Basel (Switzerland)] or the NEON transfection system [Thermo Fisher, 
Waltham (USA)]. Both systems are highly optimized for small volumes and specific 
Multi-site
Gateway
LR Reaction
pSBDEST.H
pENTR221-CMV/TO.Pro pENTR221-GLI1
pSB.H.CMV/TO.GLI1
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cell lines. For both systems cells were grown to roughly 80% confluency, detached 
and counted and finally electroporated according to the table below. 
Cell line AMAXA Protocol NEON protocol 
10µl 
NEON protocol 
100µl 
HEK293 Q-030 1x10^6, 950V, 
30ms 
1x10^6, 1050V, 
30ms 
After electroporation, the cells were seeded into fresh cell culture flasks and after 24 
hours medium was replaced and selection was started. 
3.5.2 Antibiotic selection for transformants 
To select for transformants, electroporated cells were subjected to antibiotics for 7 to 
10 days, according to manufacturer’s instructions. To determine the lethal dosage of 
each antibiotic per cell line, an individual experiment using a dilution row was carried 
out in advance of the generation of stable transfectants. In these experiments, cells 
were subjected to increasing amounts of antibiotics, which were replenished every 2-
3 days, while monitoring cell health and proliferation microscopically. To prevent 
experimental artifacts later on, concentrations were biased to the higher concentration 
in cases of doubt. The final concentrations per antibiotic used can be found in the table 
below. 
Cell Line Blasticidin 
concentration 
Hygromycin 
concentration 
Zeocin 
concentration 
G418 
concentration 
Hek293 8 µg/ml 150 µg/ml 150 µg/ml 600 µ/ml 
 
3.5.3 Stimulation and validation of reporter cell lines 
To assess the effects of specific treatments on stable reporter cell lines, cells were 
detached, counted and seeded out in 96-well format (10,000 - 20,000 cells / well). 
Depending on the stimulation needed, this was performed in in 50µl or 100µl medium, 
so that either a highly concentrated stimulation could be added in a 1µl scale or up to 
50µl of a less concentrated compound could be added. Two hours after seeding out 
the cells to the 96-wells, stimulations were added. After 24, 48 or 72 hours (depending 
on the experiment) the effects on the cell line were assayed.  
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3.5.4 Overexpression methods 
Overexpression studies were carried out similar to other stimulation experiments. Here 
however, the cells were stably transfected with the Tet-Repressor carrying reporter 
vectors and an inducible expression vector utilizing the CMV/TO promoter. When the 
Tet-Repressor protein is present in the cells, it forms dimers that block transcriptional 
activity of the CMV promoter. Upon tetracycline or doxycycline stimulation, these 
dimers are disrupted by a conformational change and the Tet-Repressor monomers 
no longer block the CMV promoter.  
Since Doxycycline has 48 hours of cell culture half-life, compared to the 24 hours of 
Tetracycline, all experiments presented here used doxycycline-based activation. Two 
hours after seeding the inducible cell line into 96-wells, at least three replicates were 
activated with 1µg/ml Doxycycline, with the controls being left untreated.  
3.5.5 Co-culture assays 
Co-culture assays were carried out similar to stimulation experiments. 10,000 – 20,000 
reporter cells were seeded out in 50µl per 96-well plate well in the same medium as 
the co-cultivated cells. After 2 hours for the reporter cells to attach to the wells, varying 
amounts of cells were added to the wells in 50µl volume. 48 hours later reporter activity 
was assayed. 
3.5.6 Luciferase Assays 
Since all reporter constructs described here use Gaussia luciferase as a reporter 
protein, its presence was assayed by addition of its substrate, coelenterazine, and 
subsequent measurement of the amount of light generated in the reaction to 
coelenteramide. coelenterazine and the appropriate reaction buffer was purchased in 
form of the BioLux Gaussia Luciferase Assay Kit [New England Biolabs, Ipswich 
(USA)] and measurements were done using 20µl of cell culture supernatant with 50µl 
of the prepared substrate / buffer solution after 45 seconds incubation using a Berthold 
Lumat LB 9507 Luminometer with 10s measurements. 
3.5.7 Harvesting and concentration of serum-free supernatants 
To assess whether soluble components of culture supernatants where capable of 
driving specific pathway activation, serum-free supernatants were generated and 
concentrated. To harvest serum-free supernatants, cells were seeded out in high 
densities in 24 well plates in medium containing no antibiotics or serum. 72 hours later 
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supernatants were harvested and centrifuged at 200 x g for 10 minutes to pellet 
remaining cells, the supernatants were then taken off again and the centrifugation step 
repeated, again taking the supernatant off. The cell-free and serum-free supernatant 
was then concentrated using an Amicon Ultra-15 10kDa Spinfilter [Merck, Darmstadt 
(Germany)] at 2000 x g. Supernatants were concentrated up to 10 fold and used in 
reporter assays as described above. All centrifugations were carried out in a Rotanta 
460R centrifuge [Hettich, Kirchlengern (Germany)]. In cases where supernatants were 
to be freed from non-soluble components, they were centrifuged at 100,000 RCF in a 
L70 Ultracentrifuge [Beckman, Brea (USA)]. 
3.5.8 Exosome Preparation 
Exosomes were prepared from harvested serum-free supernatants after 72 hours for 
conditioning either using an in-house ultracentrifugation method or using the 
commercially available Exo-Spin Purification Kit [Cell Guidance Systems, St Louis 
(USA)] as per manufacturer’s instructions. For the ultracentrifugation method, the 
following centrifugation profile was used: 10 minutes 300 RCF, 20 minutes 2000 RCF 
[both Rotanta 460R, Hettich, Kirchlengern (Germany)], 30 minutes 10,000 RCF, 70 
minutes 100,000 RCF [both L70 Ultracentrifuge, Beckman, Brea, (USA)] and then 
resuspended in sterile PBS.   
3.5.9 Determination of protein content 
Protein content for exosome preparations was determined colorimetrically using the 
Pierce BCA Protein Assay Kit [Thermo Fisher, Waltham (USA)], a two-component 
assay reagent set to measure total protein concentration compared to a protein 
standard. Measurements were done using a Genios Plus plate reader [Tecan, 
Männedorf, (Switzerland)]. 
3.6 Quantitative real-time PCR 
3.6.1 RNA Purification 
RNA was isolated from various cell lines using the PureLink RNA Mini Kit [Thermo 
Fisher, Waltham (USA)] according to manufacturer’s instructions. The optional DNase 
I [Qiagen, Hilden (Germany)] digestion step was included to remove residual genomic 
DNA from the samples. RNA was eluted in 30 μl using RNase free water.  
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3.6.3 Quantification of RNA 
Purified RNA was quantified using the Quant-IT RNA assay for the Qubit Fluorometer 
[Thermo Fisher, Waltham (USA)]. Measurements are based on and made specific for 
RNA by the chemistry of the Quant-it dyes that upon binding RNA increase their 
fluorescence several hundred-fold. All measurements were carried out based on the 
manufacturer’s instructions. 
3.6.4 Reverse Transcription 
Due to the fragile nature of RNA, all samples were transcribed into cDNA through 
reverse transcription. The resulting cDNA was quantified in a following qPCR reaction 
step. As primers designed for qPCR are usually cDNA specific, they will only amplify 
cDNA and not genomic DNA. In cases where of genes with only one exon or the 18S-
rRNA, it is impossible to design cDNA specific primers. To control for these problems, 
and to exclude a PCR signal from genomic DNA contamination in the sample, the so-
called RT- sample was added to the reverse transcription step. Here, 0.2 μg of total 
RNA, possibly containing genomic DNA contamination, was added to a set of 
reactions. These reactions equaled the RT+ batch with the exception of the reverse 
transcriptase enzyme. Since no reverse transcription could take place in these 
samples and RNA cannot be measured in qPCR, each signal that was produced by 
the RT had to originate from the combination of a cDNA unspecific primer and genomic 
DNA contamination. For the reverse transcription, 2 μg of total RNA, as measured in 
3.6.3, was added to the RT+ reaction mix and in a final volume of 40µl. 
Reagent RT+ RT- 
First-strand buffer (5x) 1x 1x 
dNTP 1.5 mM 1.5 mM 
DTT 13.4 mM 13.4 mM 
Rnasin 2.5 U/μl 2.5 U/μl 
Acrylamid, linear 0.7 μM 0.7 μM 
Hexanucleotides (10x) 0.2x 0.2x 
Superscript II 4.4 U/μl - 
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Both reaction batches were incubated at 42°C, slowly shaken in a thermo block for 
1.5 hours. For subsequent qPCR reactions, the RT+ samples were to be diluted 
1:10, whereas the RT- batch remained undiluted, leading to equal amounts of RNA 
in the RT+ and RT- reactions. All samples were stored at -20°C, until further use. 
3.6.5 Quantitative PCR (qPCR) 
qPCR is a method used to determine the relative amount of mRNA for a specific gene 
at a certain time point. The method is generally used while comparing different tissues, 
during drug treatments and to verify the presence of transgenes in engineered cell 
types. The method uses cycles of PCR amplification of specific products while 
detecting fluorescent signals. While there are multiple variants of qPCR, here only the 
SYBR green method was used. In this method a DNA intercalating dye, which is only 
detectable in its DNA bound state, serves as the readout which is measured in real 
time by the qPCR cycler device. Earlier detection of the signal means more relative 
abundance of the original mRNA in comparison to other samples. To control that the 
signal does not originate from unspecific products or DNA contamination, an additional 
step has to be included. After the amplification cycles, a melting curve of the products 
is generated which uses the loss of fluorescent signal as a readout. This way, the loss 
of signal from small DNA molecules can be separated from the loss of signal of bigger 
molecules allowing to assess specificity (single peak). 
Reagent Amount 
SYBRGreen mastermix (10x) 1X 
SYBRGreen Primer FW 10pM 
SYBRGreen Primer RV 10pM 
Taq polymerase 0.03U/µl 
H2O was added to the mastermix to reach a final volume of 18 μl. For qPCR 2 μl of 
the RT+ (1:10) dilution or 2 μl of the RT- samples were added to the master mix, to 
reach a final volume of 20 μl per well. Experiments were set up in duplicates. qPCR 
was performed on an ABIPrism7000 Sequence Detection system [Thermo Fisher, 
Waltham (USA)]. After an initial hold of 2 minutes at 50°C and 10 minutes at 95°C, the 
samples were cycled 40 times at 95°C for 15 seconds, and 60°C for 60 seconds. All 
primers are summarized in the supplementary table 1. The expression of candidate 
genes was normalized to the reference gene 18S rRNA [172]. 
Methods   52
 
3.6.6 Calculation of regulation 
The presence of a fluorescent signal in a qPCR reaction is determined with a 
threshold, dubbed Cycle Threshold (CT). This threshold is reached at a certain cycle 
in the qPCR reaction. If a sample has a low CT value it has come up in an early PCR 
cycle indicating relatively high abundance of the template, whereas if it is detected late 
(in a higher cycle number) and has a high CT value the template was less abundant. 
Since the method yields relative values instead of absolutes, it is dependent on the 
use of reference genes (also called house-keepers). These reference genes allow for 
comparisons across different samples. To optimize the CT value, the baselines for 
each individual gene were adjusted based on the fluorescence curves, positioning 
them in the linear portion of the curve. The so calculated CT values were then used to 
calculate fold changes using the Pfaffl method [173].  
3.7 Microscopy of Kidney sections 
3.7.1 Sample preparation 
Kidney samples were dehydrated with 70% ethanol for 5 hours, then 96% ethanol for 
2 hours, 100% ethanol for 3.5 hours, xylene for 2.5 hours and paraffin for 4 hours. 
Paraffination was done using liquid paraffin. To mount the samples on glass slides, 
2µm sections were cut using a microtome. Deparaffination was done 3 times in Xylene 
for 5 minutes. For rehydration, samples were incubated 3 times in 100% Ethanol for 3 
minutes, then 2 times in 95% ethanol for 3 minutes and finally for 3 minutes in 70% 
ethanol. Then samples were washed twice for 5 minutes in PBS. 
3.7.2 Immunohistochemistry 
To prepare samples for immunohistochemistry, samples were first cleared from 
internal peroxidase, to do so, the samples were incubated in 3% H2O2 in Methanol for 
20 min in the dark, then washed twice in PBS for 5 minutes. For both YAP1 and 
TAZ(WWTR1) antibodies antigen retrieval was done using an autoclave for 20 minutes 
in pH6 citric acid buffer. Blockage of endogenous biotin was done using a 
commercially Avidin/Biotin blocking kit. YAP1 antibody was diluted 1:100 in 10% 
skimmed milk powder in PBS. TAZ(WWTR1) antibody was diluted 1:50 in PBS. 
Detection was done for 1 hour at room temperature. To detect the primary antibodies, 
biotinylated secondary antibodies (5µg/ml in PBS) were used for 30 minutes. After 
incubation a commercially available kit (Vectastain) was used to detect bound 
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antibodies according to manufacturer’s instructions. For counter-staining methyl green 
was used and again quickly washed with 96% ethanol, then 100% ethanol and 
followed by xylol. To mount the slides, Vectamount [Vectorlabs, Burlingame (USA)] 
mounting medium was used. 
3.8 Generation of 2+MoPh and imDC cells 
3.8.1 Isolation of mononuclear cells from peripheral blood 
Mononuclear cells were isolated from venous blood from healthy donors (peripheral 
blood mononuclear cells, PBMCs). To prevent coagulation of blood, 50ml Syringes 
with added 1000 U Heparin were used. Blood samples were then mixed with the same 
volume of RPMI medium and layered on top of 15ml Ficoll in a 50 ml tube. Density 
gradient centrifugation (2000 rcf, 20 minutes, no brakes) served to separate the blood 
components. Erythrocytes and granulocytes sink into the Ficoll layer while 
thrombocytes float to the top. The middle phase contains the PBMCs, which was 
carefully taken off and put into a fresh 50ml tube, 1:1 mixed with RPMI medium and 
centrifuged for 12 minutes to remove remaining Ficoll. Supernatant was discarded and 
the cell pellet filtered through a cell sieve and counted.  
3.8.2 Positive isolation of monocytes from PBMC 
Isolation of monocytes from PBMC was done using the MACS technology (magnetic 
cell sorting) at 4°C. Monocytes were selected with CD14 microbeads according to 
manufacturer’s protocol with the cell pellet being resuspended in 10µl volume per 107 
cells. CD14 positive monocytes were then differentiated to either imDC or 2+MoPh 
subtypes. 
3.8.3 In-vitro-differentiation of myeloid cell types from monocytes 
All myeloid cells were cultivated in 6 well plates. To generate 2+MoPh from monocytes, 
7 x 106 cells were transferred to 3ml AIM-V-Medium (3% human serum) or 1ml of 
RCC26 conditioned supernatant in 3ml VLE-medium (6% human serum). For the 
generation of imDC cells, monocytes were cultivated in 4ml AIM-V-medium (1% 
human serum) supplemented with 80 ng/ml GM-CSF and 80 ng/ml recombinant 
human IL-4 protein. These media were replaced after two days and cells harvested on 
day 7. 
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3.9 Fluorescence activated cell scanning (FACS) Analysis 
Fluorescence activated cell scanning (FACS) analysis was used to detect surface or 
cytoplasmic factors via antibodies coupled to a fluorochrome. It was used to 
characterize the in-vitro generated 2+MoPh and imDCs, and the myeloid cell lines 
Mono-Mac-6 and THP1 (see addendum). For surface staining, 5 x 104 to 2 x 105 cells 
were suspended and washed with 500 µl ice cold FACS buffer in a 1.5 ml FACS tube. 
After centrifugation, the supernatant was discarded except for 50 µl, and the 
concentrated cells were stained with antibodies. Samples were mixed by vortexing 
and incubated for 25 min at 4°C in the dark. Then the samples were washed with 500 
µl FACS buffer and after centrifugation the supernatant discarded so that 100 µl were 
left. To control for dead cells, 10 µg/ml propidium iodide was added shortly before data 
acquisition. To be able to correct for unspecific events and define thresholds, a 
compensation matrix was generated by including single stained compensation beads. 
70 µl FACS buffer were added to 15 µl positive or negative control beads [Miltenyi 
Biotec, Bergisch-Gladbach (Germany)] and stained with 1 µl of each antibody, then 
incubated for 25 min at 4°C in the dark. Similar to the cell samples, the compensation 
beads were washed in 500 µl FACS buffer and after centrifugation, the supernatant 
discarded with 100 µl being left in the tube. Using these compensation beads, the 
software can determine the thresholds for both positive and negative signals, which is 
important when fluorochromes have overlapping spectra. All measurements were 
done using a LSR II-Flow cytometer and analyzed with the FlowJo Software suite. 
Antibodies are listed in table 2.9. 
3.10 Mass spectrometry 
3.10.1 Sample preparation for mass spectrometry 
Supernatants were proteolysed with trypsin [Promega, Mannheim (Germany)] using a 
modified filter aided sample preparation protocol [174]. 
3.10.2 LC-MS/MS analysis 
Mass spectrometry (MS) data were acquired using a data-dependent top-10 method 
on a Q Exactive (QE) high field (HF) mass spectrometer [Thermo Fisher, Waltham 
(USA)] in cooperation with Dr. C. von Törne, Protemics Core Facility, Helmholtz 
Zentrum München. Samples were automatically loaded to the online coupled RSLC 
[Ultimate 3000, Thermo Fisher, Waltham (USA)] HPLC system. A nano trap column 
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was used [LC Packings, Sunnyvale, CA (USA)] before separation by reversed phase 
chromatography [PepMap, 50 cm, 75 µm ID, 2µm/100 Å pore size; LC Packings, 
Sunnyvale, (USA)] at 50°C. Peptides were eluted from column at 300 nl/min using 
increasing acetonitrile (ACN) concentration (in 0.1% formic acid) from 3% to 40 % over 
a 90 minute gradient. MS spectra were recorded within a mass range from 300 to 1500 
Da at a resolution of 60,000. Fragmentation was performed via higher energy 
collisional dissociation (HCD) with a target value of 3e6 ions determined with predictive 
automatic gain control (AGC). Precursor peptides were isolated with a 1.6 m/z window. 
Resolution for HCD spectra was set to 15,000 at m/z 200 with an AGC target of 1e5 
and maximum ion injection time of 100 ms. The normalized collision energy was 28. 
The underfill ratio was defined as 1%. Dynamic exclusion was set to 30 seconds. 
3.10.3 Protein identification and label-free quantification 
The acquired spectra of the different samples were loaded and analyzed using 
Progenesis QI software for proteomics [Version 2.0, Nonlinear Dynamics, Waters, 
Newcastle upon Tyne (UK)] for precursor-based label-free quantification as previously 
described [175]. The proteome of native adult Muller glial cells from murine retina. Mol 
Cell Proteomics) with the following adjustments: Samples were allocated to their 
respective experimental groups imDC 46hours and 2+MoPh 46 hours. Peptide 
identification with Mascot (MatrixScience, London (UK) version 2.5.1) using the 
Ensembl Human protein database (release 80, containing 100208 sequences). 
Search parameters used were 10 ppm peptide mass tolerance, 20 mmu fragment 
mass tolerance. 
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4 Results 
4.1 Bioinformatic characterization of DN samples and calculation of 
2+MoPh presence 
It is now well established that regulatory pathways, strongly associated with renal 
development, can often become reactivated as a response to tissue damage. This 
reactivation is thought to underlie aspects of wound repair [176, 177]. The 
dysregulation, or over-activation of these pathways, has been linked to biologic 
processes underlying the pathophysiology of chronic renal disease [36, 37, 39, 40]. 
Myeloid cells have been implicated as key effector leukocytes in the repair of damaged 
tissue, and in many instances, are thought to help drive chronic fibrosing tissue 
damage [137, 138, 143-147, 150]. The goal of this thesis was to determine if a myeloid 
subtype previously identified in normal renal tissue, and found to be increased in many 
examples of renal disease, could potentially contribute to the damage seen in 
progressive diabetic nephropathy [139, 151]. To this end, we sought to determine if 
the presence of these myeloid cells could be directly linked to the activation of 
regulatory pathways associated with the progression of tissue damage seen in diabetic 
nephropathy. 
4.1.1 Dysregulation of developmental/regulatory pathways in the context 
of diabetic nephropathy 
As a first step, transcriptomic data from a cohort of patient human renal tissue was 
analyzed for the activation of pathways commonly associated with development and 
repair. Microdissected kidney samples representing the tubulointerstitial 
compartments of patients diagnosed with diabetic nephropathy, and taken during 
routine biopsies, were made available through the European Renal cDNA Bank 
(ERCB) [154]. The transcriptomic data was subsequently analyzed for the presence 
of dysregulated homeostatic pathways.  
The transcriptomic profiles of all samples had been previously measured using 
Affymetrix microarray technology. To identify and verify general alterations of 
homeostatic pathways, the kidney samples from progressed diabetic nephropathy 
(DN) patients were compared to samples taken from living donor (LD) transplant 
kidneys prior to implantation, the cleanest dataset available as an approximation of 
“normal” human control kidneys. Analysis of this transcriptomic dataset was done in 
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collaboration with Prof. Dr. M. Kretzler and V. Nair [University of Michigan, Ann Arbor 
(USA)] using procedures described in the methods section (3.1). For all bioinformatic 
analyses, 17 DN samples were used in total with a calculated eGFR MDRD [178] 
mean of 44, median of 46 and standard deviation of 25, and compared to a set of 30 
LD controls. Transcriptomic profiles were generated from microdissected 
tubulointerstitial regions of the renal biopsy samples, using Affymetrix cDNA 
microarrays. Briefly, after quality control of the samples, normalization and batch 
correction procedures were carried out. Upon comparison of the DN samples to the 
LD controls, 2739 genes were found to be significantly altered. Within this set of genes, 
many exhibited comparably small differences. To address this, a second filtering step 
using a fold change of at least a 1.3 fold threshold was applied. The results showed a 
set of 874 regulated genes that were then analyzed for alterations of homeostatic 
pathways. To allow for an unbiased approach, the Genomatix software suite, which 
contains a number of bioinformatics tools was used to analyze expression data. The 
GeneRanker program, which determines association of an input gene list with either 
pathway (canonical or based on literature mining), Gene Ontology (GO) terms or 
additional gene-sets based on diseases, transcription factors (TFs) or tissue profiles 
was applied. For this analysis, the pathway based literature mining approach was 
used, as this approach retains canonical/core pathway genes, but also extends the list 
based on published literature.  
Pathway Genomatix Pathway id p-value Obs. Exp. 
TGFβ/SMAD 
Signaling 
PW_SMAD_HOMO_SAPIENS 1,87E-04 49 28,95 
MAPK (JAK) 
Signaling 
PW_JAK_HOMO_SAPIENS 1,99E-04 30 14,96 
MAPK (STAT) 
Signaling 
PW_STAT_HOMO_SAPIENS 1,66E-03 41 25,48 
Canonical WNT 
Signaling 
PW_βCATENIN_HOMO_SAPIENS 5,75E-03 56 39,86 
Integrin Signaling PW_INTEGRIN_HOMO_SAPIENS 4,11E-10 46 16,99 
Myeloid 
Differentiation 
PW_MYD88_HOMO_SAPIENS 6,46E-05 24 10,13 
Table 1. Dysregulated homeostatic pathways in DN. Abbreviated list of gene sets 
identified as overrepresented by GeneRanker. In addition to the pathways listed here, 
a large set of inflammatory gene sets was identified, for full list see addendum 6.1.1. 
Obs. = number of observed genes, Exp. = number of expected genes. 
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This was an important step as it would potentially allow for the identification of non-
canonical signaling processes, which were suspected to play a role in DN. 
GeneRanker determines significance by calculating an expected amount of genes 
from the size of the input gene list and the number of genes in a given pathway while 
considering the number of genes in the genome as frame of reference. If a pathway is 
overrepresented, a p-value can be calculated to judge reliability. 
The GeneRanker analysis showed significant dysregulation of at least four major 
homeostatic signaling pathways: TGFβ/SMAD signaling, MAPK signaling, canonical 
WNT signaling and Integrin signaling (see table 1). Similar findings had previously 
been published for other datasets generated from microdissected kidney tissue [35, 
36, 156]. Integrins are a diverse group of transmembrane receptors which modulate 
cell-cell adhesion [179]. This signaling is strongly associated with the homeostatic 
status of cells, as well as the signaling seen during contact. A large number of immune-
associated gene sets were also found to be significantly altered (see addendum 6.1). 
Interestingly, myeloid differentiation was identified as being one of the altered gene 
sets. 
4.1.2 Detection of 2+MoPh in complex tissues by deconvolution analysis 
Our previous studies [139, 143, 146, 147, 150, 151], as well as the transcriptomic 
changes in myeloid differentiation seen during the progression of DN, prompted further 
study of the kidney resident myeloid cell composition. The recently identified 2+MoPh 
myeloid cell type, characterized by the expression of the surface markers CD209/DC-
SIGN and CD14, exhibits expression of classical DC, and in parallel, macrophage-
associated genes [151]. Originally, this phenotype was identified as being enriched in 
clear cell renal cell carcinoma (and was thus called ‘ercDC’, enriched in renal cell 
carcinoma DC). The cell type is also found in the interstitium of healthy kidneys and 
becomes increased in number in many progressive kidney pathologies [139, 151]. To 
analyze whether 2+MoPh could be detected in DN, transcriptomic profiles of in-vitro 
generated 2+MoPhs, as well as a series of other myeloid subtypes were obtained 
through our collaborators Prof. Dr. Elfriede Nößner and Dr. D. Brech [Helmholtz 
Zentrum, München (Germany)]. 
This data was then used by collaborators in the BMC, Core Facility Bioinformatics [Dr. 
Tobias Straub, Munich, (Germany)] as the input data for the generation of a 
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bioinformatics-driven deconvolution strategy to predict the presence of 2+MoPh cells 
with a high degree of accuracy within the transcriptomic data derived from complex 
tissues (Brech et al. submitted). Deconvolution strategies employ sets of marker genes 
and their dynamics to calculate proportions of cell types in complex tissues [162]. The 
deconvolution strategy developed for 2+MoPh was able to specifically segregate these 
cells from other myeloid cell subtypes (blood isolated CD1c+DC, CD141+DC, slanDC, 
monocytes; as well as in-vitro generated M1 macrophages, M2 macrophages and 
imDC) in a series of proof of principle studies and was thus judged to be specific for 
the 2+MoPh phenotype (Brech et al. submitted). 
Analysis of DN transcriptomic data using the deconvolution method identified an 
enhanced presence of 2+MoPh signatures in the tubular interstitium of DN patients in 
comparison to healthy living donor control kidneys. 
Figure. 16. Deconvolution scores for 
2+MoPh in microdissected tubular 
tissue. From ERCB living donor (LD) 
and diabetic nephropathy (DN) cDNA 
microarrays, a deconvolution score was 
calculated as an estimation of 2+MoPh 
presence. DN samples show a 
significant increase in score. 
 
 
Additionally, the deconvolution signature was found to significantly correlate with a 
decrease in glomerular filtration rate in the diseased kidneys as determined by eGFR 
MDRD (estimated glomerular filtration rate, modification of diet in renal disease) – a 
measurement of renal function.  
Figure 17. Association of glomerular 
filtration rate with 2+MoPh presence in 
DN. Yellow dots indicate deconvolution 
scores as a measurement of 2+MoPh 
presence in individual patient samples. 
There is a significant negative correlation 
with glomerular filtration rate. (r= 
correlation coefficient)  
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Together, these findings supported our hypothesis that enhanced levels of 2+MoPh 
are a factor in the development or progression of CKD caused by diabetes. To test 
this hypothesis in more detail, we then sought to determine if 2+MoPh cells could 
directly influence changes in the homeostatic status of parenchyma, as evidenced by 
the transcriptomic profiling in 4.1.1 
4.2 Cloning and Establishment of the Vector Platform 
To study the potential effect of 2+MoPh on resident kidney cells, an in-vitro cell co-
culture system was developed, which also required the design of a novel reporter and 
expression vector system [168]. An important feature of the vectors designed, was the 
ability to monitor the activation status of specific regulatory pathways. This was 
achieved by generating a series of reporter cassettes for transcription factors 
associated with the activation of select pathways. Additionally, the intricacies and 
interactions of the modulated pathways could be studied through the overexpression 
of key pathway genes. To this end, a mechanism for inducible expression was 
employed. To work efficiently with stably transfected reporter cell lines, both a 
mechanism to efficiently generate genomic insertions, and a set of different selective 
markers were also needed. The use of stable vector integration with selection, and 
pathway reporters with controlled transgene expression allowed the direct comparison 
of activation states between stimulated and unstimulated, but genetically identical, 
cells, thus greatly reducing potential variation between experiments and samples as 
commonly seen in transient assays. 
An additional component of this vector platform was the capacity for high throughput 
cloning to rapidly generate the complex transgenes required in the expression vectors. 
To do so, Gateway cloning, a highly efficient and well established recombination-
based cloning strategy was chosen [180]. The Multi Site Gateway technology was 
adopted for use in the vector platform. This tool allows cloning of up to four inserts into 
an acceptor vector dubbed the “destination vector” in an orientation specific manner.  
Potential additional issues addressed included potential promoter competition due to 
multiple inserted copies, general issues of transfection efficacy, and it was also unclear 
whether all the complex transgenes involved in the vector platform would function 
together as intended when inserted into host cell lines. 
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4.2.1 Cloning of pathway reporter vectors 
The reporter vector pSBTET-Reporter [168] was based on the pGL3-Promoter, pN3-
Bar-Gluc and pcDNA6.2/V5-PL-DEST vectors and was generated in a multistep 
cloning procedure as detailed in the methods section. In each cloning step, verification 
was carried out using sequencing, functional assays (luciferase activity), or both. The 
resultant pSBTET-Reporter represents a next generation reporter vector with a 
number of advantages over classical Firefly luciferase reporter vectors:  
Figure 18. Final version of pSBTET-
Reporter vector. 
This resulting vector allows for active, 
stable integration into host cells via 
Sleeping Beauty transposition, 
dramatically raising insertion frequency. 
Additionally, it carries constitutive 
expression of the TET-repressor gene, 
which is needed for Doxycycline based 
de-repression systems. Finally, the 
Reporter cassette driving humanized 
Gaussia luciferase allows for monitoring 
the activity of transcription factors. Since 
Gaussia luciferase is secreted into the 
supernatant, resulting reporter cells can 
be monitored in time courses without cell lysis. (also see 3.4) 
 
 It included the TET-Repressor [164] protein which allows for repression and de-
repression of compatible promoters, and thus a basis for inducible expression or 
knockdown systems where required.  
 The vectors use secreted Gaussia luciferase [181] as reporter protein, allowing 
measurements of luciferase activity without cell lysis. A property that makes the 
vectors useful for time courses and rapid screening approaches.  
 The inclusion of Sleeping Beauty transposase [165-167] compatible inverted 
terminal repeats/direct repeats allows efficient stable integration of transgenes into 
host cell genomes by an active mechanism, largely without size restrictions and 
the need for viral systems and S2 biosafety levels. 
The basic pSBTET-Reporter was then used as a basis to generate pathway specific 
reporter vectors by introducing binding sites for pathway-associated transcription 
factors. As described in 3.4.4, reporter vectors for TGFβ/SMAD signaling, canonical 
pSBTET.Reporter
8679 bp
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WNT signaling, Hippo signaling, Hedgehog signaling and AP-1/MAPK signaling were 
generated. These pathways were chosen in part based on the initial pathway screen 
of the DN samples and also because of their known interactions and crosstalk, which 
was deemed of central importance to draw a more complete picture of whether 
alterations of one pathway co-occurred with alterations of other pathways. This 
approach also expands the bioinformatic screening possibilities, as the pathway 
mapping software currently used is dependent on previously archived classical 
pathway data. We sought to also include the potential of non-canonical modes of 
pathway activation, for example, those less well defined processes induced through 
growth factors and cytokines, that may be responsible for some of the modulation of 
the homeostatic milieu seen during progressive DN.  
The Hedgehog signaling pathway, originally identified during embryonal patterning, 
has been shown to also play a role in tissue regeneration, tissue homeostasis, wound 
healing, and has been implicated in moderating aspects of progressive renal damage 
[31, 40, 52, 56]. TGFβ/SMAD signaling is involved in tissue homeostasis, wound 
healing, fibrosis and immune responses [16, 67, 68, 96, 182]. The canonical β-catenin 
centric WNT pathway is a complicated regulatory network. It has been implicated in 
cancer, tissue homeostasis, wound healing, cell migration and in control over 
proliferation and differentiation. This pathway is also strongly associated with 
progressive renal fibrosis, including the damage seen during DN [28, 31, 36, 37, 96]. 
Finally, the HIPPO pathway and its central transcriptional co-activators YAP1 and TAZ 
are new subjects of interest. The described functions of this pathway range from 
regulation of organ size, to responses to external stimuli such as mechanical stress, 
wound healing and a major role in fibrotic renal diseases [43, 44, 96, 124]. As there is 
no single transcription factor targeted by the HIPPO pathway, the associated TEAD 
transcription factors were used as the basis for the reporter vector [99]. LXRs were 
also studied as a candidate pathway, since these nuclear receptors are intricately tied 
to the regulation of innate immune responses exemplified by their role in myeloid cell 
polarization [183, 184], and chronic renal disease [185, 186]. 
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4.2.2 Cloning of Gateway Destination vectors 
A similar approach as detailed in 3.4.4 was used to generate a set of highly flexible 
Gateway cloning [180] destination vectors [168]. The Multi-Site Gateway cloning 
platform (summarized in figures 14 and 15) allows the integration of up to four 
fragments in a direction and orientation specific manner, while also providing strong 
bacterial selection mechanisms to simplify the search for correct clones [187]. Multi-
Site Gateway cloning allows the rapid design and generation of protein expression 
vectors by recombination of a promoter with a coding sequence for a gene of interest.  
Again, Sleeping Beauty transposase compatible inverted terminal repeats/direct 
repeats were included to facilitate the integration of resultant vectors into host cell 
genomes. The resulting Multi-Site Gateway destination vectors were further adapted 
by generating a set of four vector variants with different eukaryotic selection markers.  
 
 
Figure 19. Final version of pSB.DEST 
vectors. The finalized plasmid serves as a 
multi-site Gateway cloning destination vector 
while still allowing for highly efficient integration 
into host cells via Sleeping Beauty 
transposition. The choice of selective markers 
allows for combinations of multiple stably 
inserted plasmids. Multi-site Gateway cloning 
allows for the integration of up to four entry 
clones between attR recombination sites. 
 
 
 
The resulting vectors were verified by sequencing, and used in Multi-Site Gateway LR 
reactions, leading to the generation of all expression vectors used in this study. In 
cases where inducible expression vectors were necessary, the TET-Repressor 
blockable CMV/TO promoter was used as an entry clone, leading to the generation of 
Doxycycline inducible expression vectors.  
pSB.DEST.H/B/G/Z
Blasticidin
G418
Zeocin
each ~8500 bp
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4.2.3 Cloning of Entry Clones 
Two types of Multi-Site Gateway Entry Clones were generated. attL1/attL5r Entry 
clones were used for promoter fragments while attL5/attL2 were used for coding DNA 
sequences of genes of interest. This allowed for the combination of any promoter entry 
clone with any CDS entry clone to generate expression vectors. Cloning for each entry 
clone was done via PCR and BP reactions with compatible pDONR221 vectors. 
Type Insert Resulting vector 
attL1/attL5r CMV/TO Promoter pENTR221-CMV/TO Pro 
attL1/attL5r CMV Promoter pENTR221-CMV Pro 
attL5/attL2r Human YAP1 CDS, wildtype pENTR221-YAP1 WT 
attL5/attL2r Human YAP1 CDS, S127A mutant pENTR221-YAP1 CA 
attL5/attL2r Human WWTR1(TAZ) CDS, wildtype pENTR221-TAZ WT 
attL5/attL2r Human WWTR1(TAZ) CDS, S89A 
mutant 
pENTR221-TAZ CA 
attL5/attL2r Human GLI1 CDS pENTR221-GLI1 
attL5/attL2r Human NR1H2 CDS pENTR221-NR1H2 
attL5/attL2r Human NR1H3 CDS pENTR221-NR1H3 
attL5/attL2r Human TCF7 CDS pENTR221-TCF7 
attL5/attL2r Human MYDGF CDS pENTR221-MYDGF 
attL5/attL2r Human WNT1 CDS pENTR221-WNT1 
attL5/attL2r Human WNT3 CDS pENTR221-WNT3 
attL5/attL2r Human WNT3A CDS pENTR221-WNT3A 
attL5/attL2r Human SMAD3 CDS, wildtype pENTR221-SMAD3 
attL5/attL2r Human SMAD3 CDS, active mutant pENTR221-SMAD3 CA 
Table 2. Entry clones generated for this study. Using PCR overhangs and 
pDONR221 vectors from the MultiSite Gateway cloning kit, a series of Entry clones 
was generated by PCR and BP reactions. 
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4.2.4 Cloning of Expression Vectors 
Using the cloned Multi-Site Gateway entry clones and destination vectors, Expression 
vectors were generated via Multi-Site Gateway LR Reactions. The resultant vectors 
were verified by sequencing. 
 
First Entry Clone 
(attL1/attL5r) 
Second Entry clone 
(attL5/attL2r) 
Resulting vector 
pENTR221-CMV/TO 
Pro 
pENTR221-YAP1 WT pSB.H.CMV/TO.YAP1 WT 
pENTR221-CMV/TO 
Pro 
pENTR221-YAP1 CA pSB.H.CMV/TO.YAP1 CA 
pENTR221-CMV/TO 
Pro 
pENTR221-TAZ WT pSB.H.CMV/TO.TAZ WT 
pENTR221-CMV/TO 
Pro 
pENTR221-TAZ CA pSB.H.CMV/TO.TAZ CA 
pENTR221-CMV/TO 
Pro 
pENTR221-GLI1 pSB.H.CMV/TO.GLI1 
pENTR221-CMV/TO 
Pro 
pENTR221-NR1H2 pSB.H.CMV/TO.NR1H2 
pENTR221-CMV/TO 
Pro 
pENTR221-NR1H3 pSB.H.CMV/TO.NR1H3 
pENTR221-CMV/TO 
Pro 
pENTR221-TCF7 pSB.H.CMV/TO.TCF7 
pENTR221-CMV/TO 
Pro 
pENTR221-MYDGF pSB.H.CMV/TO.MYDGF 
pENTR221-CMV Pro pENTR221-WNT1 pSB.H.CMV.WNT1 
pENTR221-CMV Pro pENTR221-WNT3 pSB.H.CMV.WNT3 
pENTR221-CMV Pro pENTR221-WNT3A pSB.H.CMV.WNT3A 
pENTR221-CMV/TO 
Pro 
pENTR221-SMAD3 
WT 
pSB.H.CMV/TO.SMAD3 WT 
pENTR221-CMV/TO 
Pro 
pENTR221-SMAD3 CA pSB.H.CMV/TO.SMAD3 CA 
Table 3. Expression vectors clones generated for this study. Expression vectors 
for genes of interest were generated by MultiSite Gateway LR reaction, using the 
pSB.Dest.H vector as a basis. 
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4.2.5 Transfection of cell lines using Nucleofection techniques and the 
SB100 Transposase 
 
Figure 20. Sleeping beauty transposition 
mediated stable integration of 
transgenes into host cells.  
The vector carrying the genetic cargo (here 
exemplified by the aforementioned CMV/TO 
GLI1 expression vector) is co-transfected 
with pCMV-SB100X. This leads to the 
production of SB100 transposase protein 
inside the host cell. SB100 transposase then 
binds to Sleeping Beauty inverted terminal 
and direct repeats (SB) and, by 
transposition, stable integration of the 
genetic cargo semi randomly into the host 
cell genome. 
 
 
 
 
As HEK293 cells were originally isolated from embryonal kidneys, they were chosen 
as the experimental “parenchymal” cell line for these studies. Additionally, due to their 
fast growth and high transfectability, HEK293 cells are well established expression 
cells for the production of recombinant proteins. 
To achieve high levels of transfection, next generation electroporation methods were 
employed. AMAXA [Lonza, Basel (Switzerland)] uses electroporation cuvettes. One 
downside of this system is that work with small volumes is difficult due to the cuvette 
shape. In addition, it is impossible to fine tune parameters and settings for delivery of 
the pulse. By contrast, the NEON [Thermo Fisher, Waltham (USA)] transfection 
system uses specific pipette tips, which double as electroporation chamber and can 
thus also work with volumes as low as 10µl, allowing for high cell numbers in low 
volumes and in parallel high plasmid concentrations. In addition, one has more 
flexibility in optimizing transfection parameters. The superiority of the NEON system 
was demonstrated in a panel of three cell lines. In each case the NEON electroporator 
showed brighter GFP reporter signals, with comparable cell death (data not shown). 
pCMV-SB100X
4756 bp
pSBDEST.H.CMV-TO.Gli1
10264bp
SB CMV/TO GLI1 SV40 Hygro SBP P
SB CMV/TO GLI1 SV40 Hygro SBP P
TA
AT
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Using NEON and SB technology, reporter and expression plasmids, and co-
transfection with the pCMV(CAT)T7-SB100X transposase expression plasmid [166] 
allowed efficient transposase-mediated co-insertion of the TET-Repressor cassette, 
and the reporter cassette, (with different selective markers) into the host cell genome. 
4.2.6 Proof of principle stimulation experiments for validation of the 
vector platform 
To test the validity of the reporter genes within the vector platform, HEK293 cells were 
transfected with individual reporter constructs for a series of homeostatic pathways. 
For each pathway, a previously described control activator for the pathway reporter 
was used to validate the system. In each experiment, stably transfected cells were 
plated in a 96-well format and stimulated as described. 
 
Figure 21. Stimulation of canonical 
WNT reporter HEK293 cells with 
recombinant human WNT3A protein. 
To assess activity of the TCF/LEF 
reporter cassette, stable transfected 
HEK293 cells were treated with 400ng/ml 
WNT3A for 48 hours after which Gaussia 
luciferase reporter activity was assessed 
in the culture supernatant. Treatment 
with WNT3A strongly activates the 
TCF/LEF transcription factors and thus 
the reporter element, leading to increased luciferase expression. (three wells per 
group, experiment representative of three individual experiments, *** = p<0.0005) 
 
For the Hedgehog pathway, recombinant human epithelial growth factor (EGF) 
protein, which activates the associated GLI1 transcription factor was used [188]. The 
commercially available and in house over-expressed versions of the canonical 
Hedgehog ligands are generally found to be very inefficient for activation of these and 
other reporter constructs at physiological concentrations (data not shown). This is 
thought to be due to incomplete posttranslational modification of the ligands and is 
consistent with data for commercially available vectors employing similar reporter 
elements (http://www.sabiosciences.com/reporter_assay_product/HTML/CCS-
6030L.html). For the TGFβ/SMAD reporter, recombinant human TGFB1 protein was 
used to activate the reporter construct [189]. To assess viability of the canonical WNT 
reporter construct, reporter cells were treated with the canonical WNT ligand WNT3A 
[190]. Examples for each of these experiments can be found in the supplemental data. 
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4.2.7 Proof of principle: induced overexpression of genes within the 
vector platform 
 
Figure 22. Explanation of inducible-expression and reporter vector system. The 
vector system generated here allows inducible overexpression/knockdown of genes 
with only 2 stably integrated vectors. One vector carries constitutive expression of the 
Tet-Repressor gene, a luciferase reporter cassette and Blasticidin selection. The other 
vector allows for Gateway engineered and Doxycycline inducible overexpression, with 
a number of selective markers exemplified by Hygromycin here. Both vectors can be 
stably integrated into cells with the SB100 transposase. In unstimulated cells, the Tet-
Repressor molecules form dimers and bind to binding sites introduced into the CMV 
Promoter, blocking transcription. Upon Doxycycline stimulation, the Tet-Repressor 
molecules bind Doxycycline, which leads to a conformational change, monomerization 
and loss of DNA binding capacity. This then activates the transgene in the second 
plasmid (purple). The transgene will then have effects on the host cell, potentially 
modulating activation of the reporter cassette (green) of the first plasmid. 
After validating the pathway-specific reporter constructs, as a next step the de-
repression/gene activation system was verified in-vitro. HEK293 cells were transfected 
either in sequence (first the reporter then an overexpression construct) or together. As 
an example of this principle, inducible expression vectors for pathway associated 
transcription factors based on the de-repressible CMV/TO promoter [191] were 
generated. These constructs were blocked by TET-Repressor protein dimers 
expressed by the reporter vector. Upon stimulation with Doxycycline, a conformational 
change in the TET-Repressor protein was induced causing it to monomerize and 
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detach from DNA, allowing transcription from the now open CMV promoter. This 
approach could be used, for example, for the induced overexpression of a gene linked 
to the biology of the specific pathway reporter vector (see figure 22). This approach is 
exemplified here with transcription factors directly driving reporter activity. 
As a proof of concept, an inducible GLI1 expression cassette was introduced in 
Hek293 cells engineered to monitor the activity of the Hedgehog pathway. GLI1 is a 
well-studied transcription factor associated with Hedgehog signaling [192]. For 
canonical WNT, TCF7 was used. TCF7 is a high mobility group (HMG) box 
transcription factor activated by β-catenin stabilization, a hallmark of the pathway 
[193]. For TGFβ/SMAD signaling, SMAD3 was overexpressed [194]. Example 
experiments for each of these signaling platforms can be found in the addendum (see 
6.2). These results showed that the two vectors stably introduced into the reporter cells 
could efficiently interact to provide the required signals. 
 
Figure 23. Hek293 Hedgehog reporter 
stimulation by overexpression, proof 
of principle. 
Hek293 Hedgehog Reporter cells were 
transfected with a Doxycycline-inducible 
GLI1 overexpression construct. After 48 
hours of Doxycycline treatment, 
luciferase expression and activity was 
strongly increased. (three wells per 
group, experiment representative of three 
individual experiments, **** = p<0.0001) 
 
As a further step for validation of in-vitro activity of the inducible overexpression 
vectors, a qPCR assay using GLI1 and GLI2 as readouts was employed. Hek293 cells 
carrying both the Hedgehog reporter with the included TET-Repressor expression 
cassette, as well as the inducible GLI1 expression construct were stimulated with 
either recombinant human EGF protein or Doxycycline to induce the expression of 
GLI1. qPCR for GLI1 was used as an additional readout of Hedgehog/GLI1 activation 
since activation of Hedgehog signaling will increase mRNA levels for GLI1 [195]. 
Treatment with EGF showed increased GLI activity for both GLI1 and GLI2, while 
Doxycycline induced overexpression of GLI1 led to highly increased levels of GLI1 but 
not GLI2. 
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Figure 24. qPCR for GLI1 and GLI2 in 
an inducible GLI1 overexpression 
background. Hek293 Hedgehog 
Reporter cells were transfected with a 
Doxycycline-inducible GLI1 
overexpression construct and relative 
mRNA levels for GLI1 and GLI2 
assessed by quantitative real time PCR. 
Treatment with recombinant human EGF 
protein for 48 hours induced expression 
of both GLI1 and GLI2, while Doxycycline 
based induction of GLI1 overexpression only increased levels of GLI1. (Data 
representative of two 48 wells per group.) 
 
4.3 In-vitro model for myeloid infiltrate driven signaling alterations in the 
kidney  
Using the tools described in 4.2, a series of experiments were designed to mimic and 
characterize potential alterations of homeostatic signaling pathways in kidney 
parenchymal cells conferred by contact with 2+MoPh and related imDC cells using 
reporter engineered HEK293 cells as model parenchymal cells.  
4.3.1 Flow cytometric characterization of myeloid cells 
To verify whether the lab cultivation and polarization to classical imDCs (IL-4/GM-CSF 
immature DCs) and the 2+MoPh phenotype was successful, the surface markers of 
the resulting cell populations were analyzed by flow cytometry (see figure 25). The 
markers included CD209/DC-SIGN, CD163, CD14, the defining markers for the 
2+MoPh cell type [151] and markers to define to define DC or macrophage polarisation: 
CD40, HLA-DR and CD80 mainly expressed by DCs, CD64 expressed by M1 
macrophages, MerTK expressed by M2 macrophages [196, 197].The in-vitro derived 
2+MoPh were positive for these markers. imDC were positive for CD209, but negative 
for CD163 and CD14. They expressed HLA-DR, the costimulatory molecules CD40, 
CD80 at about the same intensity as 2+MoPh. The M1 polarization marker CD64 was 
only marginally expressed while MER-TK was highly expressed.  
All data involving myeloid differentiation or characterization was generated in 
collaboration with Prof. Dr. E. Nößner and Dr. D. Brech (Immunoanalytics- Core 
Facility & Research Group Tissue Control of Immunocytes, Helmholtz Zentrum 
München) 
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Figure 25. Flow cytometric characterization of 2+MoPh and imDC. In-vitro 
polarized 2+MoPh cells were characterized by flow cytometry. Red curves indicate the 
corresponding marker specific antibody, blue curves indicate the corresponding 
isotype controls. Cells were stained according to the protocol in 3.9. Numbers are 
median intensity of fluorescence.  
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4.3.2 2+MoPh and related myeloid cells can activate homeostatic 
pathways by co-incubation with reporter cells 
To better understand the potential effect of different myeloid cells on the homeostatic 
milieu of experimental renal parenchymal cells, 2+MoPh and imDC cells were co-
cultured with Hek293 cells engineered to express a series of reporters linked to 
homeostatic pathways associated with progressive renal damage, and additional 
candidate signaling networks.  
In a pilot experiment to determine if the myeloid cells were toxic for the reporter cells, 
2+MoPh and imDCs were co-cultured with HEK293 cells. To mimic varying degrees of 
immune-infiltration, the ratio between the model interstitial cells and the infiltrate was 
adjusted by adding different amounts of 2+MoPh/imDCs and no cytotoxic or growth 
impeding effects could be detected microscopically. 
 
 
Figure 26. Varying 
amounts of myeloid cells 
co-cultured with 20,000 
HEK293 reporter cells  
20,000 HEK293 reporter 
cells were seeded in 96-well 
format and either  
A) 100 myeloid cells  
B) 10,000 myeloid cells 
C) 40,000 myeloid cells 
added in co-culture for 48 
hours. No cell death or 
growth impediment of 
HEK293 cells was observed. 
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Using a panel of reporters (see 4.2.1.), co-incubation experiments were performed 
using 20,000 HEK293 reporter cells plated into 96-wells, and after 48 hours 40,000 
imDC or 2+MoPh were added to the wells. 48 hours later conditioned supernatant was 
sampled and reporter activity measured.  
The results showed robust activation of the Hegehog, MAPK and TGFβ pathways, 
with less activation of WNT and LXR by 2+MoPh. imDCs had only minor effects on the 
various reporters. The HIPPO/TEAD pathway was slightly induced by 2+MoPh, but not 
by imDCs.  
Figure 27. Hek Reporter cells co-
cultured with primary, polarized 
myeloid cells. 20,000 Hek293 
reporter cells were co-cultured for 
48 hours with 40,000 imDC or 
2+MoPh cells. Supernatants were 
sampled for luciferase activity. Co-
culture with 2+MoPh lead to robust 
activation of the Hedgehog, TGFβ 
and AP-1 reporters, less effect was 
observed on WNT and LXR, while 
HIPPO/TEAD signaling was largely 
unaffected. Co-culture with imDCs yielded less signal than co-culture with 2+MoPh. 
(three wells per group, experiment representative of three individual experiments, 
changes are all highly significant between imDC and 2+MoPh treatment, all p<0.005). 
 
These results suggest that the 2+MoPh cells may have direct effects on the 
homeostatic pathways of parenchymal cells. As a next experiment, the dose 
dependent nature of the response was assessed using Hedgehog reporter cells and 
titrating the amount of 2+MoPh cells applied to the 96-wells. 
 
Figure 28. Hedgehog Reporter 
titration with 2+MoPh cells. 20,000 
HEK293 Hedgehog reporter cells 
were co-cultured with serial 
dilutions of 2+MoPh cells. (three 
wells per group, experiment 
representative of two individual 
experiments). 
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A robust dose-dependent response was found. The experiment was then expanded 
to the other homeostatic pathways. A dose dependency could be shown for each 
reporter. Here, HIPPO/TEAD was not included due to its dependency on contact 
inhibition (also see addendum 6.5). Each pathway showed a dose dependency similar 
to that seen for the Hedgehog pathway. 
 
Figure 29. Reporter titration with 
2+MoPh cells. 20,000 HEK293 
reporter cells for Hedgehog, TGFβ, 
WNT or LXR signaling were co-
cultured with dilutions of 2+MoPh cells. 
(three wells per group, experiment 
representative of three individual 
experiments). 
 
 
4.3.3 The factor(s) responsible for the activation of these pathways are 
secreted by 2+MoPh cells 
To define whether the signals produced by myeloid cells where transduced through 
cell-cell contact, by soluble factors in the media, or by exosomes, various treatments 
of serum free supernatants were tested. To help facilitate these, and related 
experiments, experimental myeloid cell lines were tested for potential ability to activate 
the same pathways identified in the 2+MoPh experiments. The identification of a 
myeloid cell line would be helpful as the primary myeloid cells were difficult to 
generate, and generally showed poor viability under the serum starvation conditions 
needed to perform many of the following experiments.  
To this end, THP1 and Mono-Mac-6 cell lines which were originally derived from 
patients with acute monocytic leukemia, and show suitable growth characteristics, 
were tested [198, 199]. Surface marker characterization of the Mono-Mac-6 and THP-
1 cell lines are found in the addendum (6.3). 
 
 
Hedgehog TGF WNT LXR
0
5.0 105
1.0 106
1.5 106
2.0 106
2.5 106 Control
100 2+MoPh
1000 2+MoPh
10,000 2+MoPh
40,000 2+MoPh
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Figure 30. Hek293 Reporter cells 
co-cultured with myeloid cell 
lines. 
To test whether model parenchymal 
cell reporter lines could be activated 
by co-Incubation with myeloid cell 
lines, a panel of HEK293 reporter 
lines were co-incubated with the 
myeloid leukemia lines Mono-Mac-
6 (MM6) and THP1. Reporter cells 
for Hedgehog, TGFβ, and, to a 
lesser degree, LXR and WNT 
signaling pathways showed induction following co-incubation, while TEAD was 
unchanged. 20,000 Hek293 reporter cells were co-incubated with 40,000 myeloid cells 
for 48 hours in 96-well plates, 100µl volume per well. Secreted Gaussia luciferase 
reporter activity was measured from the growth media. Data represent relative light 
units (RLU) normalized to assay medium or myeloid conditioned assay media. 
Experiment representative of three individual experiments, three wells per treatment 
group. Changes are highly significant (p<0.0005) for HH, TGF, WNT and LXR 
reporters when co-incubated with Mono-Mac-6 cells. 
 
The cell lines were then tested in co-culture with a panel of reporter cells. The Mono-
Mac-6 cell line strongly activated the Hedgehog reporter as well as the TGFβ, WNT 
and LXR reporters. TEAD was not activated. Due to technical problems, AP-1 
activation experiments using Mono-Mac-6 cells were done individually, but also 
showed strong activation for Mono-Mac-6 cells (see supplement 6.3.1). THP-1 cells 
showed the same general activation profile, but the level of stimulation was far weaker 
than that seen with the Mono-Mac-6 cells. The Mono-Mac-6 results showed a good 
correlation with the data generated from the 2+MoPh cells, and were used in a series 
of experiments to help characterize the nature of the signal driving activation seen. 
The overall level of activation seen were generally weaker with Mono-Mac-6 than with 
2+MoPh cells. 
A series of Mono-Mac-6 cells dilutions was used in co-culture experiments using the 
Hedgehog and TGFβ reporter HEK293 cell lines. A strong dosage dependency was 
observed. 
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Figure 31. Mono-Mac-6 titration 
with Hek293-reporter lines. To 
assess whether the effects shown in 
figure 30 are dose-dependent, a 
serial dilution of Mono-Mac-6 (MM6) 
cells was added to 20,000 Hek293 
cells reporter cells in 96-well format 
for 48 hours. TGFβ and Hedgehog 
reporter lines showed a dose 
dependent increase in signal, with 
the Hedgehog signal being 
stronger. Three 96-wells per group, 
experiment representative of three 
individual experiments. 
 
To assess whether the signal(s) delivered by myeloid cell lines could also be conferred 
by conditioned medium from Mono-Mac-6 cells, Hedgehog and TGFβ reporter 
HEK293 cells were tested in parallel in a stimulation experiment.  
 
Figure 32. Mono-Mac-6 
conditioned media stimulation of 
Hek293 reporter cell lines. 
As Mono-Mac-6 (MM6) co-
incubation had strong effects the 
next question was whether the 
effect depended on cell-cell contact 
or was also conferred by 
conditioned Mono-Mac-6 medium.  
Since there was a strong dosage-
dependency observed in the co-
culture experiments, 20,000 Hek293 Hedgehog and TGFβ reporter cells were seeded 
in 96-well plates and stimulated for 48 hours with dilutions of Mono-Mac-6 conditioned 
(72h) medium. Similar to the findings in direct co-culture, activation of the Hedgehog 
signaling pathway was stronger than for TGFβ/SMAD signaling. Three 96-wells per 
group, experiment representative of three individual experiments. 
 
 
While this experiment showed that conditioned supernatants could activate the 
reporter cells in a dose dependent manner, it also became clear that the activation 
potential of these supernatants was much reduced in comparison to co-culture. To 
increase the efficacy of the Mono-Mac-6 supernatants, the harvested, serum-free 
supernatants were then concentrated to increase their stimulation potential. This was 
done using concentration spin columns with a 10kDa cut-off as described in the 
methods section.  
R
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Figure 33. Concentrated Mono-
Mac-6 conditioned media 
stimulated Hek293 Hedgehog 
reporter cells. 
To amplify effects seen with 
conditioned medium, the serum-
free Mono-Mac-6 conditioned 
medium was concentrated to 10X 
using spin filters with 10kDa 
exclusion. This lead to a maximum 
final concentration of 5X in the 
assay by dilution with FCS 
containing assay medium. Results show a dramatic increase in signal with increased 
concentration. Three 96-wells per group, experiment representative of three individual 
experiments 
The concentrated supernatants showed an enhanced potential to activate the reporter 
cell lines, while diluting the concentrated supernatant reduced efficacy, again 
indicating a dose dependency. Having determined that the signal did not require direct 
cell-cell contact, the nature of signal(s) within the conditioned media were further 
shown to be sensitive to heat denaturation and protease treatment. The results 
strongly suggest secreted protein(s)/peptide(s) as the activating factor(s). 
Figure 34. Destruction of signal 
conferring components in Mono-
Mac-6 supernatants. Mono-Mac-6 
(MM6) supernatant was either 
heated at 98°C for 30 minutes or 
digested with Proteinase K in a 1:50 
w/w dilution (enzyme / protein 
content) for 60 minutes and then 
heat inactivated for 10 minutes at 
98°C. The resulting inactivated 
supernatants were used to 
stimulate 20,000 Hedgehog 
reporter carrying HEK293 cells for 
48 hours. Heat inactivation dramatically reduced activation of reporter cells, 
Proteinase K digest removed the signal. Single experiment with five individual 96-wells 
per treatment group. 
 
Exosomes are secreted by many cell types, including myeloid cells. They are small 
lipid encapsulated microbodies between 30 and 100nm in diameter that can activate 
target cells either through molecules on their surface, or other factors delivered to the 
target cell upon exosome fusion or uptake [200]. To determine if exosomes present in 
the supernatants could influence luciferase production by the reporter cells, exosomes 
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were purified either using a previously described ultracentrifugation method, or using 
a commercially available exosome preparation kit.  
Figure 35. Exosome treatment of 
Hek293 Hedgehog reporter cells. 
Exosomes were prepared from 48h 
conditioned, serum-free Mono-
Mac-6 medium using two different 
techniques, and used to stimulate 
HEK293 Hedgehog reporter cells 
for 48 hours. Exosomes were 
prepared from 52ml of conditioned 
medium for each preparation with a 
final ~100µl resultant concentrated 
exosome volume (Undiluted 
concentrations: ExoSpin Prep: 
0.35mg/ml, Ultracentrifuge Prep: 
0.27mg/ml). Addition of concentrated exosomes had no effect on Hek293 Hedgehog 
reporter cells. Controls are untreated Hek293 reporter cells. Two experiments with 
three 96-wells per group. 
Neither preparation technique showed any activation of the Hedgehog reporter cell 
line, even though this reporter showed the strongest activation with the full 
supernatants and in co-culture experiments. Since this result suggested that the signal 
was transduced by a soluble factor, depletion of exosomes from the supernatants 
should not diminish the activation seen with complete supernatant. To verify this, 
complete supernatant was cleared of non-soluble components, such as exosomes, by 
ultracentrifugation.  
Figure 36. Hek293 reporter cells 
treated with exosome depleted, 
and 4X concentrated medium. To 
further validate a lack of impact of 
exosomes on stimulation of the 
Hek293 Hedgehog signaling 
reporter cells, conditioned myeloid 
supernatants were processed either 
by low speed or by ultra-
centrifugation (100,000 RCF, 
relative centrifugal force). Ultra-
centrifugation removed cell debris 
and all microparticles (including exosomes), yielding medium containing only soluble 
factors. Centrifugation at 2,000 RCF was done to remove cells and cell debris, but did 
not remove microparticles. Both preparations (after concentration to 8X, yielding 4X 
concentrated medium in the assay) showed strong induction of the Hek293-Hedgehog 
and –TGF reporters suggesting again that exosomes are not responsible for the 
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signaling events seen. Controls are untreated Hek293 reporter cells. Two experiments 
with three 96-wells per group. 
Supernatants subjected to ultracentrifugation did not show any significant differences 
in activation experiments to the activation seen with non-exosome depleted 
supernatants. The results suggest that a soluble factor, probably a peptide, was the 
causal component. 
4.3.4 Proteomics 
To identify candidate soluble factors responsible for activation of the reporter lines, 
conditioned supernatants from lab polarized 2+MoPh and imDCs were analyzed 
proteomically in an initial set of experiments. Immediately after polarization, 2+MoPh 
and imDCs were cultured in the same serum-free assay medium for 46 hours. 
Supernatants were then harvested, proteolyzed with trypsin and their composition 
analyzed by mass spectrometry using a Q Exactive high field mass spectrometer by 
our collaboration partners at the Research Unit Protein Science, Helmholtz Zentrum 
München as detailed in 3.10. Out of the total 1807 identified components in the 
supernatants, 11 known growth factors, ligands, chemokines and cytokines were 
detected (see table 4). Importantly, ligands for the WNT or Hedgehog pathways were 
absent from the list, suggesting that a non-canonical mode of activation may be 
responsible for the pathway stimulation caused by 2+MoPh co-culture. Similarly, while 
the TGFB1 ligand was present, its protein level was elevated in the imDC sample as 
compared to the 2+MoPh sample and thus a stronger TGFβ/SMAD signal for imDC 
than 2+MoPh in co-culture experiments would have been expected. Two potential 
explanations for the contrary results seen in-vitro, are that there may be differences in 
either the processing of the latent TGFB1 protein, or there may be additional activation 
of TGFβ/SMAD signaling via cross-talk or non-canoncial activation of the pathway. 
A large number of surface proteins were also identified in the culture supernatants, 
this may result either from proteolytic cleavage from the cell surface, or by their 
presence on/in microbodies. Parallel experiments carried out using Mono-Mac-6 cells 
showed overlapping results with the 2+MoPh findings. 
Based on these initial findings, direct stimulation experiments of HEK293 reporters 
were carried out using recombinant version of the candidates CXCL8 (IL-8), CCL2 
(MCP-1) and IL18. Stimulation with these factors failed to activate the Hedgehog 
reporter cells (data not shown). MYDGF (short for myeloid derived growth factor), an 
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interesting candidate protein, was tested by its overexpression in a second, co-
cultured cell line (using the inducible expression vector), but it was also found to have 
no discernible effect on Hedgehog pathway activation (data not shown).  
Soluble Factor Foldchange 2+MoPh to imDC 
CCL2 158 
CXCL8 123 
NCF4 12 
IL18 7 
MYDGF 2 
TGFBI -2 
CXCL16 -2 
IL16 -2 
HDGF -2 
CXCL10 -14 
CCL17 -521 
Table 4. Growth factors, cytokines and chemokines identified via mass 
spectrometry. 
 
4.3.5 Inhibitor studies were used to identify potential upstream signaling 
cascades 
Since no causal factor could be readily identified proteomically, and to further 
characterize the nature of the signal cascade leading to activation of the relevant 
reporter lines, a series of small molecule inhibitors that target specific signaling 
cascades was employed. Since Hedgehog signaling showed the strongest activation 
across multiple experiments and myeloid cells, and cell lines, this reporter was chosen 
as a general read-out. The Hedgehog signaling pathway is known to have one 
canonical and at least two non-canonical branches [58, 61, 62]. Since no Hedgehog 
ligands were identified in the proteomics screen, a non-canonical activation was a 
potential explanation for the effects seen. In a first experiment, the GLI1/GLI2 inhibitor 
GANT61 was used in conjunction with concentrated Mono-Mac-6 supernatant. This 
control inhibitor specifically inhibits binding of the activated GLI1/2 transcription factor 
to DNA, thus further validating activation of the Hedgehog pathway [201].  
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Figure 37. Hek293 Hedgehog 
reporter cells treated with 
GANT61. Hek293 Hedgehog 
signaling reporter cells were treated 
with or without conditioned Mono-
Mac-6 supernatant (MM6 SN) and 
the GLI1/GLI2 specific DNA binding 
inhibitor GANT61. Treatment with 
GANT61 strongly decreased the 
activation seen with Mono-Mac-6 
supernatant. Experiment 
representative of three individual experiments, three 96-wells per treatment group. 
 
The reporter activation seen with the Mono-Mac-6 supernatant was strongly reduced 
with GANT61 treatment. As Kinase signaling pathways are thought to be major 
contributing factors for the non-canonical Hedgehog signaling branches [63, 64], 
inhibitors for mTOR [202], ERK/MAPK and PI3K were then tested. Inhibition of 
ERK/MAPK with PD98059 [203] showed the strongest reduction of activity, with the 
PI3K [204] inhibitor Wortmannin [205] also showing significant reduction of the signal. 
These results suggest that a major component of the conditioned supernatants acts 
via stimulation of the MAPK / PI3K signaling network. 
Figure 38. Hek293 Hedgehog 
reporter cells treated with 
Rapamycin, PD98059 or 
Wortmannin. 
20,000 Hek293 Hedgehog 
signaling reporter cells were treated 
with or without 5X concentrated 
conditioned Mono-Mac-6 
supernatant (MM6) and either the 
mTOR inhibitor Rapamycin 
(250nM), the MAPK/ERK inhibitor 
PD98059 (25µM) or the PI3K 
inhibitor Wortmannin (200nM) for 48 hours in 96-well format. Treatment with PD98059 
and Wortmannin strongly decreased the activation seen with Mono-Mac-6 
supernatant, while Rapamycin slightly increased activation, possibly by modulating 
other signaling processes and resulting increased Hedgehog activity. Three 96-wells 
per treatment group, experiment representative of three individual experiments. All 
changes are significant with at least p<0.005. 
 
To assess whether a known non-conical Hedgehog activator, human epithelial growth 
factor (EGF) [117, 188], could also activate the reporter in this context, and whether 
this effect could be reduced by PD98059 or Wortmannin, an additional set of 
experiments was conducted.  
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Figure 39. Hek293 Hedgehog 
reporter cells treated with rhEGF 
and PD98059 or Wortmannin. 
Hek293 Hedgehog signaling 
reporter cells were treated with or 
without recombinant human EGF 
protein and the MAPK/ERK inhibitor 
PD98059 (25µM) or the PI3K 
inhibitor Wortmannin (200nM). 
Treatment with rhEGF strongly 
activated the Hedgehog reporter, 
while treatment with PD98059, but 
not Wortmannin, strongly reduced the reporter activity. Three 96-wells per treatment 
group, experiment representative of two individual experiments. 
 
As previously reported, EGF was able to strongly activate the HEK293 Hedgehog 
reporter cells, and thus demonstrated non-canonical Hedgehog activation. PD98059 
was subsequently shown to reduce the EGF-mediated signal. More importantly, this 
assay also showed that Wortmannin could not reduce the activation seen analogous 
to the supernatant stimulation experiments, suggesting that there is another signal not 
provided by EGF-mediated signals that may be relevant for the 2+MoPh-mediated 
effects.  
4.3.6 Can LXR activation modulate 2+MoPh and imDC activation 
patterns? 
After the observation that co-culture with 2+MoPh and imDC cells could also activate 
the LXR reporter (see 4.3.2 and 6.4), modulation of myeloid cell activation patterns by 
targeted activation of LXR was studied. These studies were in part based on previous 
findings showing the importance of LXR signaling in the polarization and maturation 
of myeloid cell populations [183, 184]. In addition, increased LXR levels have been 
shown to suppress chronic damage in renal allograft and other disease models [185, 
186], and their presence is also known to be important for regulation of renal sodium–
phosphate transporters, as well as glucose and fatty acid homeostasis [206, 207]. 
As a first step, the functional range of the synthetic, non-steroidal LXR agonist 
GW3965 [208] was determined in the HEK293 LXR reporter cells. A titration 
experiment identified the function range of the agonist and showed that higher 
dosages of GW3965 appear toxic to the HEK293. 
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Figure 40. Stimulation of LXR reporter 
HEK293 cells with the synthetic LXR 
Agonist GW3965. To assess a functional 
range of GW3965 in HEK293 cells, stable 
transfected HEK293 LXR reporter cells 
were treated with varying doses of 
GW3965 for 48 hours after which reporter 
activity was assessed. Treatment with 
GW3965 activates the LXR nuclear 
receptors in a dosage dependent 
manner, with high doses being toxic to 
the cells. 3 wells per group, experiment 
representative of three individual 
experiments. 
 
After determining an optimal concentration to use for LXR-based activation using 
GW3965, a variation of the co-culture experiments detailed in 4.3.2 was used to 
assess whether activation of LXR in polarized myeloid cells by GW3965 treatment 
would change their activation potential as measured with HEK293 reporter cell lines. 
 
Figure 41. GW3965 Effect on primary cells: 20,000 reporter cells were co –cultured 
with 40.000 2+MoPh or imDC with and without GW3965. 100nM/1µM GW3965 was 
administered at the beginning of co-culture. Effects on LXR Reporter cells were 
assayed as an internal control for G3965 efficacy. GW3965 treatment had no effect 
on primary myeloid cell activation of HEK293 reporter cells. Three wells per treatment 
group, two experiments. 
 
Since no differences could be detected with GW3965 treatment outside the HEK293 
LXR control reporter cells, the treatment was deemed to have no effect on the 
secretion patterns of either fully polarized 2+MoPh or imDC. To determine whether the 
treatment with GW3965 could influence the pathway at an earlier point in myeloid 
polarization, 2+MoPh and imDCs were treated with 1µM GW3965 either at the 
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beginning of the polarization regimen or at the initiation of co-culture. In this 
experiment, the amount of 2+MoPh in the co-culture was reduced in order to enhance 
potential GW3965-mediated effects. No effect of GW3965 was observable (for 
additional characterization of LXR signaling see addendum 6.4).  
Figure 42. GW3965 Effect on 
diluted primary cells. 20,000 
HEK293 reporter cells for 
Hedgehog were co–cultured with 
different amounts of 2+MoPh cells 
with and without GW3965. 1µM 
GW3965 was administered either at 
the beginning of co-culture or prior, 
directly during polarization. 
GW3965 treatment had no effect on 
primary myeloid cell activation of 
HEK293 reporter cells. Three wells per treatment group, two experiments. 
 
4.4 Bioinformatic analysis of pathway alterations associated with 2+MoPh 
in DN patient biopsies 
Based on the results of the in-vitro studies detailed above, a set of the homeostatic 
pathways were experimentally validated in the experimental parenchymal cells to be 
activated by the presence of 2+MoPh cells. In addition, the data suggest that the effects 
occur via a MAPK-mediated non-canonical activation. To further expand our analysis 
to the DN patient data, we then sought to determine, if gene signatures representing 
the pathways identified in the in-vitro studies could be significantly correlated with the 
presence of 2+MoPh cells in human renal biopsy samples. To this end, the 
deconvolution signature that allowed the selective identification and quantification of 
2+MoPh signals within complex transcriptomic data (detailed in 4.1.2) was applied. All 
subsequent analyses were based on transcriptomic data collected from the 17 
microdissected DN biopsies and set of 30 LD control renal biopsies as described in 
4.1.2. 
4.4.1 Identification of co-regulated gene modules by weighted gene co-
expression network analysis (WGCNA) 
To determine the potential association of activated pathways identified in-vitro with the 
presence of 2+MoPh in patient biopsy samples, a detailed list of genes known to be 
associated with the four general homeostatic pathways identified in the in-vitro studies 
was first compiled. The sources for these gene lists included commercially available 
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pathway research tools, and pathway databases (Genomatix, 
http://www.genomatix.de/, literature-derived gene lists for RT-PCR arrays from Qiagen 
/ SABiosciences, http://www.sabiosciences.com/ArrayList.php, and the Wikipathways 
platform http://www.wikipathways.org/index.php/WikiPathways). The list eventually 
comprised 773 genes previously established to be broadly associated with the WNT, 
Hedgehog, TGFβ/SMAD and MAPK pathways. Hippo signaling genes were omitted 
from the final gene list due to the very low levels of activation in co-culture experiments 
(see also Addendum 6.5). LXR signaling was also omitted for the following analysis. 
Of the 773 genes, 680 were shown to be expressed in the tubulointerstitial 
compartment of the human kidney samples were studied. The goal was then to 
determine if changes in specific pathway signatures could significantly correlate with 
2+MoPh deconvolution scores. As expected, the pathways exhibited diverse 
regulatory patterns for their individual component genes. Because of the potential for 
pathway crosstalk and evidence for non-canonical signaling, the genes were further 
grouped based on their expression patterns, irrespective of their classical association 
with a respective pathway. To this end, a weighted correlation network analysis 
(WGCNA) strategy was applied [163]. This bioinformatics tool was used to help identify 
clusters (also called modules) of highly co-regulated genes, which could then be used 
in place of individual genes for subsequent downstream correlation with the 2+MoPh 
deconvolution score. The general approach allowed us to focus on smaller groups of 
genes linked to the biology of specific pathways. Additionally, the WGCNA method 
was used to identify intramodular hub genes, allowing a measure of biological context 
in comparing the individual modules. In order to avoid potential bias in the analysis by 
adding a hierarchy, the individual modules were assigned an arbitrary color.  
 
Table 5. Modules identified 
by WGCNA. A pseudo-
module was generated for 
unassigned genes; nine 
modules were identified using 
weighted correlation network 
analysis. The defining hub 
genes for each module are 
indicated in the table. Bold font 
indicates significant 
correlation with 2+MoPh 
 
Module identifier Hub Gene 
black HOXA5 
blue CAMK2A 
brown SNX4 
green GDF9 
pink UBE2L3 
red TCF7L2 
turquoise CDKN1A 
yellow RAC2 
grey (remaining genes) ROR1 
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As detailed above, the correlation of the individual modules to the deconvolution 
scores from 4.1.2 was used as a screening criterion to discern which modules, and 
thus which pathway gene sets, changed transcriptomically with an increased 2+MoPh 
signature in the tubulointerstitial regions during DN disease progression (as evidenced 
with reduced eGFR in 4.1.2). A p-value based on the correlation of the genes with the 
individual samples was calculated to discern significant correlation. These studies 
were performed in collaboration with Ms. V. Nair, University of Michigan, Ann Arbor. 
Figure 43. Correlation 
of modules identified 
by WGCNA to 
deconvolution score.  
Expression profiles of 
modules across DN 
samples were 
correlated to the 
2+MoPh deconvolution 
score calculated for the 
same samples to 
identify transcriptomic 
changes coinciding 
with increased 2+MoPh 
presence. Modules 
turquoise and yellow 
exhibited a significant 
positive correlation, module brown exhibited a significant negative correlation. C: 
correlation coefficient, p: p-value, heat scale indicates correlation coefficient, with red 
being positive and green being negative. 
 
The WGCNA strategy identified three significantly correlated modules: turquoise, 
yellow and brown. Turquoise and yellow exhibited positive correlation, indicating 
upregulated genes during DN, brown showed negative correlation indicating 
downregulation. 
4.4.2 Genetic composition of modules 
After filtering for significantly altered modules, the composition of the individual 
modules was studied in more detail. For each gene, an individual correlation 
coefficient to the deconvolution score was used as a measure of 2+MoPh presence, 
with a corresponding p-value calculated to allow for additional filtering. This filtering 
yielded 23 significant genes for module “brown”, 62 genes for module “turquoise” and 
38 genes for module “yellow” (for a full list see the addendum). Through a literature 
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search, each gene was then assigned to functional or regulatory groups. The most 
highly represented groups per module can be found in table 6. 
 
Module Functional Group Percentage in Module 
“brown” MAPK associated 52% 
 WNT associated 13% 
 Proteasome associated 9% 
“turquoise” MAPK associated 33% 
 WNT associated 16% 
 Proteasome associated 13% 
 TGFβ/SMAD associated 8% 
 ECM/Fibrosis associated 6% 
“yellow” MAPK associated 39% 
 Regulation of Cell Cycle 16% 
 WNT associated 13% 
 TGFβ/SMAD associated 8% 
 ECM/Fibrosis associated 8% 
Table 6. Most highly represented functional groups per module. For each module, 
the genes with expression patterns significantly correlating with 2+MoPh presence as 
determined with the deconvolution analysis were considered. Genes were then 
grouped based on functional or regulatory context and percentages calculated in 
reference to the total number of genes in the corresponding module.  
 
For the three modules, the MAPK associated group represented the largest 
component. The “brown” module was negatively correlated with 2+MoPh presence, 
while the “turquoise” and “yellow” modules were positively correlated. Similarly, WNT 
associated genes made up a large portion of all three modules. In contrast, 
proteasome, TGFβ/SMAD or ECM/Fibrosis associated genes varied more between 
the modules. The “yellow” module is different from the other two modules due to its 
comparably large component of genes important for the regulation of the cell cycle, 
which underlies the control of cell proliferation. 
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4.4.3 Potential “high impact” pathway genes within modules 
Within the function or pathway associated groups for each module, a number of well-
characterized proteins associated with tissue homeostatic pathways were identified. 
This does not imply that genes not listed here (see addendum 6.1) do not play a role 
during DN, but many of these candidate genes are not well enough studied to provide 
a perspective on their potential to impact disease progression. For similar reasons, 
transcription factors that are not classically associated with a homeostatic pathway 
were omitted from this list as their regulation patterns are often highly context 
dependent and have rarely been exhaustively studied. For the sake of simplifying 
description of these “high impact” genes, the “turquoise” and “yellow” modules will be 
viewed together due to both of them being positively correlated to 2+MoPh presence 
at similar levels (and thus have a higher expression in comparison to control kidneys), 
while the “brown” module showed negative correlation (and thus downregulation in 
comparison to controls).  
All changes are summarized in table 7. In the MAPK signaling network, the associated 
RTK ligands VEGFA, VEGFC and EGF showed altered expression, with VEGFA and 
EGF found to be downregulated and VEGFC upregulated [103]. The MAPK associated 
receptors RYK [209], MET [210], and the JAK/STAT co-receptor JAK1 [112] exhibited 
uniform upregulation and similar patterns could be found for the signal transducing 
MAP kinases MAP3K5, MAP3K8 [211] and STAT1, a pivotal transcription factor of the 
JAK/STAT branch [112]. MAP3K12 showed downregulation. The dimeric AP-1 
transcription factor subunits that are also downstream of the MAPK network were 
upregulated, as evidenced by JUN, JUNB and FOS [212]. Finally, the MYC 
transcription factor was overrepresented while MYCN was downregulated [213].  
In the WNT pathway, the WNT2B and WNT7A ligands were increased, while WNT8B 
was reduced [214]. All three ligands are considered canonical WNTs, and thus their 
presence leads to β-catenin stabilization. Complications in interpreting WNT ligand 
functions stem in part from the multitude of FZD ligands and their varying specificity 
for the individual ligands. In the DN setting, FZD2, FZD6, FZD7, FZD10 and FZDB 
were all upregulated and correlated with the 2+MoPh deconvolution signature [215]. 
Interestingly, the co-receptor LRP6 was reduced, while the signal transducing casein 
kinases were increased in expression. LRP6 is a component of the canonical pathway, 
but has also been shown to act in non-canonical contexts [190, 216, 217]. WNT/PCP 
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signaling interacts with JNK signaling, making the interplay of the two pathways in DN 
an interesting object to study [82]. 
In the TGFβ/SMAD pathway, the TGFBR2 receptor was found to be upregulated with 
the deconvolution signature. In the BMP/SMAD pathway, the BMP2 ligand was 
significantly increased. TGFβ target genes were also identified as being 
overrepresented in the samples. Matrix metalloproteinase-7 (MMP7) is associated 
with ECM turnover, the processing of growth factors, and has been reported to be 
upregulated in the context of renal fibrosing diseases [218, 219]. CTGF [220] and 
CYR61 [221] were also identified here, and are also known to be elevated during most 
fibrosing diseases, and implicated in wound healing programs. 
 
Pathway Gene name Function Regulation 
MAPK VEGFA Ligand / growth factor Down 
 VEGFC Ligand Up 
 EGF Ligand Down 
 RYK Receptor Up 
 MET Receptor Up 
 JAK1 Co-receptor Up 
 STAT1 Signal transducer / transcription factor Up 
 MAP3K5 Signal transducer Up 
 MAPK3K8 Signal transducer Up 
 MAP3K12 Signal transducer Down 
 JUN AP-1 component, transcription factor Up 
 JUNB AP-1 component, transcription factor Up 
 FOS AP-1 component, transcription factor Up 
 MYC Transcription factor Up 
 MYCN Transcription factor Down 
WNT WNT2B Ligand Up 
 WNT7A Ligand Up 
 WNT8B Ligand Down 
 FZD2 Receptor Up 
 FZD6 Receptor Up 
 FZD7 Receptor Up 
 FZD10 Receptor Up 
 FZDB Receptor Up 
 LRP6 Receptor Down 
 CSNK1A1 Signal transducer Up 
 CSNK1G3 Signal transducer Up 
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Pathway Gene name Function Regulation 
TGFβ/SMAD BMP2 Ligand Up 
 TGFBR2 Receptor Up 
 CTGF TGFβ target, wound healing and fibrosis Up 
 CYR61 TGFβ target, wound healing and fibrosis Up 
 MMP7 TGFβ target, ECM degradation Up 
Table 7. Dysregulated pathway genes correlating to 2+MoPh. 
 
In addition to the alterations of core pathway genes, changes in the expression of gene 
ontological groups influenced by the homeostatic signaling pathways were observed. 
The upregulation of cyclins and cyclin dependent kinases suggests increased cell 
cycle activity and proliferation, potentially linked to the activation of wound healing 
programs [222, 223].  
Increased ECM deposition, a hallmark of DN, was observed on the transcriptomic level 
with the increased expression of Galectin, Laminin, Fibronectin, Collagens and 
Versican [224]. The aforementioned TGFβ associated markers MMP7, CTGF and 
CYR61 support this observation.  
Finally, genes associated with the proteasome were upregulated, with five proteasome 
subunits found to be upregulated, and two subunits decreased. Additionally, the 
ubiquitination mediators Cullin1 and UBE2E1 were also upregulated [225]. These 
alterations are summarized in table 8. 
 
Function Gene Description Regulation 
Cell cycle CDKN1A Cyclin dependent kinase inhibitor Up 
 CDK1 Cyclin dependent kinase Up 
 CCNB1 Cyclin B1 Up 
 CCNB2 Cyclin B2 Up 
 CCND2 Cyclin D2 Up 
 CCND3 Cyclin D3 Up 
ECM LGALS3 Galectin 3 Up 
 LAMC1 Laminin subunit gamma Up 
 FN1 Fibronectin Up 
 COL1A1 Collagen type I alpha 1 chain Up 
 COL1A2 Collagen type I alpha 2 chain Up 
 VCAN Versican Up 
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Function Gene Description Regulation 
Proteasome PSMA2 Proteasome subunit alpha 2 Down 
 PSMA4 Proteasome subunit alpha 4 Up 
 PSMB8 Proteasome subunit beta 8 Up 
 PSMB9 Proteasome subunit beta 9 Up 
 PSMB10 Proteasome subunit beta 10 Up 
 PSMC2 proteasome 26S subunit, ATPase Down 
 CUL1 Cullin 1,  Up 
 UBE2E1 Ubiquitin conjugating enzyme Up 
Table 8. Pathway-associated genes correlating to 2+MoPh sorted by function.
Discussion   92
 
5 Discussion 
DN develops as a complication of diabetes [14, 15, 18, 21]. It is characterized by 
morphological changes in the kidney including a thickening of the glomerular 
basement membranes and the mesangium, glomerular sclerosis and progressive 
fibrosis of the interstitial region [22]. The fibrotic processes seen in most progressive 
chronic kidney diseases are thought to result in part from overly active wound healing 
programs leading to increased ECM deposition by fibroblasts and epithelial cells [29, 
39]. An enhanced immune cell infiltrate, especially myeloid derived cells such as 
macrophages, DCs and other rMoPh, is associated with progressive DN [143, 146, 
147, 150, 151]. The composition of the infiltrate may have direct effects on the 
parenchymal tissues.  
Recently, the 2+MoPh cell type was described in normal kidney and shown to be 
increased in renal cell carcinoma and in examples of CKD [139, 151]. 2+MoPh 
expression patterns have been shown to be distinct from classical dendritic cells and 
to overlap with macrophage-associated genes. The renal 2+MoPh phenotype is 
thought to derive from invading monocytes that become conditioned by renal-
associated signals, leading to the specific myeloid subtype [151]. A 2+MoPh-like 
phenotype can also be derived in-vitro through the treatment of peripheral blood 
monocytes with kidney epithelial, or renal cell carcinoma conditioned supernatants 
(Brech et al. submitted). Interestingly, 2+MoPh also express high levels of CCL2 (see 
4.3.4), a chemokine ligand for the CCR2 receptor, suggesting that 2+MoPh may show 
a positive feedback, or amplification of myeloid infiltration.  
Treatment with CCR2 antagonists could act by blocking the recruitment of 2+MoPh or 
related myeloid progenitors and thus impact the development of chronic damage. A 
series of preclinical DN studies have demonstrated the therapeutic efficacy of myeloid 
cell infiltration blockades via use of the CCR2 chemokine receptor antagonists 
RS504393, RO523444 and RS102895 [24, 226-229]. Treated kidneys in mouse 
models showed ameliorated albuminuria, renal dysfunction and less histological 
changes. Additionally, two recent clinical studies using the orally available CCR2 
inhibitor CCX140-B [230] and the CCL2 inhibitor NOX-E36 [231] showed positive 
effects on urine albumin-to-creatinine ratio and slight reduction of HbA1c in diabetic 
nephropathy patients, even after cessation of treatment.  
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These general observations lead to our hypothesis that 2+MoPh may exert direct 
effects on the homeostatic pathways controlling tissue morphology in kidney 
parenchymal cells. If so, 2+MoPh would represent a key cell type in the progression of 
fibrosis leading to damage to the kidney fine structure, and ultimately resulting in 
nephron loss of function. Genes classically associated with fibrosis include CTGF and 
CYR61, downstream targets of the TGFβ signaling pathway [34, 220, 221]. Similarly, 
members of the WNT and Hedgehog signaling pathways are strongly dysregulated 
during fibrotic renal disease progression [31, 37, 40]. To study the potential direct 
effect of 2+MoPh on kidney cells in the context of DN, a strategy combining 
bioinformatic analyses and in-vitro experiments was devised.  
 
Figure 44. Experimental outline. Outline of the strategy applied for this study. 
(gray: pre-existing data, yellow: bioinformatic studies, red: in-vitro experiments.) 
 
5.1 Initial transcriptomic findings 
As a first step, a human microarray dataset generated from microdissected tubular 
interstitial samples taken from biopsies of DN patients, and control samples from living 
donor kidneys was transcriptomically analyzed [154]. Specifically, altered homeostatic 
pathways were identified in a non-biased approach to verify that the data set showed 
similar dysregulatory patterns as in previously published data [31, 35, 36, 156]. In a 
next step, the level of 2+MoPh transcripts in the human biopsy samples was estimated 
using a bioinformatics-based deconvolution strategy [162].  
Deconvolution strategies allow a general calculation of the cellular composition of 
complex tissues based on gene profiles. 2+MoPh gene signatures were found to be 
significantly increased in the DN samples (see 4.1.2), as compared to the LD controls, 
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and in addition, the 2+MoPh gene signatures correlated negatively with glomerular 
filtration rate calculated for the patients at the time of biopsy demonstrating that the 
presence of 2+MoPh cells is strongly associated with progressive DN. 
5.2 Development of a next generation vector system 
To directly measure the potential effects of 2+MoPh cells on the activation of 
homeostatic pathways in experimental parenchymal cells, a vector platform and co-
culture assay was developed. As designed, the vector system that lies behind the cell-
based assay allows for the efficient generation of reporter and expression constructs, 
and active vector integration based on Sleeping Beauty transposon technology [165, 
166]. The pSBTET.Reporter vector platform was used to facilitate pathway screening 
and titration strategies [168]. Based on the secreted Gaussia luciferase reporter gene, 
reporter measurements can be performed in a time course without cell lysis [181]. 
Previously described transcription factor binding sites/reporter elements were adapted 
to create the different reporter gene and vector backbones, and offered measurement 
of a dynamic range between unstimulated and stimulated samples (see 4.2 and 
addendum). Similarly, the Gateway cloning technology was used to allow the rapid 
generation of complex expression constructs in the pSBDEST vector [168]. The 
combination of reporter and expression vector families allowed the inducible 
expression of transgenes under the control of the CMV/TO promoter. The vectors were 
designed such that they can be integrated together or in series into the host cell. With 
a high degree of efficiency and flexibility, the vector platform should be easily 
adaptable to most cloning projects, and thus greatly expands our molecular toolkit 
[168]. 
5.3 2+MoPh in-vitro findings 
In this doctoral work, stably engineered HEK293 reporter cells were used as model 
parenchyma-reporter cells that were then co-cultured with different myeloid cells 
including in-vitro-derived 2+MoPh. The results of the in-vitro reporter cell studies 
showed a direct activation of the MAPK, Hedgehog, TGFβ and WNT pathways in 
HEK293 cells by co-incubation with the 2+MoPh cells, while Hippo signaling, which is 
associated with cell-cell contact, was largely unchanged. 
While both imDC and 2+MoPh could activate MAPK, Hedgehog, TGFβ and WNT 
pathways in the reporter cell lines, the strength of the activation varied significantly. 
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Hippo did not exhibit strong activation patterns, but standard cell culture on plastic 
surfaces may not be ideal setting to study this pathway [44, 88, 170]. Across all 
activated reporter cell lines, 2+MoPh showed a much higher activation than imDC. 
imDC essentially define conventional dendritic cells, while the 2+MoPh phenotype 
exhibits both DC and macrophage traits [139, 151, 196, 197]. 
Since myeloid development genes were also altered transcriptomically in the DN 
microarray dataset, a series of experiments targeting the myeloid differentiation 
pathway LXR were carried out [183-185, 206]. Treatment with the synthetic agonist 
GW3965 [208] efficiently activated the LXR reporter cells, but no differences in the 
secretion patterns for either imDC or 2+MoPh could be detected, even if GW3965 was 
added during polarization of the monocytes. While LXR signaling may still play 
important roles during myeloid development, it is probably not causal for the 
polarization to the 2+MoPh phenotype. 
The precise nature of the signal exerted by 2+MoPh could not be determined in this 
study. The signal was shown to be soluble and probably protein/peptide based 
(exosome-based signals could be eliminated). While proteomic analysis of the 
conditioned supernatants identified candidate cytokines, recombinant versions of 
these candidates failed to replicate the activation seen. Thus, the central effector 
remains inconclusive. This may be due to technical reasons, or because a novel 
signaling protein/peptide is causal to the activation patterns exhibited.  
5.3 Evidence implicating MAPK as pivotal for the homeostatic alterations 
caused by 2+MoPh presence 
While the causal protein/peptide component underlying activation of the MAPK, 
Hedgehog, TGFβ and WNT pathways in co-culture/supernatant studies with 2+MoPh 
could not be determined, inhibitor studies could be used to identify signaling 
components contributing to the effects seen.  
Using the Hedgehog pathway reporter cells as a readout, with stimulation provided by 
myeloid derived serum-free supernatants, a panel of inhibitors targeting different 
signaling components of the mTOR [202], MAPK [103, 105] and PI3K [204] pathways 
was used to identify potential upstream signaling mechanisms. Treatment with the 
MAPK inhibitor PD98059 [203] and the PI3K inhibitor Wortmannin [205] led to a 
significant reduction in reporter signal. Wortmannin can exhibit some MAPK inhibition. 
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PD98059, by contrast, is specific for MEK (or MAP2K) and thus inhibits only MAPK 
associated signaling processes. Because EGF is a MAPK activating growth factor 
[232], an additional set of control experiments were performed which exhibited a 
similar activation of Hedgehog signaling and a reduction of signaling by treatment with 
PD98059. Interestingly, in this experiment, Wortmannin did not significantly alter the 
signal, suggesting that the signal exerted by myeloid cells may not be based on a 
single factor. The MAPK associated MAPK, JNK and JAK/STAT pathways were 
identified as contributing to activation of homeostatic signaling pathways in the co-
culture experiments. While individual signaling pathways are generally still studied as 
somewhat distinct entities, their interaction (or cross-talk) suggests that viewing them 
in a larger “network” context may be a better approximation of biology involved in the 
processes being studied [233]. 
5.4 Identification of transcriptomically altered pathway components 
using the WGCNA method strongly hints at MAPK 
After identifying 2+MoPh-driven alterations of the MAPK, Hedgehog, TGFβ and WNT 
signaling network in-vitro, genes associated with these pathways were pooled for an 
in-depth study and validation using a WGCNA-based method [163]. The analysis was 
based on the same cDNA microarrays previously shown to have increased presence 
of 2+MoPh as calculated by deconvolution [162], and taken from patients showing 
decreased renal function as calculated by GFR MDRD [178]. The WGCNA approach 
led to the identification of co-regulated gene “modules” across this gene network 
identified in an unbiased manner, from a list of pathway associated genes. For each 
WGCNA derived gene cluster, a module eigengene, a summarization strategy 
representing the regulatory trends across the module was calculated. This module 
eigengene was then used for a correlation analysis with the 2+MoPh deconvolution 
score per sample. Clusters of genes that showed either significant positive or negative 
correlation with the calculated amount of 2+MoPh signals were selected for further 
study, and the remaining clusters discarded. Out of the three significantly correlated 
modules, two showed upregulation as compared to normal control samples, and one 
showed downregulation.  
When analyzing the genes comprising each module, a strong MAPK-association 
component was identified in each module. These results were strongly supported by 
the results of the in-vitro MAPK inhibition studies, which showed strongly reduced 
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reporter activity. Together, the findings strongly suggest a potential clinical importance 
for MAPK based signaling processes underlying key pathophysiologic processes in 
the renal parenchyma as a consequence of enhanced myeloid (2+MoPh) infiltration.  
Analysis of the individual, dysregulated and 2+MoPh correlated genes from the three 
most relevant modules identified a strong association with the pathophysiology of 
chronic fibrosis. Many of these genes represent core genes associated with specific 
pathways, or with phosphorylation-based signal transduction events of the relevant 
signaling cascade. In the MAPK network, the RTK-associated ligands VEGFA, 
VEGFC and EGF [103] were found to be significantly altered in steady state 
expression, and to correlate with changes in the deconvolution score. VEGFA and 
EGF were decreased, while VEGFC was increased. VEGFA is classically associated 
with angiogenesis [234], but can also serve as a chemotractant for myeloid cells [235]. 
VEGFC, by contrast, is involved in lymphangiogenesis (and chronic inflammation) 
[236, 237]. EGF plays a role in cellular proliferation, differentiation, and survival [49]. 
It was found to be reduced relative to the 2+MoPh signal. While the potential effects of 
these events are hard to predict, downregulation of EGF and VEGFA may occur as a 
compensation for the high activation levels of the MAPK network as indicated by the 
expression levels of most associated transcription factors. The MAPK associated 
receptors RYK [209], MET [210] and the JAK/STAT co-receptor JAK1 [110-112] were 
shown to be increased with deconvolution score. The function of the atypical receptor 
tyrosine kinase RYK is not fully understood, as it seems to lack kinase activity in its C-
terminal domain. Since RYK is conserved across a number of species, it is likely to 
have an important albeit currently unknown function. MET (also known as HGFR) is a 
more classical RTK shown to activate MAPK, STAT and PI3K. JAK1 is a well-studied 
co-receptor in the JAK/STAT pathway and is linked to immunity, proliferation, 
differentiation, apoptosis. The signaling components MAP3K5, MAP3K8 [102] and 
STAT1 [110-112] were increased with 2+MoPh signals, while MAP3K12 [102] was 
decreased. MAP3K5, MAP3K8 and MAP3K12 are all upstream kinases that interact 
with different downstream MAP2Ks, and thus, the consequences of their dysregulation 
are hard to predict, but are likely significant, as the signals transmitted by them are 
amplified through the signaling cascade [106]. STAT1 is the target of JAK1, and can 
serve as a transcription factor, but it also directly interacts with other MAPKs and JNKs 
[112]. Finally, dramatic changes in the activity of the MAPK network were also evident 
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based on the strongly upregulated transcription factors JUN, JUNB and FOS. These 
are subunits of the dimeric AP-1 transcription factor. AP-1 is pivotal in mediating 
signals linked to cell growth and regeneration, differentiation, and apoptosis [212]. 
MYC was found to be increased, while MYCN was decreased in the progressive DN 
biopsy samples. The MYC family is a downstream target of WNT and helps control 
cell proliferation, growth, differentiation and apoptosis [213, 238]. The MYC family has 
also been shown to upregulate the cyclins, which are also increased in DN [239]. 
MYCN is less well studied, but has been shown to be highly important in the 
development of various cancers [240, 241]. Its functions in the kidney however are not 
well understood.  
Under the current paradigm, that disease progression in DN results in part from failed 
or overly active regenerative processes [18-20], the potential impact of MAPK 
activated programs represents a novel potential pathophysiologic mechanism. 
Regeneration, differentiation, proliferation, and apoptosis, are all required to restore 
tissue in the context of damage [242]. However, the precise control over these 
processes may be lost in the context of excessive MAPK signaling leading to 
progressive tissue fibrosis and damage. In addition to the Hedgehog pathway [63], 
MAPK signaling has also been shown to influence both TGFβ and WNT signaling [71, 
120, 121], pathways associated with the progressive damage seen in DN samples. 
MAPK driven alteration of WNT signaling has been suggested to mediate changes in 
the expression of β-catenin and provides additional levels of modulation [243]. In the 
present study, canonical WNT2B and WNT7A ligands (downstream Hedgehog 
targets) were found to be increased with deconvolution score, while WNT8B was 
decreased [214]. No clear function has thus far been described for WNT2B. Mouse 
deletion mutants for WNT2B are viable, and it is implicated in some cancers [244]. For 
WNT7A the potential ramifications are also not clear. While WNT7B has been 
associated with renal repair [245], no parallel role has been identified for WNT7A. 
WNT7A has been shown to be important for angiogenesis of the forebrain [246] and 
has been implicated in cancers [247]. WNT7A is thought to also signal via the non-
canonical WNT/PCP pathway [248]. Similar to WNT7A, WNT8B is present during 
neurogenesis [249]. The dynamics of the Frizzled receptors and ligand binding are 
also very complex [215], however the Frizzled receptors are important signaling 
molecules and required for WNT ligand-mediated signaling. FZD2, FZD6, FZD7, 
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FZD10 and FZDB were all upregulated in the context of the 2+MoPh presence, 
supporting the observation of an increased activity of WNT signaling during 
progressive DN. Interestingly, LRP6, which has been shown to be required for 
canonical WNT signaling but also acts in non-canonical ways [190, 216, 217] was 
reduced. 
Finally, in the TGFβ/SMAD pathway, TGFBR2 and BMP2 showed altered expression 
[194]. In addition, expression of the well-characterized fibrosis-associated TGFβ 
related target genes MMP7 [218, 219], CTGF [220] and CYR61 [221] correlated with 
the deconvolution signature. Other direct links to fibrosis-related biology were also 
shown to correlate with the presence of 2+MoPh cells in the DN biopsy samples. An 
increased level of expression of genes directly linked to the genesis of ECM (galectin, 
laminin, fibronectin, collagens and versican) [224] was identified in the DN samples. 
Cell proliferation is thought to be increased in ongoing damage to kidney tissues, and 
can be evidenced here by alteration in the expression of cycline and cycline dependent 
kinase expression patterns [222, 223]. Finally, proteasome associated genes were 
also shown to be modulated, possibly as a response to the alterations to cell cycle. 
The ubiquitin/proteasome pathway plays an important role in the activation of MAPK 
derived signals during the detection of bacterial LPS and subsequent induction of 
cytokine production [250-252]. Additionally, the protease inhibitor camostat mesilate 
has proven effective in reducing kidney damage following the sterile unilateral ureteral 
obstruction disease model in rats [253]. These observations suggest protease 
inhibitors as a potential avenue in DN treatment. 
5.5 Working model  
The presence of 2+MoPh in the DN transcriptomic data, as evidenced by the 2+MoPh 
deconvolution score, was correlated with a decrease in eGFR (MDRD) [178], 
suggesting that factors produced by 2+MoPh cells may play a role in driving renal 
fibrosis. A direct effect of 2+MoPh cells on the activation of a series of homeostatic 
pathways in experimental parenchyma was validated. The relevant signals from the 
2+MoPh cells were not direct cell-cell contact dependent, as they could be mimicked 
using 2+MoPh supernatant. Taken together, the results further suggest that increasing 
levels of 2+MoPh may directly activate homoeostatic pathways linked to progressive 
tissue damage in the renal tubulointerstitial regions. 
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Figure 45. Current interpretation of the observations presented here. Increasing 
presence of 2+MoPh caused by metabolic changes in diabetes leads to increased 
secretion of growth factors that cause the activation of MAPK signaling in the kidney 
parenchyma via a receptor, potentially an RTK. Activation of MAPK signaling leads to 
secondary activation of TGFβ, WNT and Hedgehog signaling. As a consequence, cell 
cycle genes, ECM production and proteasome activity are dysregulated, contributing 
to kidney damage as the disease progresses.  
 
Based on the findings discussed here, we propose the following model. Due to the 
tissue stress situation caused by diabetes, an enhanced recruitment of myeloid cells 
into the tubular interstitium of the kidney leads to increased levels of the macrophage 
like 2+MoPh phenotype. This renal myeloid phenotype in turn secretes growth factors 
that can directly influence kidney parenchyma, causing the activation of an RTK or 
JAK-like receptor, leading to phosphorylation and activation of a MAPK associated 
signaling pathway. MAPK signaling then causes activation of additional homeostatic 
pathways (Hedgehog, WNT, SMAD) either by phosphorylation of their components, or 
direct interaction of the MAPK linked AP-1 or MYC transcription factors with pathway 
specific TFs. The potential signals mediating the activation of these pathways were 
shown to be soluble, not associated with exosomes, and to be probably 
protein/peptide based. Harvested supernatants were analyzed using proteomic 
platforms yielding potential candidate factors. 
As a consequence, a homeostatic shift towards fibrosis, cell cycle alterations and 
proteasome activation occurs, contributing to disruptions of the kidney fine structure 
and gradual loss of function. The amount of 2+MoPh increases during disease 
progression, potentially exacerbated by a feedback mechanism caused by the high 
expression levels of the myeloid cell chemotractant CCL2 found in 2+MoPh. 
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Potential treatment strategies to target this biology include a blockade of CCR2 
signaling to reduce the influx of myeloid infiltrates into the kidney, and targeting the 
proteasome to reduce signals leading to the activation of MAPK signaling processes. 
Identification of the pivotal signaling molecules could allow for more specific clinical 
intervention to suppress damaging changes to the kidney fine structure. 
Addendum   102
 
6 Addendum 
6.1 Supplemental tables 
6.1.1 Full list of dysregulated pathways from 4.1.1 
Pathway Genomatix Pathway id p-value Obs Exp 
IMMUNE PW_IMMUNE_HOMO_SAPIENS 4.54E-18 93 35.
9 
INFLAMMATORY PW_INFLAMMATORY_HOMO_SAPIEN
S 
3.33E-14 80 32.
7 
MATRIX 
METALLOPROTEINASE 
PW_MMP_HOMO_SAPIENS 3.24E-10 51 19.
9 
INTEGRIN PW_INTEGRIN_HOMO_SAPIENS 4.11E-10 46 17.
0 
CHEMOKINE (C C MOTIF) 
LIGAND 2 
PW_CCL2_HOMO_SAPIENS 6.50E-10 30 8.4 
TOLL LIKE RECEPTOR PW_TOLL_HOMO_SAPIENS 2.71E-09 46 18.
0 
ANGIOGENESIS PW_ANGIOGENESIS_HOMO_SAPIEN
S 
2.66E-08 47 19.
9 
TUMOR NECROSIS 
FACTOR (TNF 
SUPERFAMILY, MEMBER 
2) 
PW_TNF_HOMO_SAPIENS 2.82E-07 46 20.
8 
INTERLEUKIN 6 
(INTERFERON, BETA 2) 
PW_IL6_HOMO_SAPIENS 4.11E-07 36 14.
6 
ZETA CHAIN (TCR) 
ASSOCIATED PROTEIN 
KINASE 70KDA 
PW_ZAP_70_HOMO_SAPIENS 7.28E-07 22 6.8 
THROMBOSPONDIN 1 PW_THBS1_HOMO_SAPIENS 9.15E-07 17 4.4 
NF KAPPA B PW_NFKB_HOMO_SAPIENS 9.24E-07 64 34.
5 
T CELL RECEPTOR CD3 
COMPLEX 
PW_CD3_HOMO_SAPIENS 9.35E-07 24 8.0 
INTERLEUKIN 18 
(INTERFERON GAMMA 
INDUCING FACTOR) 
PW_IL18_HOMO_SAPIENS 1.72E-06 19 5.6 
CD2 PW_CD2_HOMO_SAPIENS 2.70E-06 17 4.7 
LYMPHOCYTE SPECIFIC 
PROTEIN TYROSINE 
KINASE 
PW_LCK_HOMO_SAPIENS 4.97E-06 22 7.6 
CHEMOKINE (C C MOTIF) 
RECEPTOR 2 
PW_CCR2_HOMO_SAPIENS 8.04E-06 14 3.6 
CADHERIN 1, TYPE 1, E 
CADHERIN (EPITHELIAL) 
PW_CDH1_HOMO_SAPIENS 8.40E-06 30 12.
7 
V YES 1 YAMAGUCHI 
SARCOMA VIRAL 
RELATED ONCOGENE 
HOMOLOG | LCK/YES 
RELATED NOVEL PROTEIN 
TYROSINE KINASE 
PW_LYN_HOMO_SAPIENS 1.31E-05 24 9.2 
PTK2B PROTEIN 
TYROSINE KINASE 2 BETA 
PW_PTK2B_HOMO_SAPIENS 1.72E-05 21 7.6 
PROTEIN TYROSINE 
PHOSPHATASE, 
RECEPTOR TYPE 
PW_PTPR_HOMO_SAPIENS 1.80E-05 25 10.
0 
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Pathway Genomatix Pathway id p-value Obs Exp 
CD36 MOLECULE 
(THROMBOSPONDIN 
RECEPTOR) 
PW_CD36_HOMO_SAPIENS 2.29E-05 18 6.0 
VASCULAR ENDOTHELIAL 
GROWTH FACTOR 
PW_VEGF_HOMO_SAPIENS 2.66E-05 35 16.
8 
CHEMOKINE (C C MOTIF) 
RECEPTOR 7 
PW_CCR7_HOMO_SAPIENS 2.88E-05 14 4.0 
CD19 PW_CD19_HOMO_SAPIENS 5.10E-05 14 4.2 
ATP BINDING CASSETTE, 
SUB FAMILY B (MDR/TAP) 
PW_ABCB_HOMO_SAPIENS 5.25E-05 22 8.8 
MYELOID 
DIFFERENTIATION 
PRIMARY RESPONSE 
GENE (88) 
PW_MYD88_HOMO_SAPIENS 6.46E-05 24 10.
1 
SNAIL FAMILY ZINC 
FINGER 1 
PW_SNAIL_HOMO_SAPIENS 6.60E-05 25 10.
8 
NUCLEOTIDE 
OLIGOMERIZATION 
DOMAIN/CASPASE 
RECRUITMENT DOMAIN 
PROTEIN FAMILY 
PW_NOD_HOMO_SAPIENS 9.24E-05 22 9.1 
CLASSICAL COMPLEMENT PW_CLASSICAL_COMPLEMENT_HO
MO_SAPIENS 
1.01E-04 12 3.4 
INTERLEUKIN 1 PW_IL1_HOMO_SAPIENS 1.28E-04 31 15.
3 
FOCAL ADHESION KINASE 
1 
PW_FAK_HOMO_SAPIENS 1.56E-04 34 17.
6 
HEPATOCYTE GROWTH 
FACTOR RECEPTOR 
PW_HGF_HOMO_SAPIENS 1.59E-04 23 10.
1 
TISSUE INHIBITOR OF 
METALLOPROTEINASE 
PW_TIMP_HOMO_SAPIENS 1.62E-04 17 6.3 
MOTHERS AGAINST DPP 
HOMOLOG 
PW_SMAD_HOMO_SAPIENS 1.87E-04 49 29.
0 
JANUS KINASE PW_JAK_HOMO_SAPIENS 1.99E-04 30 15.
0 
NITRIC OXIDE PW_NITRIC_OXIDE_HOMO_SAPIENS 2.27E-04 25 11.
6 
B CELL RECEPTOR PW_BCR_HOMO_SAPIENS 3.04E-04 24 11.
2 
COAGULATION FACTOR II 
(THROMBIN) RECEPTOR 
PW_F2R_HOMO_SAPIENS 3.13E-04 15 5.5 
PLATELET/ENDOTHELIAL 
CELL ADHESION 
MOLECULE 1 (CD31) 
PW_PECAM1_HOMO_SAPIENS 3.58E-04 12 3.9 
LYMPHOTOXIN ALPHA 
(TNF SUPERFAMILY, 
MEMBER 1) 
PW_LTA_HOMO_SAPIENS 3.92E-04 9 2.4 
SPLEEN TYROSINE 
KINASE 
PW_SYK_HOMO_SAPIENS 4.86E-04 23 10.
9 
RIBONUCLEASE L PW_RNASEL_HOMO_SAPIENS 6.55E-04 8 2.0 
SPHINGOMYELIN 
PHOSPHODIESTERASE 1, 
ACID LYSOSOMAL 
PW_SMPD1_HOMO_SAPIENS 6.55E-04 8 2.0 
TOLL LIKE RECEPTOR 
ADAPTOR MOLECULE 1 
(TICAM1) 
PW_TRIF_HOMO_SAPIENS 7.86E-04 14 5.4 
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Pathway Genomatix Pathway id p-value Obs Exp 
INTERLEUKIN 10 PW_IL10_HOMO_SAPIENS 8.71E-04 23 11.
3 
B CELL TRANSLOCATION 
GENE (BTG/TOB FAMILY) 
PW_BTG_HOMO_SAPIENS 9.00E-04 10 3.1 
ALTERNATIVE 
COMPLEMENT 
PW_ALTERNATIVE_COMPLEMENT_H
OMO_SAPIENS 
9.00E-04 10 3.1 
CCAAT/ENHANCER 
BINDING PROTEIN 
(C/EBP), ALPHA 
PW_CEBPA_HOMO_SAPIENS 1.07E-03 15 6.1 
T CELL RECEPTOR PW_TCR_HOMO_SAPIENS 1.08E-03 30 16.
5 
GUANINE NUCLEOTIDE 
EXCHANGE FACTOR VAV 
PW_VAV_HOMO_SAPIENS 1.17E-03 20 9.5 
DOUBLE STRANDED RNA 
DEPENDENT PROTEIN 
KINASE/EUKARYOTIC 
INITIATION FACTOR 
2ALPHA 
PW_PKR_HOMO_SAPIENS 1.49E-03 15 6.3 
INTERLEUKIN 3 (COLONY 
STIMULATING FACTOR, 
MULTIPLE) 
PW_IL3_HOMO_SAPIENS 1.51E-03 16 7.0 
SIGNAL TRANSDUCER 
AND ACTIVATOR OF 
TRANSCRIPTION 
PW_STAT_HOMO_SAPIENS 1.66E-03 41 25.
5 
LOW DENSITY 
LIPOPROTEIN RECEPTOR 
RELATED PROTEIN 
PW_LRP_HOMO_SAPIENS 1.74E-03 23 11.
9 
PHOSPHOLIPASE C PW_PLC_HOMO_SAPIENS 1.95E-03 26 14.
2 
CYCLIC ADP RIBOSE 
HYDROLASE (CD38) 
PW_CD38_HOMO_SAPIENS 2.32E-03 11 4.1 
TYROSINE PROTEIN 
KINASE SRC 
PW_SRC_HOMO_SAPIENS 2.37E-03 38 23.
6 
STRESS PW_STRESS_HOMO_SAPIENS 2.38E-03 37 22.
8 
COLONY STIMULATING 
FACTOR 1 
PW_CSF1_HOMO_SAPIENS 3.02E-03 14 6.1 
INTERLEUKIN 4 PW_IL4_HOMO_SAPIENS 3.03E-03 19 9.5 
CAVEOLIN 1 PW_CAVEOLIN_HOMO_SAPIENS 3.21E-03 16 7.5 
PARATHYROID HORMONE PW_PTH_HOMO_SAPIENS 3.30E-03 15 6.9 
PHOSPHOLIPASE A2 PW_PLA2_HOMO_SAPIENS 3.30E-03 15 6.9 
INTERLEUKIN 12 PW_IL12_HOMO_SAPIENS 3.36E-03 17 8.2 
CADHERIN 5, TYPE 2 
(VASCULAR 
ENDOTHELIUM) 
PW_CDH5_HOMO_SAPIENS 3.39E-03 11 4.3 
VERY LOW DENSITY 
LIPOPROTEIN RECEPTOR 
PW_VLDLR_HOMO_SAPIENS 3.94E-03 7 2.1 
CALCIUM PW_CALCIUM_HOMO_SAPIENS 4.10E-03 59 41.
8 
INTEGRIN LINKED KINASE PW_ILK_HOMO_SAPIENS 4.32E-03 15 7.1 
CHEMOKINE (C X C MOTIF) 
RECEPTOR 4 
PW_CXCR4_HOMO_SAPIENS 4.91E-03 16 7.8 
TGF BETA PW_TGFBR_HOMO_SAPIENS 5.15E-03 67 49.
1 
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Pathway Genomatix Pathway id p-value Obs Exp 
CCAAT/ENHANCER 
BINDING PROTEIN 
(C/EBP), BETA 
PW_CEBPB_HOMO_SAPIENS 5.33E-03 16 7.9 
NITRIC OXIDE SYNTHASE PW_NOS_HOMO_SAPIENS 5.42E-03 20 10.
8 
BETA CATENIN PW_BETA CATENIN_HOMO_SAPIENS 5.75E-03 56 39.
9 
F BOX AND WD REPEAT 
DOMAIN CONTAINING 7 
PW_FBXW7_HOMO_SAPIENS 5.77E-03 10 4.0 
ADIPOQ PW_ADIPONECTIN_HOMO_SAPIENS 6.01E-03 13 6.0 
NUCLEAR RECEPTOR 
SUBFAMILY 0, GROUP B, 
MEMBER 2 
PW_NR0B2_HOMO_SAPIENS 7.74E-03 9 3.5 
NUCLEAR RECEPTOR 
SUBFAMILY 4, GROUP A, 
MEMBER 3 
PW_NR4A3_HOMO_SAPIENS 7.99E-03 5 1.3 
PEROXISOME 
PROLIFERATOR 
ACTIVATED RECEPTOR 
DELTA 
PW_PPARD_HOMO_SAPIENS 8.13E-03 10 4.2 
GLYCOGEN SYNTHASE 
KINASE 
PW_GSK_HOMO_SAPIENS 8.18E-03 31 19.
7 
TYROSINE PROTEIN 
KINASE FYN 
PW_FYN_HOMO_SAPIENS 8.28E-03 21 12.
0 
CD40 LIGAND PW_CD40_HOMO_SAPIENS 9.09E-03 11 4.9 
INTERFERON (ALPHA, 
BETA AND OMEGA) 
RECEPTOR 
PW_IFNAR_HOMO_SAPIENS 9.82E-03 9 3.7 
Table 9. Full GeneRanker results, supplemental to 4.1.1. Obs. = number of 
observed genes, Exp. = number of expected genes. 
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6.1.2 Full gene list from 4.4.3 
Geneset Gene / 
Module 
color 
Annotation 
.14-3-3/HIPPO YWHAH tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein eta(YWHAH) 
.14-3-3/HIPPO YWHAZ tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta(YWHAZ) 
? TBL1XR1 transducin β like 1 X-linked receptor 1(TBL1XR1) 
? AP2B1 adaptor related protein complex 2 β 1 
subunit(AP2B1) 
? NRCAM neuronal cell adhesion molecule(NRCAM) 
? EDN1 endothelin 1(EDN1) 
? PPP2R5B protein phosphatase 2 regulatory subunit 
B'β(PPP2R5B) 
? IKBKB inhibitor of kappa light polypeptide gene enhancer 
in B-cells, kinase β(IKBKB) 
? CCL4 C-C motif chemokine ligand 4(CCL4) 
? SP3 Sp3 transcription factor(SP3) 
cell cycle CDKN1A cyclin dependent kinase inhibitor 1A(CDKN1A) 
cell cycle CDK1 cyclin dependent kinase 1(CDK1) 
cell cycle CCND3 cyclin D3(CCND3) 
cell cycle CCNB1 cyclin B1(CCNB1) 
cell cycle CCND2 cyclin D2(CCND2) 
cell cycle CCNB2 cyclin B2(CCNB2) 
cell cycle STIL SCL/TAL1 interrupting locus(STIL) 
cell cycle? TFDP2 transcription factor Dp-2(TFDP2) 
Fibrotic gene PITX2 paired like homeodomain 2(PITX2) 
Fibrotic gene LGALS3 galectin 3(LGALS3) 
Fibrotic gene CEBPB CCAAT/enhancer binding protein β(CEBPB) 
Fibrotic gene LAMC1 laminin subunit gamma 1(LAMC1) 
Fibrotic gene FN1 fibronectin 1(FN1) 
Fibrotic gene COL1A2 collagen type I alpha 2 chain(COL1A2) 
Fibrotic gene COL1A1 collagen type I alpha 1 chain(COL1A1) 
Fibrotic gene VCAN versican(VCAN) 
Hippo? 
Regulates RUNX 
CBFB core-binding factor β subunit(CBFB) 
inflammatory PROC protein C, inactivator of coagulation factors Va and 
VIIIa(PROC) 
inflammatory SPP1 secreted phosphoprotein 1(SPP1) 
inflammatory LYN LYN proto-oncogene, Src family tyrosine 
kinase(LYN) 
inflammatory ITK IL2 inducible T-cell kinase(ITK) 
kidney TF HNF1A HNF1 homeobox A(HNF1A) 
MAPK CAMK2G calcium/calmodulin dependent protein kinase II 
gamma(CAMK2G) 
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Geneset Gene / 
Module 
color 
Annotation 
MAPK MAP3K12 mitogen-activated protein kinase kinase kinase 
12(MAP3K12) 
MAPK EGF epidermal growth factor(EGF) 
MAPK MYCN v-myc avian myelocytomatosis viral oncogene 
neuroblastoma derived homolog(MYCN) 
MAPK RAF1 Raf-1 proto-oncogene, serine/threonine 
kinase(RAF1) 
MAPK VEGFA vascular endothelial growth factor A(VEGFA) 
MAPK LRPAP1 LDL receptor related protein associated protein 
1(LRPAP1) 
MAPK GRB2 growth factor receptor bound protein 2(GRB2) 
MAPK SNX4 sorting nexin 4(SNX4) 
MAPK RAC3 ras-related C3 botulinum toxin substrate 3 (rho 
family, small GTP binding protein Rac3)(RAC3) 
MAPK RHOA ras homolog family member A(RHOA) 
MAPK EGR1 early growth response 1(EGR1) 
MAPK ETS2 ETS proto-oncogene 2, transcription factor(ETS2) 
MAPK STAT1 signal transducer and activator of transcription 
1(STAT1) 
MAPK MYC v-myc avian myelocytomatosis viral oncogene 
homolog(MYC) 
MAPK UBE2I ubiquitin conjugating enzyme E2 I(UBE2I) 
MAPK JAK1 Janus kinase 1(JAK1) 
MAPK VEGFC vascular endothelial growth factor C(VEGFC) 
MAPK CALM2 calmodulin 2(CALM2) 
MAPK GNAS GNAS complex locus(GNAS) 
MAPK FOS Fos proto-oncogene, AP-1 transcription factor 
subunit(FOS) 
MAPK JUNB JunB proto-oncogene, AP-1 transcription factor 
subunit(JUNB) 
MAPK FHL2 four and a half LIM domains 2(FHL2) 
MAPK JUN Jun proto-oncogene, AP-1 transcription factor 
subunit(JUN) 
MAPK MET MET proto-oncogene, receptor tyrosine 
kinase(MET) 
MAPK ARF5 ADP ribosylation factor 5(ARF5) 
MAPK TRRAP transformation/transcription domain associated 
protein(TRRAP) 
MAPK SHC1 SHC adaptor protein 1(SHC1) 
MAPK RAC2 ras-related C3 botulinum toxin substrate 2 (rho 
family, small GTP binding protein Rac2)(RAC2) 
MAPK ARHGEF
6 
Rac/Cdc42 guanine nucleotide exchange factor 
6(ARHGEF6) 
MAPK RYK receptor-like tyrosine kinase(RYK) 
MAPK CXCL8 C-X-C motif chemokine ligand 8(CXCL8) 
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Geneset Gene / 
Module 
color 
Annotation 
MAPK TIAM1 T-cell lymphoma invasion and metastasis 
1(TIAM1) 
MAPK FGR FGR proto-oncogene, Src family tyrosine 
kinase(FGR) 
MAPK DAPP1 dual adaptor of phosphotyrosine and 3-
phosphoinositides 1(DAPP1) 
MAPK HCK HCK proto-oncogene, Src family tyrosine 
kinase(HCK) 
MAPK MAP3K8 mitogen-activated protein kinase kinase kinase 
8(MAP3K8) 
MAPK MEF2C myocyte enhancer factor 2C(MEF2C) 
MAPK ARRB1 arrestin β 1(ARRB1) 
MAPK MAP3K5 mitogen-activated protein kinase kinase kinase 
5(MAP3K5) 
MAPK LCK LCK proto-oncogene, Src family tyrosine 
kinase(LCK) 
MAPK EFNB2 ephrin B2(EFNB2) 
MAPK 
associated 
AKT1 AKT serine/threonine kinase 1(AKT1) 
MAPK, among 
others 
TP53 tumor protein p53(TP53) 
MAPK/EGF CELSR1 cadherin EGF LAG seven-pass G-type receptor 
1(CELSR1) 
MAPK/PI3K 
family member 
PRKDC protein kinase, DNA-activated, catalytic 
polypeptide(PRKDC) 
MAPK/TGFβ PTEN phosphatase and tensin homolog(PTEN) 
MAPK? CALM1 calmodulin 1(CALM1) 
MTOR MTOR mechanistic target of rapamycin(MTOR) 
MTOR FKBP1A FK506 binding protein 1A(FKBP1A) 
Notch MAML1 mastermind like transcriptional coactivator 
1(MAML1) 
nuclear importer KPNA2 karyopherin subunit alpha 2(KPNA2) 
Proteasome PSMC2 proteasome 26S subunit, ATPase 2(PSMC2) 
proteasome PSMA2 proteasome subunit alpha 2(PSMA2) 
proteasome PSMB9 proteasome subunit β 9(PSMB9) 
proteasome PSMB8 proteasome subunit β 8(PSMB8) 
proteasome UBE2D1 ubiquitin conjugating enzyme E2 D1(UBE2D1) 
proteasome CUL1 cullin 1(CUL1) 
proteasome PSMB10 proteasome subunit β 10(PSMB10) 
proteasome PSMA4 proteasome subunit alpha 4(PSMA4) 
proteasome RBX1 ring-box 1(RBX1) 
proteasome HSPA5 heat shock protein family A (Hsp70) member 
5(HSPA5) 
proteasome UBE2E1 ubiquitin conjugating enzyme E2 E1(UBE2E1) 
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Geneset Gene / 
Module 
color 
Annotation 
regulation of 
transcription 
HDAC6 histone deacetylase 6(HDAC6) 
regulation of 
transcription 
RBBP7 RB binding protein 7, chromatin remodeling 
factor(RBBP7) 
MAPK 
target/TGFβ 
GJA1 gap junction protein alpha 1(GJA1) 
TGFβ TGFBR2 transforming growth factor β receptor 2(TGFBR2) 
TGFβ MMP7 matrix metallopeptidase 7(MMP7) 
TGFβ ENG endoglin(ENG) 
TGFβ ZEB1 zinc finger E-box binding homeobox 1(ZEB1) 
TGFβ/BMP BMP2 bone morphogenetic protein 2(BMP2) 
TGFβ/HIPPO CTGF connective tissue growth factor(CTGF) 
TGFβ/HIPPO CYR61 cysteine rich angiogenic inducer 61(CYR61) 
WNT WNT8B Wnt family member 8B(WNT8B) 
WNT LRP6 LDL receptor related protein 6(LRP6) 
WNT FZD7 frizzled class receptor 7(FZD7) 
WNT CSNK1A
1 
casein kinase 1 alpha 1(CSNK1A1) 
WNT CSNK1G
3 
casein kinase 1 gamma 3(CSNK1G3) 
WNT CDH1 cadherin 1(CDH1) 
WNT MACF1 microtubule-actin crosslinking factor 1(MACF1) 
WNT FZD6 frizzled class receptor 6(FZD6) 
WNT TLE1 transducin like enhancer of split 1(TLE1) 
WNT WNT7A Wnt family member 7A(WNT7A) 
WNT FZD10 frizzled class receptor 10(FZD10) 
WNT WNT2B Wnt family member 2B(WNT2B) 
WNT FRZB frizzled-related protein(FRZB) 
WNT FZD2 frizzled class receptor 2(FZD2) 
WNT target CD44 CD44 molecule (Indian blood group)(CD44) 
WNT/Hedgehog VDR vitamin D (1,25- dihydroxyvitamin D3) 
receptor(VDR) 
WNT/Hedgehog GPC4 glypican 4(GPC4) 
WNT MDFIC MyoD family inhibitor domain containing(MDFIC) 
Table 10. Full list of dysregulated and 2+MoPh correlated genes, supplemental 
to 4.4.3 
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6.2 Proof of principle and validation of reporter tools 
 
 
Figure 46. Stimulation of Hedgehog reporter HEK293 cells with recombinant 
human EGF protein. To assess activity of the GLI reporter cassette, stable 
transfected HEK293 cells were treated with 20ng/ml EGF for 48 hours after which 
reporter activity was assessed. Treatment with EGF strongly activates the GLI 
transcription factors. 
 
 
 
Figure 47. Stimulation of TGFβ/SMAD reporter HEK293 cells with recombinant 
human TGFB1 protein. To assess activity of the TGFβ/SMAD reporter cassette, 
stable transfected HEK293 cells were treated with 10ng/ml TGFB1 for 48 hours after 
which reporter activity was assessed. Treatment with TGFB1 strongly activates the 
SMAD transcription factors. 
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Figure 48. Stimulation of canonical WNT reporter HEK293 cells with 
recombinant human WNT3A protein. To assess activity of the TCF/LEF reporter 
cassette, stable transfected HEK293 cells were treated with 400ng/ml WNT3A for 48 
hours after which reporter activity was assessed. Treatment with WNT3A strongly 
activates the TCF/LEF transcription factors. 
 
 
 
Figure 49. Canonical WNT reporter TCF7 overexpression: Stable Hek293 WNT 
reporter cells were transfected with a Doxycycline-inducible TCF7 overexpression 
construct. Overexpression of TCF7 leads to greatly induced WNT Reporter activity. 
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6.3 Flow cytometric characterization of myeloid cell lines 
 
Figure 50. Flow cytometric characterization of 2+MoPh cells 
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Figure 51. Flow cytometric characterization of Mono-Mac-6 (MM6) cells 
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Figure 52. Flow cytometric characterization of THP1 cells 
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6.3.1 AP-1 reporter titration with Mono-Mac-6 cells 
 
 
Figure 53. Hek293 AP-1 reporter, Mono-Mac-6 Co-culture 
HEK293 cells were co-incubated for 48 with either 40,000, 20,000 or 10,000 or Mono-
Mac-6 cells. After 48 hours Luciferase activity was measured. A strong and dose 
dependent activation of the reporter construct could seen. 
 
6.4 Additional characterization of LXR signaling 
The Liver X Receptor (LXR) family of nuclear receptor has been implicated in myeloid 
regulation and activation and was thus an interesting target [183, 185]. Additionally we 
had seen that HEK293 LXR reporter cells get activated to a significant degree during 
the co-culture experiments with 2+MoPh and imDC cells. To better understand the 
underlying mechanisms, a number of LXR modulation experiments were done using 
the synthetic, non-steroidal LXR ligand GW3965 [208] and engineered reporter / LXR 
expression cells. 
6.4.1 Elucidation of the modulatory effect of LXR Signaling on homeostatic 
signaling pathways 
As an important tool for crosstalk studies, HEK293 cells carrying a reporter construct 
and an inducible NR1H2 (LXRβ) or NR1H3 (LXRα) expression construct were 
generated. LXR reporter cells with NR1H2 / NR1H3 served as an important internal 
control, to prove the bioactivity of the LXR constructs. These cells were stimulated with 
Doxycycline, to activate expression of the transgene, and/or the synthetic LXR agonist 
GW3965 to activate LXR activity in a highly specific manner. Since the cells carry the 
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reporter for LXR activity the effects of both GW3965 and the expression of the 
transgene could be directly detected. 
Figure 54. Inducible LXR 
overexpression and treatment 
with GW3965. Stable Hek293 LXR 
Reporter cells were transfected with 
Doxycycline inducible LXR alpha 
and beta (NR1H3, NR1H2) 
overexpression constructs. Upon 
induction for 48 hours, the cells 
showed more LXR activity due to 
overexpression. Stimulation with 
only GW3965 for the same time 
frame lead to increased activity, 
same as cells carrying only the 
reporter. Combined treatment with 
Doxycycline and GW3965 showed 
additive effects. 4 wells per group, 
single experiment. 
 
The experiment shows that the generated LXR expression constructs are bioactive 
and have an additive effect with GW3965 treatment.Additionally the LXR antagonist 
GSK2033 was used to inhibit LXR signaling. 
 
Figure 55. Effects of the LXR 
antagonist GSK2033 on LXR 
reporter cells. 20,000 Hek293 LXR 
reporter cells were treated with 
GSK2033, GW3965 or both for 48 
hours. GSK2033 greatly reduced 
reporter activity. 3 wells per 
treatment group, experiment 
representative of 2 individual 
experiments. 
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6.4.2 Crosstalk between LXR and other pathways 
To assess the effects LXR signaling can have on other pathways, HEK293 reporter 
cells for other 2+MoPh and imDC modulated pathways were stimulated with GW3965 
to activate LXR signaling. 
 
Figure 56. Hek293 TGFβ reporter 
cells stimulation with recombinant 
TGFB1 and GW3965. Hek cells stably 
transfected with a TGFβ reporter 
plasmid were treated with either 
10ng/ml TGFB1 alone or TGFB1 + 
0.3µM GW3965 for 48hours. GW3965 
had no impact on activation. 3 wells 
per group, experiment representative 
of two individual experiments. 
 
TGFβ signaling was not modulated by addition of GW3965, independent on whether 
that pathway was activated by adding recombinant human TGFβ or not. 
 
Figure 57. Hek293 WNT reporter 
cells stimulation with recombinant 
Wnt3a and GW3965. Hek cells stably 
transfected with a WNT reporter 
plasmid were treated with either 
400ng/ml WNT3A or WNT3A + 0.3µM 
GW3965 for 48 hours. GW3965 had 
limited impact on activation. 3 wells 
per group, experiment representative 
of two individual experiments. 
 
Similarly, GW3965 treatment did not impact the activation of the WNT reporter cells 
with recombinant human WNT3A protein. 
As there is no known ‘simple’ activation method for the Hippo pathway, cells were 
seeded out dilute (analogous to 6.5) with or without added GW3965. No differences in 
Hippo activation state could be detected with GW3965. 
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Figure 58. Impact of GW3965 on 
the Hippo Pathway. 60,000 Hek 
TEAD or LXR reporter cells were 
seeded out in various well sizes for 
48 hours. The Hippo Pathway 
activity is strongly regulated by cell 
density and greatly activated by 
seeding in subconfluent cell 
numbers. LXR activation, via 
GW3965, does not modulate this 
activation, but activates the LXR 
reporter. Control cells carrying an 
empty pseudo-reporter construct 
were included to control for cytotoxic effects. 3 wells per group, experiment 
representative of two individual experiments. 
In a next set of experiments, the effect of GW3965 was to be ‘magnified’ by 
engineering the same reporter cells with inducible NR1H2 / NR1H3 expression 
constructs. The idea was that the reporter cells potentially had too low expression 
levels of NR1H2 / NR1H3 to detect the usually comparably weak crosstalk effects.  
TGFβ/SMAD reporter cells were transfected with either inducible NR1H2 or inducible 
NR1H3 overexpression constructs and after selection, seeded out and (pre-)treated 
with either Doxycyline, GW3965 or recombinant human TGFB1 protein. 
Figure 59. LXR overexpression 
and stimulation in Hek293 TGFβ 
reporter cells. Stable Hek293 
TGFβ/SMAD Reporter cells were 
transfected with Doxycycline 
inducible LXR alpha and beta 
overexpression constructs. Cells 
were prestimulated (or not, as 
control) with Doxycycline for 24 
hours, then stimulated with TGFB1 
or TGFB1 + 1µM GW. 
Overexpression of LXRalpha and 
beta did not change the effects of 
GW3965. 3 wells per group, experiment representative of two individual experiments. 
Unfortunately, no significant effects could be detected with added overexpression of 
NR1H2 or NR1H3. A parallel experiment was done for the WNT reporter cells. WNT 
reporter cells were transfected with inducible NR1H2 / NR1H3 expression constructs 
and treated with Doxycycline, recombinant WNT3A and/or GW3965.  
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Figure 60. LXR overexpression 
and stimulation in Hek293 WNT 
reporter cells. Stable Hek293 WNT 
Reporter cells were transfected with 
Doxycycline inducible LXR alpha 
and beta overexpression 
constructs. Cells were 
prestimulated (or not, as control) 
with Doxycycline for 24 hours, then 
stimulated with WNT3A or TGFB1 + 
1µM GW. Overexpression of 
LXRalpha and beta did not change 
the effects of GW3965. 3 wells per 
group, experiment representative of 
two individual experiments. 
 
The same as for TGFβ/SMAD signaling, no modulation of WNT with doxycycline or 
GW3965 could be observed. Finally, a third experiment with Hippo reporter cells was 
done in a similar way. HIPPO reporter cells were transfected with inducible NR1H2 / 
NR1H3 expression constructs and treated with Doxycycline and/or GW3965 while 
seeding the same amount of cells in differently sized culture wells. 
Figure 61. LXR overexpression in 
Hek293 Hippo Reporter cells. To 
assess whether an increased dose 
of NR1H2/H3 expression would 
lead to modulated Hippo Pathway 
activity, TEAD reporter cells were 
transfected with inducible 
NR1H2/H3 reporter plasmids. Cells 
were seeded either confluent or 
diluted and treated with Doxycycline 
or Doxycycline and GW3965. See 
next section for particulars on this 
biology. 4 wells per group, 
experiment representative of two 
individual experiments. 
Hippo signaling, like TGFβ and canonical WNT signaling was not modulated by 
GW3965 stimulation.  
After ascertaining that the canonical pathways in the reporter cells were not regulated 
by GW3965 treatment or NR1H2 / NR1H3 overexpression, LXR modulation in myeloid 
cells was studied. 
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6.4.3 GW3965 effects on myeloid cell lines 
To establish the regulatory effect of GW3965 on myeloid cell lines, experiments using 
Mono-Mac-6 cells were done. The very first step was to verify that GW3965 used at 
the same concentrations used for HEK293 cells was not toxic to Mono-Mac-6 cells 
and by inference 2+MoPh and imDCs. As Mono-Mac-6 cells proliferate in cell culture 
conditions, cell number along with trypan blue staining of dead cells was used to 
assess toxicity. 
 
Figure 62. Toxicity of GW3965 on 
Mono-Mac-6 cells. Mono-Mac-6 
cells were cultured either in medium 
with 10% FCS, or in serum-free 
medium. GW3965 in the range used 
was toxic only to cells cultured 
without FCS. Assessment of 
viability was done after 48 hours 
with Trypan-blue staining. Single 
experiment, two 12wells per 
treatment group. 
 
The essay showed that concentrations up 10 µM of GW3965 were not toxic in culture 
conditions containing serum, in serum free cultures toxicity started at around 1 µM 
GW3965. Since all previous experiments had been carried out using 1µM GW3965 
and with serum, this would not pose a problem for co-culture studies. 
To measure whether GW3965 would regulate the expression of NR1H3 as previously 
described, qPCR was done on Mono-Mac-6 cells treated with GW3965. 
Figure 63. Effect of GW3965 on 
LXR.Mono-Mac-6 cells were 
treated with GW3965 for 24 hours, 
cells were then lysed and qPCR 
performed. NR1H3 (LXRalpha) is 
upregulated upon GW3965 
treatment. NR1H2 (LXRbeta) is 
slightly upregulated, but overall 
remains at comparably low levels. 
Summary data for 2 wells per 
treatment group, single experiment. 
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To test the effect pre-treatment with GW3965 has on myeloid cells, the Mono-Mac-6 
model cell line was once again chosen. Mono-Mac-6 cells were pre-treated with serial 
dilutions of GW3965 for 18 hours, then washed and put into co-culture with HEK293 
reporter cell lines. After further 48 hours, reporter activity was measured.   
Figure 64. Co-Incubation of 
Hek293 reporter cells with 
GW3965 pre-treated Mono-Mac-6 
cells. treatment of Mono-Mac-6 
cells with GW3965 could modulate 
the activation Mono-Mac-6 cells 
confer to Hek reporter cell lines. 
Mono-Mac-6 cells were treated for 
18hours with various 
concentrations of GW3965 in 10% 
FCS containing media, afterwards 
washed with PBS and then cultured 
in GW3965 free medium together 
with Hek293 reporter cell lines. 
Measurements were done after 48h 
co-culture. Hedgehog and TGFβ/SMAD signaling were inhibited by presence of 
GW3965, LXR reporter cells were activated due to GW3965 presence. There was no 
effect on the Hippo reporter. Three wells per treatment group, experiment 
representative of two individual experiments. 
While LXR activity was increased in a dosage dependent manner, which serves as an 
internal control, Hedgehog and TGFβ/SMAD signaling were reduced. Hippo was 
unchanged. To rule out the possibility that GW3965 treatment modulated the reporter 
cells (except for the LXR reporter line) a parallel experiment was carried out using 
Mono-Mac-6 conditioned medium concentrated 5X with added GW3965.  
Figure 65. Effect of GW3965 on 
Hek293 reporter cells under 
Mono-Mac-6 conditioned media 
stimulation. To verify that GW3965 
does not directly inhibit the Hek293 
reporter cells, cells were treated for 
48h with either Mono-Mac-6 
conditioned medium or the same 
conditioned medium with added 
GW3965. GW3965 treatment lead 
to no difference in signal except for 
the LXR reporter which can be 
directly activated with GW3965. 
LXR reporter cells serve as internal control for LXR activation and are strongly 
activated. Three wells per treatment group, experiment representative of two individual 
experiments. 
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As expected, GW3965 only modulated the LXR reporter line in addition to the effect 
seen by addition of Mono-Mac-6 conditioned medium. This shows that any effects 
witnessed with GW3965 pre-treated Mono-Mac-6 cells occur due to modulation of the 
Mono-Mac-6 cells, not the parenchymal model HEK293 cells. 
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6.5 Additional characterization of Hippo signaling 
6.5.1 Do the transcriptional co-activators YAP1 and TAZ (WWTR1) modulate 
the Hedgehog, TGFβ, WNT signaling network? 
The homeostatic signaling pathways at work in renal development and that 
coordinately regulate complex processes during wound repair and chronic tissue 
damage, can be shown to be linked together through crosstalk suggesting that the 
pathways are really part of a larger regulatory network that drives the specific biologic 
process [155]. Hippo signaling is an important mediator of responses linked to contact 
inhibition, cell-cell contact, mechanical cues and certain extracellular factors [88, 89, 
99, 170]. As Hippo signaling has been described to crosstalk with TGFβ and canonical 
WNT signaling [96], two pathways strongly modulated by co-incubation with 2+MoPh 
and to a lesser degree imDC cells, the question arose whether Hippo signaling could 
act as a major contributing factor in the activation state of the regulatory network 
formed by these pathways. To elucidate the importance of YAP1 and TAZ, the 
transcriptional co-activators central to the Hippo pathway, first the dynamics of Hippo 
signaling in HEK293 cells were characterized and then the effects of YAP1 and TAZ 
overexpression on other pathways studied. The presence of nuclear YAP1 and TAZ 
in damaged kidney was first established by microscopy. 
 
Figure 66. Kidney sections stained for YAP1 or TAZ. For both YAP1 and TAZ 
nuclear localization can be observed in proximal tubules. Distal tubules exhibit 
cytoplasmatic localization of YAP1/TAZ. (DT = Distal tubulus, PT = Proximal Tubulus, 
CL=Cytoplasmatic Localization, NL= Nuclear Localization) 
A first step in establishing activity of the Hippo Reporter construct was to find a way to 
ensure Hippo activation/deactivation in a previously described manner. To verify the 
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function of the Hippo/TEAD reporter a simple stimulation experiment is problematic 
since this pathway is mainly activated by cell-cell contact and mechanical signals. To 
mimic differences in cell density in a tissue, cells were seeded out diluted, largely 
depriving them of cell-cell contact and the resulting signals. Practically this was done 
by seeding the same amount of cells with the same amount of medium in cell culture 
dishes of varying size. 
Figure 67. HIPPO/TEAD reporter 
activity and dilute seeding. Hippo 
signaling activity increases with 
reduced cell-cell contact, so 
seeding 60,000 TEAD reporter cells 
in larger surface areas for 24 hours 
increases reporter activity. As a 
control, a stable cell line carrying an 
inert reporter element was used. 
Activity of the control cells does not 
increase with dilute seeding. Three 
wells per treatment group, 
experiment representative of two 
individual experiments. 
Originally the hope was to use one of a few previously described lipid compounds to 
activate Hippo signaling in-vitro. To that end, lysophosphatidic acid (LPA), which had 
been shown to activate Hippo signaling in MCF10A cells, was used [98]. Since the 
function of the reporter plasmids had already been ascertained by dilute seeding 
experiments (see 4.2.6), treatment with LPA and parallel dilute seeding was chosen 
to contrast stimulation and dilute seeding and potentially magnify the effects of 
stimulation with LPA. 
Figure 68. Stimulation of Hek293 
TEAD reporter cells with LPA. 
Hek293 TEAD Reporter cells were 
treated with LPA (Lysophosphatidic 
Acid) for 24h with or without 
decreased cell-cell contact. The 
general effects of LPA on the TEAD 
reporter were weak, but 
measurable. Three wells per 
treatment group, experiment 
representative of two individual 
experiments. 
In addition to establishing the Hippo reporter element, inducible overexpression 
constructs for wildtype and constitutively active mutant versions of YAP1 and TAZ 
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were generated and tested for bioactivity. In a first experiment, HEK293 Hippo reporter 
cells were transfected with YAP1 or TAZ constitutively active mutant variants in a 
Doxycycline inducible manner.  
Figure 69. YAP1 / TAZ 
overexpression in Hippo reporter 
cells: Stable Hek293 TEAD 
reporter cells were transfected with 
Doxycycline-inducible YAP1 / TAZ 
(WWTR1) overexpression 
constructs and cultured with or 
without Doxycycline for 48 hours. 
Over-expression of YAP1 / TAZ 
leads to greatly induced TEAD 
Reporter activity. In this experiment 
constitutively active (CA) mutant 
variants of YAP1 and TAZ were 
used. Three wells per treatment 
group, experiment representative of two individual experiments. 
While there was an increased signal with LPA treatment, this effect was too weak to 
be considered for cross-talk studies, where the changes in signal are expected to be 
much weaker than for the actually targeted Hippo associated TEAD transcription 
factors. As an additional control for the activating properties of LPA on the Hippo 
pathway and it’s feasibility as an activating agent for cross talk studies HEK293 TEAD 
reporter cells were engineered with inducible overexpression constructs for Wildtype 
YAP1 or TAZ(WWTR1) and then stimulated with LPA. 
Figure 70. LPA effect on 
overexpression of wildtype 
YAP1/TAZ. Hek293 Hippo reporter 
cells were engineered with 
inducible overexpression 
constructs for wildtype YAP1 or 
TAZ (WWTR1) and stimulated with 
LPA and or Doxycycline for 48 
hours to induce expression of the 
transgene. While there was a slight 
increase in reporter activity with 
added LPA, the differences were 
too weak to use LPA as a 
stimulating reagent, even with 
overexpressed YAP1 / 
TAZ(WWTR1). Three wells per treatment group, experiment representative of two 
individual experiments. 
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Same as in the Hippo reporter-only Hek293 cells, there was some activating effect of 
LPA, but this effect was deemed too small for crosstalk studies. In addition to better 
characterize the reporter, HEK293 cells carrying the inducible YAP1 or TAZ(WWTR1) 
wildtype expression cassette were seeded dilute (as in fig 67) but with or without 
induction of the transgene. 
Figure 71. Overexpression of 
wildtype YAP1/TAZ and effect on 
dilute seeding. Stable Hek293 
TEAD reporter cells were 
transfected with Doxycyclin-
inducible wildtype YAP1/TAZ 
overexpression constructs and 
seeded out in varying well sizes. 
Upon induction the activity of the 
reporter constructs increased 
greatly and dependent on the 
dilution. TAZ overexpression 
showed stronger activation 
potential than YAP1 overexpression. Three wells per treatment group, experiment 
representative of two individual experiments. 
 
Dilute seeding showed a strong additive effect with overexpression of YAP1 or 
TAZ(WWTR1), with the TAZ effects being stronger. 
Another potential activation mechanism of the Hippo pathway besides dilute seeding, 
stimulation with lipid compounds like LPA and overexpression of YAP1 and TAZ is the 
cultivation of the cells on soft substrates to modulate mechanotransduction which will 
in turn regulate activity of YAP1 and TAZ [44, 88, 170]. To assess the viability of this 
approach Hippo reporter cells were seeded out on 2.5% Collagen1 gels. This much 
softer surface was then contrasted to standard plastic surfaces from routine cell culture 
plates. 
Figure 72. Hippo reporter cells on 
soft substrates. Hippo reporter 
cells were plated on soft substrate 
(2.5% Collagen1 Gel). Cells on soft 
substrate proliferate less and give 
less TEAD/Hippo signal. Three 
wells per treatment group, 
experiment representative of two 
individual experiments. 
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Growth on collagen strongly reduced the activity of the Hippo reporter in contrast to 
growth on the hard plastic surfaces. Additionally, there was less cell proliferation 
observable on the soft surface.  
Figure 73. Overexpression of 
YAP1/TAZ and growth on soft 
substrates. Hippo reporter cells 
transfected with inducible 
YAP1/TAZ constitutively active 
mutant overexpression constructs 
were plated on soft substrate (2,5% 
Collagen1 Gel) and stimulated with 
Doxycycline. Overexpression of 
YAP1/TAZ does not restore 
proliferation to the levels seen on 
plastic. Three wells per treatment 
group, experiment representative of 
two individual experiments. 
 
To see whether the same effect would be observable with overexpressed and 
constitutively active mutant variants of YAP1 and TAZ(WWTR1) or the effect could be 
rescued, Hippo reporter cells with inducible expression cassettes for these activate 
variants were generated and seeded the same way as in fig 67 but with or without 
added Doxycycline. YAP1 and TAZ overexpression could not rescue the phenotype 
and growth on soft substrates still caused reduced proliferation, while the reporter 
constructs were strongly activated with YAP1 and TAZ overexpression. This showed 
that cultivation on soft in comparison to hard surfaces would introduce experimental 
artifacts and thus would be a very problematic read-out of YAP1 and TAZ effect on 
other pathways. 
Having assessed these multiple avenues of Hippo activation, the best strategy to 
assess crosstalk proved to be direct overexpression of constitutively active YAP1 and 
TAZ(WWTR1) in reporters for other pathways. Overexpression lines of YAP1 / 
TAZ(WWTR1) were established for the TGFβ/SMAD, canonical WNT and the 
Hedgehog reporter. Each line was seeded out and treated with Doxycycline for 48 
hours or not. 
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Figure 74. YAP1 / TAZ 
Overexpression in Hek293 TGFβ, 
WNT and Hedgehog reporter 
cells. Stable Hek293 TGFβ, WNT 
or Hedgehog reporter cells were 
transfected with Doxycycline - 
inducible YAP1 / TAZ(WWTR1) 
constitutively active mutant 
constructs and treated with 
Doxycyline or not. Upon Doxycyline 
treatment the activity of the 
reporters was increased, though 
not to the same extent as with 
myeloid cell co-culture. Three wells per treatment group, single experiment for each 
pathway. 
 
Overexpression of YAP1 and TAZ(WWTR1) activated each pathway to a small but 
significant degree, and much less than the effects of co-culture with myeloid cells or 
cell lines. This shows that while Hippo signaling may be a contribution factor for the 
effects exhibited by co-culture with myeloid cells, it most certainly is not the key 
modulating component. So the nature of the myeloid signal had to be further 
determined.
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